<SEC-DOCUMENT>0001104659-23-047884.txt : 20230420
<SEC-HEADER>0001104659-23-047884.hdr.sgml : 20230420
<ACCEPTANCE-DATETIME>20230420172031
ACCESSION NUMBER:		0001104659-23-047884
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20230607
FILED AS OF DATE:		20230420
DATE AS OF CHANGE:		20230420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immunome Inc.
		CENTRAL INDEX KEY:			0001472012
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770694340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39580
		FILM NUMBER:		23833984

	BUSINESS ADDRESS:	
		STREET 1:		665 STOCKTON DRIVE
		STREET 2:		SUITE 300
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341
		BUSINESS PHONE:		610-321-3700

	MAIL ADDRESS:	
		STREET 1:		665 STOCKTON DRIVE
		STREET 2:		SUITE 300
		CITY:			EXTON
		STATE:			PA
		ZIP:			19341
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>tm232159d3_def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">the Securities Exchange Act of 1934(Amendment
No.&nbsp; )</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT></TD><TD STYLE="text-align: justify">Preliminary
                                            Proxy Statement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><B>Confidential,
                                            for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD><TD STYLE="text-align: justify">Definitive
                                            Proxy Statement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Definitive
                                            Additional Materials</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting
                                            Material under &sect;240.14a-12</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 14pt"><B>IMMUNOME,&nbsp;INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant as Specified In Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-top: Black 1.5pt solid">(Name of Person(s)&nbsp;Filing
Proxy Statement, if other than the Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check all boxes that apply):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#120;</FONT></TD><TD STYLE="text-align: justify">No
                                            fee required</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee
                                            paid previously with preliminary materials</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Fee
                                            computed on table in exhibit required by Item 25(b)&nbsp;per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and
                                            0-11</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm232159d1_pre14aimg01.jpg" ALT="" STYLE="height: 58px; width: 239px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNOME,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>665 Stockton Drive, Suite&nbsp;300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exton, PA 19341</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2023 ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>To be Held on June&nbsp;7, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April&nbsp;20, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Stockholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are pleased to invite you to attend Immunome,&nbsp;Inc.&rsquo;s
2023 Annual Meeting of Stockholders which will be held at 1:00 p.m., Eastern Time, on Wednesday, June&nbsp;7, 2023. The annual meeting
will be held entirely online. We believe that hosting the Annual Meeting virtually will enable greater stockholder attendance and participation
and improves our ability to communicate more effectively with our stockholders. The Annual Meeting can be accessed via the Internet at:
<U>www.virtualshareholdermeeting.com/IMNM2023</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Details regarding the business to be conducted
at the Annual Meeting are more fully described in the accompanying Notice of 2023 Annual Meeting of Stockholders and 2023 Annual Meeting
Proxy Statement. Other than the proposals described in the Proxy Statement, the Board is not aware of any other matters to be presented
for a vote at the Annual Meeting. Under Securities and Exchange Commission rules&nbsp;that allow companies to furnish proxy materials
over the Internet, we have elected to deliver our proxy materials to the majority of our stockholders over the Internet. This delivery
process allows us to provide stockholders with the information they need, while at the same time conserving natural resources and lowering
the cost of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Your vote is important. Whether or not you plan
to attend virtually the Annual Meeting, we hope you will vote as soon as possible. Information about voting methods is set forth in the
accompanying Notice and Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you have any questions with respect to voting,
please call our Corporate Secretary at 610-321-3700.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Sincerely,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="tm232159d1_pre14aimg02.jpg" ALT=""></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Purnanand D. Sarma, Ph.D.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: italic 10pt Times New Roman, Times, Serif">President, Chief Executive Officer and Director</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THIS PROXY STATEMENT AND ENCLOSED PROXY CARD
ARE FIRST BEING MADE AVAILABLE <BR>
ON OR ABOUT APRIL 21, 2023.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm232159d1_pre14aimg01.jpg" ALT="" STYLE="height: 58px; width: 239px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNOME,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dear Stockholders:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You are invited to attend Immunome,&nbsp;Inc.&rsquo;s
2023 Annual Meeting of Stockholders. At the Annual Meeting, stockholders will vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>elect the two director nominees that are set forth in the attached
                                            Proxy Statement to serve as Class&nbsp;III directors, whose term will expire in 2026;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>to approve a proposed amendment to our Amended and Restated Certificate
                                            of Incorporation to reflect new Delaware law provisions regarding officer exculpation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>to ratify the appointment of Ernst&nbsp;&amp; Young LLP as our independent
                                            registered public accounting firm for the 2023 fiscal year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stockholders also will transact any other business
that may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MEETING INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 15%">Date:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%">June&nbsp;7, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Time:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">1:00 p.m.&nbsp;Eastern Time</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Location: &nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Via the Internet</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><U>www.virtualshareholdermeeting.com/IMNM2023</U></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><B>Record Date:</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">You can vote if you were a stockholder of record on April&nbsp;14, 2023. A list
    of stockholders of record will be available at the annual meeting and, during the 10 days prior to the annual meeting, at our principal
    executive offices located at 665 Stockton Drive, Suite&nbsp;300, Exton, Pennsylvania 19341.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Your vote matters. Whether or not you plan to virtually attend
the Annual Meeting, please ensure that your shares are represented by voting, signing, dating and returning your proxy in the enclosed
envelope, which requires no postage if mailed in the United States.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">By Order of the Board of Directors</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="tm232159d1_pre14aimg02.jpg" ALT=""></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Purnanand D. Sarma, Ph.D. April&nbsp;20, 2023</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IMPORTANT NOTICE REGARDING AVAILABILITY OF PROXY MATERIALS. This
Proxy Statement and the proxy card are being furnished to our stockholders on or about April&nbsp;21, 2023. This Proxy Statement and
our 2022 Annual Report are available to holders of our common stock at <I>www.investors.immunome.com/financials/sec-filings/</I>. If
you would like to receive, without charge, a paper copy of our 2022 Annual Report, including the financial statements, please send your
request to our Chief Financial Officer,&nbsp;Immunome,&nbsp;Inc., 665 Stockton Drive, Suite&nbsp;300, Exton, PA 19341.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_01"></A><B>SUMMARY INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To assist you in reviewing this year&rsquo;s
proposals, we call your attention to the following proxy summary. This is only a summary; please review this Proxy Statement and our
2022 Annual Report in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 44%; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2023 Annual Meeting of Stockholders</I></B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Time and Date</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%; border-bottom: black 1pt solid; text-align: center"><B>Record Date</B></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 38%; border-bottom: black 1pt solid; text-align: center"><B>Location</B></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">1:00 p.m., Eastern Time, on June&nbsp;7, 2023</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">April&nbsp;14, 2023</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Via the Internet</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Summary of Matters for Stockholder Vote</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; width: 59%; vertical-align: bottom"><B>Proposal</B></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; width: 13%; text-align: center"><B>For More Information</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; width: 24%; text-align: center"><B>Board of Directors <BR>
    Recommendation</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1: </B>Election of Class&nbsp;III Directors for a Three-Year
    Term Expiring in 2026</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD>Page 7&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">&uuml;</FONT> <B>FOR Each Nominee</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Richard A. Baron and Philip Wagenheim</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Item 2:&nbsp;&nbsp;</B>Amendment to our Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions
    regarding officer exculpation</TD>
    <TD>&nbsp;</TD>
    <TD>Page 7&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">&uuml;</FONT> <B>FOR</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Item 3:&nbsp;&nbsp;</B>Ratification of Appointment of Ernst&nbsp;&amp; Young LLP (&ldquo;Ernst&nbsp;&amp; Young&rdquo;) as
    our Independent Registered Public Accounting Firm for 2022</TD>
    <TD>&nbsp;</TD>
    <TD>Page 7&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings">&uuml;</FONT> <B>FOR</B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our Director Nominees</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You are being asked to vote on the election of
Richard A. Baron and Philip Wagenheim as Class&nbsp;III directors, each to serve for a three-year term expiring at our 2026 Annual Meeting
of Stockholders. The number of members of the Board is currently set at seven members and is divided into three classes, each of which
has a three-year term. Class&nbsp;I consists of three directors and Classes II and III each consist of two directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The term of office of our Class&nbsp;III directors
expires at the 2023 Annual Meeting of Stockholders, or the Annual Meeting. We are nominating Messrs.&nbsp; Baron and Wagenheim for re-election
at our Annual Meeting, to serve until the 2026 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed,
or their respective earlier death, resignation, retirement, disqualification or removal. Directors are elected by a plurality of the
votes cast by our stockholders at the Annual Meeting. The two nominees receiving the most FOR votes (among votes properly cast online
at the meeting or by proxy) will be elected. If no contrary indication is made, shares represented by executed proxies will be voted
FOR the election of Messrs.&nbsp;Baron and Wagenheim. Each nominee has agreed to serve as a director if elected, and we have no reason
to believe that any nominee will be unable to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 28%; border-bottom: black 1pt solid"><B>Name of Nominee</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 22%; border-bottom: black 1pt solid; text-align: center"><B>Age</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 22%; border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Director</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Since</B></P></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 22%; border-bottom: black 1pt solid; text-align: center"><B>Independent</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Richard A. Baron</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">67</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">2020</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Yes</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>Philip Wagenheim</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">53</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">No</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_01"><FONT STYLE="font-size: 10pt">SUMMARY INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_01"><FONT STYLE="font-size: 10pt">i</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 92%; text-align: left"><A HREF="#a_02"><FONT STYLE="font-size: 10pt">PROXY STATEMENT
    FOR IMMUNOME,&nbsp;INC.</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: right"><A HREF="#a_02"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_03"><FONT STYLE="font-size: 10pt">GENERAL INFORMATION ABOUT THE
    ANNUAL MEETING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_03"><FONT STYLE="font-size: 10pt">2</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_04"><FONT STYLE="font-size: 10pt">ITEMS TO BE VOTED ON</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_04"><FONT STYLE="font-size: 10pt">7</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_05"><FONT STYLE="font-size: 10pt">INFORMATION REGARDING THE BOARD</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_05"><FONT STYLE="font-size: 10pt">9</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_06"><FONT STYLE="font-size: 10pt">INFORMATION REGARDING OUR DIRECTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_06"><FONT STYLE="font-size: 10pt">11</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_07"><FONT STYLE="font-size: 10pt">CORPORATE GOVERNANCE AND RISK
    MANAGEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_07"><FONT STYLE="font-size: 10pt">13</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_08"><FONT STYLE="font-size: 10pt">DIRECTOR COMPENSATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_08"><FONT STYLE="font-size: 10pt">18</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_09"><FONT STYLE="font-size: 10pt">EQUITY COMPENSATION PLAN INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_09"><FONT STYLE="font-size: 10pt">20</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_10"><FONT STYLE="font-size: 10pt">INDEPENDENT REGISTERED PUBLIC
    ACCOUNTING FIRM</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_10"><FONT STYLE="font-size: 10pt">22</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_11"><FONT STYLE="font-size: 10pt">AUDIT COMMITTEE REPORT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_11"><FONT STYLE="font-size: 10pt">23</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_12"><FONT STYLE="font-size: 10pt">EXECUTIVE OFFICERS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_12"><FONT STYLE="font-size: 10pt">24</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_13"><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_13"><FONT STYLE="font-size: 10pt">25</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_14"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED
    PARTY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_14"><FONT STYLE="font-size: 10pt">32</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_15"><FONT STYLE="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN
    BENEFICIAL OWNERS AND MANAGEMENT</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_15"><FONT STYLE="font-size: 10pt">34</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_16"><FONT STYLE="font-size: 10pt">OTHER INFORMATION</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#a_16"><FONT STYLE="font-size: 10pt">36</FONT></A></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#ja_002">APPENDIX A</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><A HREF="#ja_002">A-1</A></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNOME,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>665 Stockton Drive, Suite&nbsp;300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exton, PA 19341</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_02"></A><B>PROXY STATEMENT FOR IMMUNOME,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD
ON JUNE 7, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Proxy Statement, with the enclosed proxy
card, is being furnished to stockholders of Immunome,&nbsp;Inc. in connection with the solicitation by the Board of proxies to be voted
at our Annual Meeting and at any postponements or adjournments thereof. The Annual Meeting will be held on Wednesday, June&nbsp;7, 2023,
at 1:00 p.m., Eastern Time, via the Internet at <U>www.virtualshareholdermeeting.com/IMNM2023</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Proxy Statement and the enclosed proxy card
are first being furnished to our stockholders on or about April&nbsp;21, 2023. The Notice of Internet Availability of Proxy Materials
being mailed to the stockholders is not part of the Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_03"></A><B>GENERAL INFORMATION ABOUT THE ANNUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>The Board of Directors (the &ldquo;Board&rdquo;)
of Immunome,&nbsp;Inc. (the &ldquo;Company&rdquo;) is soliciting your vote on matters that will be presented at the 2023 Annual Meeting
of Stockholders (the &ldquo;Annual Meeting&rdquo;) and at any adjournment or postponement. This Proxy Statement contains information
on these matters to assist you in voting your shares. Below is a list of questions that you may have about the Annual Meeting and voting
process and our answers to these questions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Why will stockholders receive a notice regarding
the availability of proxy materials on the Internet?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board is soliciting your proxy to vote at
the Annual Meeting, including at any adjournments or postponements of the Annual Meeting. In accordance with rules&nbsp;adopted by the
Securities and Exchange Commission (the &ldquo;SEC&rdquo;), we have elected to provide access to this Proxy Statement, our Annual Report
on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2022, and related proxy materials over the Internet. Accordingly, we intend
to mail a Notice of Internet Availability of Proxy Materials (the &ldquo;Notice&rdquo;) on or about April&nbsp;21, 2023 to all stockholders
of record entitled to vote at the Annual Meeting. All stockholders will have the ability to access the proxy materials on the website
referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials
over the Internet or to request a printed copy may be found in the Notice. On the date of mailing the Notice, stockholders will be able
to access all of the proxy materials on the website at <U>www.proxyvote.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How do stockholders attend the Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Annual Meeting will be held on Wednesday,
June&nbsp;7, 2023 at 1:00 p.m.&nbsp; Eastern Time. The meeting will take place via live webcast on the Internet at <U>www.virtualshareholdermeeting.com/IMNM2023</U>.
Online check-in will begin at approximately 12:45 pm Eastern Time. You can attend the Annual Meeting, vote your shares and submit your
questions during the live webcast. You will need your 16-digit control number included in the Notice, the proxy card, or in the instructions
that accompany your proxy materials. You cannot attend the Annual Meeting in person. Information on how to vote at the Annual Meeting
is discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you do not have your 16-digit control number,
you will be able to access and listen to the Annual Meeting, but you will not be able to vote your shares or submit questions during
the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you encounter any technical difficulties during
check-in time or the live webcast of the Annual Meeting, please call 800-586-1548 (US toll-free) or 303-562-9288 (international) and
technical representatives will be able to assist you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What matters are stockholders being asked to vote on?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">There are three matters scheduled for a vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>election of two Class&nbsp;III directors nominated by the Board
                                            to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly
                                            elected and qualified (Proposal 1);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>amendment to our Amended and Restated Certificate of Incorporation
                                            to reflect new Delaware law provisions regarding officer exculpation (Proposal 2); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>ratification of the appointment of Ernst&nbsp;&amp; Young LLP
                                            as independent registered public accounting firm of the Company for its fiscal year ending
                                            December&nbsp;31, 2023 (Proposal 3).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board knows of no other matters that will
be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, it is the
intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How can stockholders ask questions at the Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our live webcast Annual Meeting has been designed
to allow stockholders to submit questions up to 15 minutes before and during the Annual Meeting by logging into the webcast using your
16-digit control number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who can vote at the Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Only stockholders of record at the close of business
on April&nbsp;14, 2023, referred to as the record date, will be entitled to vote at the Annual Meeting. On the record date, there were
12,213,401 shares of our common stock outstanding and entitled to vote. Voting can occur in the following two ways, depending on how you
hold your shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Stockholder of Record: Shares Registered in
Your Name: </I>If on the record date your shares were registered directly in your name with the Company&rsquo;s transfer agent, American
Stock Transfer&nbsp;&amp; Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote electronically
at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting via the live webcast, we urge you to fill
out and return the enclosed proxy card as instructed to ensure your vote is counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Beneficial Owner: Shares Registered in the
Name of a Broker or Bank: </I>If on the record date your shares were held in an account at a brokerage firm, bank or similar organization
instead of directly in your name, then you are the beneficial owner of shares held in &ldquo;street name&rdquo; and the Notice will be
forwarded to you by that organization. The organization holding your account is considered to be the stockholder of record for voting
at the Annual Meeting. As a beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the
shares in your account. You are also invited to attend the Annual Meeting via the live webcast. However, since you are not the stockholder
of record, you may not vote your shares at the Annual Meeting unless you request and obtain a valid proxy from your broker, bank or other
agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How do I vote?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">You may either vote &ldquo;For&rdquo; both of
the nominees to the Board or you may &ldquo;Withhold&rdquo; your vote for both nominees, or for either nominee you specify. For each
of the other matters to be voted on, you may vote &ldquo;For&rdquo; or &ldquo;Against&rdquo; or abstain from voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Your vote can be cast in the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Stockholder of Record: Shares Registered in
Your Name: </I>If you are a stockholder of record, you may vote electronically at the Annual Meeting, vote by proxy over the telephone,
vote by proxy through the Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later
time. Whether or not you plan to attend the Annual Meeting via the live webcast, we urge you to vote by proxy to ensure your vote is
counted. You may still attend the Annual Meeting via the live webcast and vote electronically even if you have already voted by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>To vote electronically at the Annual Meeting, attend the live
                                            webcast at <U>www.virtualshareholdermeeting.com/IMNM2023</U> and use your 16-digit control
                                            number included in the Notice, the proxy card, or in the instructions that accompany your
                                            proxy materials.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>To vote using the proxy card, simply complete, sign and date
                                            the proxy card that may be delivered and return it promptly in the envelope provided. If
                                            you return your signed proxy card to us before the Annual Meeting, we will vote your shares
                                            as you direct.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>To vote over the telephone, dial toll-free 800-690-6903 using
                                            a touch-tone phone and follow the recorded instructions. You will be asked to provide the
                                            company number and control number from the Notice. Your telephone vote must be received by
                                            11:59 p.m.&nbsp; Eastern Time on June&nbsp;6, 2023 to be counted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>To vote through the Internet, go to <U>http://www.proxyvote.com
                                            </U>to complete an electronic proxy card. You will be asked to provide the company number
                                            and control number from the Notice. Your Internet vote must be received by 11:59 p.m.&nbsp;Eastern
                                            Time on June&nbsp;6, 2023 to be counted. Please be aware that you must bear any costs associated
                                            with your Internet access, such as usage charges from Internet access providers and telephone
                                            companies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Beneficial Owner: Shares Registered in the
Name of Broker or Bank: </I>If you are a beneficial owner of shares registered in the name of your broker, bank or other organization,
you should have received a Notice containing voting instructions from that organization rather than from Immunome. Simply follow the
voting instructions in the Notice to ensure that your vote is counted. To vote electronically during the Annual Meeting, you must obtain
a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other organization included with
these proxy materials, or contact that organization to request a proxy form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How many votes do I have?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On each matter to be voted upon, you have one
vote for each share of Immunome common stock you own as of April&nbsp;14, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>If I am a stockholder of record and I do not vote, or if I return
a proxy card or otherwise vote without giving specific voting instructions, what happens?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you are a stockholder of record and do not
vote by completing your proxy card, by telephone, through the Internet or electronically at the Annual Meeting, your shares will not
be voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you return a signed and dated proxy card or
otherwise vote without marking voting selections, your shares will be voted, as applicable and &ldquo;For&rdquo; the election of both
nominees for director, &ldquo;For&rdquo; the amendment to our Amended and Restated Certificate of Incorporation to reflect new Delaware
law provisions regarding officer exculpation and &ldquo;For&rdquo; the ratification of the appointment of Ernst&nbsp;&amp; Young as our
independent registered public accounting firm. If any other matter is properly presented at the meeting, your proxyholder (one of the
individuals named on your proxy card) will vote your shares using his or her best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What happens with my vote if I am a beneficial owner of shares
held in street name and I do not provide my broker or bank with voting instructions?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you are a beneficial owner of shares held
in street name and you do not instruct your broker, bank or other organization how to vote your shares (or do not provide instructions
by the deadline prescribed by it), your broker, bank or other organization may still be able to vote your shares in its discretion. Generally,
if shares are held in street name, the beneficial owner of the shares is entitled to give voting instructions to the broker or nominee
holding the shares. If the beneficial owner does not provide voting instructions, the broker or nominee can still vote the shares with
respect to matters that are considered to be &ldquo;routine,&rdquo; but not with respect to &ldquo;non-routine&rdquo; matters. Under
the rules&nbsp;and interpretations of the Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;), &ldquo;non-routine&rdquo; matters may substantially
affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested)
and executive compensation, including the advisory stockholder votes on executive compensation and on the frequency of stockholder votes
on executive compensation. Proposals 1 and 2 is considered to be non-routine. Proposal 3 is considered to be routine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Can I change my vote after submitting my proxy?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Stockholder of Record: Shares Registered in
Your Name: </I>If you are the record holder of your shares, you can revoke your proxy at any time before the final vote at the Annual
Meeting. Your most current proxy card or telephone or Internet proxy is the one that will be counted. You may revoke your proxy in any
one of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>You may submit another properly completed proxy card with a later
                                            date;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>You may grant a subsequent proxy by telephone or through the
                                            Internet;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>You may send a timely written notice that you are revoking your
                                            proxy to the Company&rsquo;s Secretary at Immunome,&nbsp;Inc., 665 Stockton Drive, Suite&nbsp;300,
                                            Exton, PA 19341; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>You may attend the Annual Meeting via the live webcast and vote
                                            electronically, but simply attending the Annual Meeting via the live webcast without voting
                                            will not, by itself, revoke your proxy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Beneficial Owner: Shares Registered in the
Name of Broker or Bank: </I>If your shares are held by your broker, bank or other agent, you should follow the instructions provided
by your broker, bank or other agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How are votes counted?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Votes will be counted by the inspector of election appointed for the
Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>For Proposal 1</I>, election of directors, the two nominees
                                            receiving the most &ldquo;For&rdquo; votes properly cast and entitled to vote on the election
                                            of directors will be elected (i.e., a plurality of the votes cast). Only votes &ldquo;For&rdquo;
                                            will affect the outcome.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>For Proposal 2</I>, amendment to our Amended and Restated
                                            Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation,
                                            &ldquo;For&rdquo; votes from the holders of a majority of the shares of our common stock
                                            outstanding as of the Record Date must be received to approve this proposal. If you &ldquo;Abstain&rdquo;
                                            from voting, it will have the same effect as an &ldquo;Against&rdquo; vote. Broker non-votes
                                            will have the same effect as an &ldquo;Against&rdquo; vote.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD><I>For Proposal </I>3, ratification of the appointment of Ernst&nbsp;&amp;
                                            Young LLP as the Company&rsquo;s independent registered public accounting firm for the fiscal
                                            year ending December&nbsp;31, 2023, &ldquo;For&rdquo; votes from the holders of a majority
                                            of votes properly cast and entitled to vote on the matter must be received to approve this
                                            proposal. If you &ldquo;Abstain&rdquo; from voting, it will have no effect. Broker non-votes
                                            will also have no effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes how votes, abstentions
and broker non-votes are treated with respect to our proposals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 30%"><B>Proposal</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 15%; text-align: center"><B>Votes<BR>
 Required</B></TD>
    <TD STYLE="white-space: nowrap; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 35%; text-align: center"><B>Treatment
    of <BR>
Abstentions and Broker <BR>
Non-Votes</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 14%; text-align: center"><B>Broker <BR>
Discretionary<BR>

    Voting</B></TD></TR>
  <TR>
    <TD><B>Item 1:&nbsp;&nbsp;</B>Election of Class&nbsp;III Directors for a Three-Year
    Term Expiring in 2026</TD>
    <TD>&nbsp;</TD>
    <TD>Plurality of the votes cast</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Abstentions and broker non-votes will
not be taken into account in determining the outcome of the proposal</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">No</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD><B>Item 2:&nbsp;&nbsp;</B>Amendment to our Amended and Restated Certificate
    of Incorporation to reflect new Delaware law provisions regarding officer exculpation</TD>
    <TD>&nbsp;</TD>
    <TD>Majority of shares outstanding</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Abstentions and broker non-votes will
have the same effect as an &ldquo;Against&rdquo; vote</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">No</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD><B>Item 3:&nbsp;&nbsp;</B>Ratification of Appointment of Ernst&nbsp;&amp; Young
    as our Independent Registered Public Accounting Firm for 2023</TD>
    <TD>&nbsp;</TD>
    <TD>Majority of the votes cast</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Abstentions and broker non-votes will
not be taken into account in determining the outcome of the proposal</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Yes</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What are &ldquo;broker non-votes&rdquo;?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As discussed above, when a beneficial owner of
shares held in street name does not give voting instructions to his or her broker, bank or other securities intermediary holding his
or her shares as to how to vote on matters deemed to be &ldquo;non-routine&rdquo;, the broker, bank or other such agent cannot vote the
shares. These un-voted shares are counted as &ldquo;broker non-votes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As a reminder, if you a beneficial owner of shares
held in street name, in order to ensure your shares are voted in the way you would prefer, you must provide voting instructions to your
broker, bank or other agent by the deadline provided in the materials you receive from your broker, bank or other agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What is the quorum requirement?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">A quorum of stockholders is necessary to hold
a valid Annual Meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote
are present at the Annual Meeting via the live webcast or represented by proxy. On the record date, there were 12,213,401 shares outstanding
and entitled to vote. Thus, the holders of 6,106,701 shares must be present at the Annual Meeting via the live webcast or represented
by proxy to have a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Your shares will be counted towards the quorum
only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote electronically
at the Annual Meeting. Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders
of a majority of shares present at the Annual Meeting via the live webcast or represented by proxy may adjourn the Annual Meeting to
another date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How can I find out the results of the voting at the Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Preliminary voting results will be announced
at the Annual Meeting. In addition, final voting results will be published in a current report on Form&nbsp;8- K that we expect to file
within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form&nbsp;8-K within
four business days after the meeting, we intend to file a Form&nbsp;8-K to publish preliminary results and, within four business days
after the final results are known to us, file an additional Form&nbsp;8-K to publish the final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who pays the costs of this proxy solicitation?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will pay all the costs of soliciting
proxies. In addition to these proxy materials, our directors and employees may also solicit proxies by telephone, or by other means of
communication, and they will not be paid any additional compensation for solicitation. We may also reimburse brokerage firms, banks and
other agents for the cost of forwarding proxy materials to beneficial owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What does it mean if I receive more than one Notice?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If you receive more than one Notice, your shares
may be registered in more than one name or in different accounts. Please follow the voting instructions on the Notices to ensure that
all of your shares are voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_04"></A><B>ITEMS TO BE VOTED ON</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 1:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ELECTION OF CLASS&nbsp;III DIRECTORS FOR A
THREE-YEAR TERM EXPIRING IN 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">At the Annual Meeting, our stockholders will
vote on the election of two Class&nbsp;III director nominees named in this Proxy Statement as directors, each to serve until our 2026
Annual Meeting of Stockholders and until their respective successors are elected and qualified. The Board has unanimously nominated Richard
A. Baron and Philip Wagenheim for election to the Board at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of the nominees has agreed to be named and
to serve, and we expect each nominee to be able to serve if elected. If any nominee is unable to serve, the Nominating and Corporate
Governance Committee will recommend to the Board a replacement nominee. The Board may then designate the other nominee to stand for election.
If you voted for the unavailable nominee, your vote will be cast for his replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE BOARD UNANIMOUSLY RECOMMENDS STOCKHOLDERS
VOTE <U>FOR</U> THE ELECTION OF RICHARD A. BARON AND PHILIP WAGENHEIM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 2:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENT OF OUR AMENDED AND RESTATED CERTIFICATE
OF INCORPORATION TO REFLECT NEW DELAWARE LAW PROVISIONS REGARDING OFFICER EXCULPATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The State of Delaware, which is our state of
incorporation, recently enacted legislation that enables Delaware companies to limit the liability of certain of their officers in limited
circumstances under Section&nbsp;102(b)(7)&nbsp;of the Delaware General Corporate Law (&ldquo;DGCL&rdquo;). The Board has determined
that it is advisable to amend our Amended and Restated Certificate of Incorporation (the &ldquo;Certificate of Incorporation&rdquo;),
subject to stockholder approval, to provide for the elimination or limitation of personal liability of certain of our officers for monetary
damages in the specific circumstances authorized by Delaware law, and has voted to recommend that the stockholders approve this amendment.
Article&nbsp;VI of our Amended and Restated Certificate of Incorporation currently provides for the elimination of the monetary liability
of directors to the fullest extent under applicable law and this proposed amendment would provide for the same treatment for our officers.
The proposed amendment would eliminate or limit the personal liability of certain of the Company&rsquo;s officers for monetary damages
for breach of the duty of care in certain actions. The provision would not apply to breaches of the duty of loyalty to the Company or
its stockholders, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or any transaction
in which the officer derived an improper personal benefit. The provision also would not eliminate or limit the liability of such officers
for claims brought by or in the right of the corporation, such as derivative claims. The full text of the proposed amendment to the Certificate
of Incorporation is attached to this proxy statement as Appendix A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board believes that it is necessary to provide
protection to officers to the fullest extent permitted by law in order to attract and retain top talent. Taking into account the limitations
on the types of exculpation permitted, the Board believes that the proposed amendment balances stockholders&rsquo; interest in accountability
and their interest in the Company being able to attract and retain quality officers. The affirmative vote of a majority of the shares
of common stock outstanding and entitled to vote at the Annual Meeting is required to approve the amendment to our Amended and Restated
Certificate of Incorporation to reflect the new Delaware law provisions regarding officer exculpation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE BOARD UNANIMOUSLY RECOMMENDS STOCKHOLDERS
VOTE <U>FOR</U> THE AMENDMENT TO OUR AMENDED AND RESTATED CERTIFICATE OF INCORPORATION.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 3:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RATIFICATION OF APPOINTMENT OF ERNST&nbsp;&amp;
YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee of the Board has selected
Ernst&nbsp;&amp; Young to serve as our independent registered public accounting firm to audit the financial statements of the Company
for the fiscal year ending December&nbsp;31, 2023, and to perform audit-related services. Ernst&nbsp;&amp; Young has served as our independent
registered public accounting firm since October&nbsp;4, 2022. From December&nbsp;3, 2019 until our engagement of Ernst&nbsp;&amp; Young,
Deloitte&nbsp;&amp; Touche served as our independent accounting firm to perform audit services. Stockholders are hereby asked to ratify
the Audit Committee&rsquo;s appointment of Ernst&nbsp;&amp; Young as our independent registered public accounting firm for the fiscal
year ending December&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Although stockholder ratification of the appointment
of Ernst&nbsp;&amp; Young to serve as our independent registered public accounting firm is not required, the Board is submitting the
appointment of Ernst&nbsp;&amp; Young for ratification to obtain the views of stockholders and as a matter of good corporate governance.
If the appointment is not ratified, the Audit Committee will reconsider whether to retain Ernst&nbsp;&amp; Young.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Representatives of Ernst&nbsp;&amp; Young are
expected to virtually attend the Annual Meeting where they will be available to respond to appropriate questions and, if they desire,
to make a statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE BOARD UNANIMOUSLY RECOMMENDS A VOTE <U>FOR
</U>THE RATIFICATION OF ERNST&nbsp;&amp; YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE COMPANY FOR THE FISCAL YEAR
ENDING DECEMBER 31, 2023.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_05"></A><B>INFORMATION REGARDING THE BOARD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD STRUCTURE AND COMPOSITION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board is the Company&rsquo;s ultimate decision-making
body, except with respect to those matters reserved to the stockholders under applicable law. The Board selects the members of our senior
management team, who in turn are responsible for the day-to-day operations of the Company. The Board acts as an advisor and counselor
to senior management team and oversees their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our Amended and Restated Bylaws, or Bylaws, provide
that the number of members of the Board shall be fixed by the Board from time to time. The Board consists of directors divided into three
classes, with each class holding office for a three-year term. Messrs. Baron and Wagenheim, current Class&nbsp;III directors, have
been nominated by the Board for election at the Annual Meeting for three-year terms that will expire at the 2026 Annual Meeting of Stockholders
and until their respective successors, if any, are elected or appointed, or their respective earlier death, resignation, retirement,
disqualification or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each nominee has agreed to be named and to serve,
and we expect each nominee to be able to serve if elected. If any nominee is unable to serve, the Nominating and Corporate Governance
Committee will recommend to the Board a replacement nominee. The Board may then designate the other nominee to stand for election. If
you voted for the unavailable nominee, your vote will be cast for their replacement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
of the Board is responsible for recommending the composition and structure of the Board, for developing criteria for Board membership
and identifying individuals that it believes are qualified to become Board members. This committee regularly reviews director competencies,
qualities and experiences, with the goal of ensuring that the Board is comprised of an effective team of directors who function collegially
and who are able to apply their experience toward meaningful contributions to our business strategy and oversight of our performance,
risk management, organizational development and succession planning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CRITERIA FOR BOARD MEMBERSHIP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board will determine the appropriate characteristics,
skills and experience for the Board as a whole and for its individual members. The Board considers director nominee recommendations from
the Nominating and Corporate Governance Committee. The Board will consider the minimum general criteria set forth below, and may add
any specific additional criteria with respect to specific searches, in selecting candidates and existing directors for service on the
Board. An acceptable candidate may not fully satisfy all of the criteria, but is expected to satisfy nearly all of them. The Board believes
that director candidates should have certain minimum qualifications, including being able to read and understand basic financial statements
and having the highest personal integrity and ethics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In considering candidates recommended by the
Nominating and Corporate Governance Committee, the Board intends to consider such factors as: (i)&nbsp;possessing relevant expertise
upon which to be able to offer advice and guidance to management; (ii)&nbsp;having sufficient time to devote to the affairs of the Company;
(iii)&nbsp;demonstrating excellence in his or her field; (iv)&nbsp;having the ability to exercise sound business judgment; (v)&nbsp;experience
as a Board member or executive officer of another publicly held company; (vi)&nbsp;having a diverse personal background, perspective
and experience; and (vii)&nbsp;having the commitment to rigorously represent the long-term interests of the Company&rsquo;s stockholders.The
Board reviews candidates for director nomination in the context of the current composition of the Board, the operating requirements of
the Company and the long-term interests of the Company&rsquo;s stockholders. In conducting this assessment, the Board considers diversity,
age, skills, and such other factors as it deems appropriate given the current needs of the Board and the Company to maintain a balance
of knowledge, experience and capability. In the case of incumbent directors whose terms of office are set to expire, the Board reviews
such directors&rsquo; overall service to the Company during their term, including the number of meetings attended, level of participation,
quality of performance, and any other relationships and transactions that might impair such directors&rsquo; independence. In the case
of new director candidates, the Board also determines whether the nominee must be independent for purposes of satisfying applicable listing
requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SELECTION OF CANDIDATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Process for Identifying and Evaluating Nominees for Director</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
will evaluate director nominees in the context of the current composition of the Board, the operating requirements of the Company and
the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee will consider
the Board membership criteria set forth above, as well as such other factors as it deems appropriate given the current needs of the Board
and the Company to maintain a balance of knowledge, experience and capability. While the Company does not have a formal policy on Board
diversity, the Nominating and Corporate Governance Committee considers the value of diversity on the Board in evaluating director nominees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Accordingly, the Nominating and Corporate Governance
Committee&rsquo;s evaluation of director nominees for service on the Board includes consideration of their ability to contribute to the
diversity of personal and professional experiences, opinions, perspectives and backgrounds on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In the case of incumbent directors whose terms
of office are set to expire, the Nominating and Corporate Governance Committee will review such directors&rsquo; overall service to the
Company during their term, including the number of meetings attended, level of participation, quality of performance, and any other relationships
and transactions that might impair such directors&rsquo; independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
will also determine whether the potential candidates satisfy the independence requirements of Nasdaq, which determination will be based
upon applicable rules&nbsp;of the exchange, the applicable rules&nbsp;and regulations of the SEC and the advice of counsel, if necessary.
In the case of new director candidates, the Nominating and Corporate Governance Committee will use its network of contacts to find a
list of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and Corporate
Governance Committee will conduct any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates
after considering the function and needs of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
will periodically meet to discuss and consider potential new candidates. After conducting the required diligence, if the Nominating and
Corporate Governance Committee so determines by majority vote, it will select a nominee for recommendation to the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stockholder Recommendations of Director Nominees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
will consider director candidates recommended by Company stockholders. The Nominating and Governance Committee does not intend to alter
the manner in which it evaluates a candidate for nomination to the Board based on whether or not the candidate was recommended by a Company
stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Company stockholders who wish to recommend individuals
for consideration by the Nominating and Governance Committee to become nominees for election to the Board at an annual meeting of stockholders
must do so pursuant to the terms of and procedures specified in our Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_06"></A><B>INFORMATION REGARDING OUR DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CLASS&nbsp;III DIRECTORS (OUR NOMINEES)&thinsp;&mdash;&thinsp;PRESENT
TERMS EXPIRING AT THE ANNUAL MEETING AND PROPOSED TERMS TO EXPIRE IN 2026</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 32%; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Richard A. Baron</TD><TD STYLE="text-align: left; width: 2%; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><B>Director Since:</B> 2020</TD><TD STYLE="text-align: left; width: 2%; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><B>Committee Memberships:</B> Audit (Chair), Compensation,
    Science and Technology</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Richard A. Baron</B>, age 67, has served as a member of the Board
since September&nbsp;2020. Since 2011, Mr.&nbsp;Baron has served as a strategic advisor to early stage companies in the pharmaceuticals,
biotechnology and technologies industries through RA Baron Associates LLC. From March&nbsp;2015 to August&nbsp;2016, he was Vice President
of Finance and Chief Financial Officer of Zynerba Pharmaceuticals,&nbsp;Inc., a specialty pharmaceuticals company. Prior to that, he
served as Senior Vice President of Finance and Chief Financial Officer of Globus Medical,&nbsp;Inc., an orthopedic spine company, from
2012 to January&nbsp;2015. In addition to these roles, Mr.&nbsp;Baron has been the Chief Financial Officer for various companies in the
biotechnology, managed care and generic pharmaceuticals industries. Mr.&nbsp;Baron began his career in audit and tax services at PricewaterhouseCoopers
and Ernst&nbsp;&amp; Young. Mr.&nbsp;Baron received his B.S. in Economics at The Wharton School of the University of Pennsylvania and
earned a C.P.A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications: </I></B>Mr.&nbsp;Baron&rsquo;s
industry experience and significant financial expertise qualify him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; width: 32%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><B>Philip Wagenheim</b></TD><TD STYLE="text-align: left; width: 2%; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><B>Director Since:</B> 2017</TD><TD STYLE="text-align: left; width: 2%; font: bold 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: left"><B>Committee Memberships:</B> None</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Philip Wagenheim</B>, age 52, has served as a member of the Board
since December&nbsp;2017 and served as our interim Chief Executive Officer from January&nbsp;2017 to March&nbsp;2017. Mr.&nbsp;Wagenheim
has served as a Managing Member of Broadband Capital Partners, LLC since April&nbsp;2016. He has also served as Vice Chairman of and
held various leadership roles at Broadband Capital Management LLC and its affiliates since March&nbsp;2000. He also served as Secretary,
President and a member of the board of directors of Committed Capital Acquisition Corporation II from April&nbsp;2014 to June&nbsp;2017.
Mr.&nbsp;Wagenheim received his B.B.A. from the University of Miami in 1992.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications: </I></B>Mr.&nbsp;Wagenheim&rsquo;s
extensive experience as a venture capital investor in the life science industry and financial expertise qualifies him to serve on the
Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONTINUING DIRECTOR</B>S</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CLASS&nbsp;I DIRECTORS&thinsp;&mdash;&thinsp;TERMS EXPIRING
AT THE 2024 ANNUAL MEETING OF STOCKHOLDERS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>John L. LaMattina, Ph.D.</b></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Director Since:</B> 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Committee
    Memberships:</B> Audit, Compensation (Chair), Nominating and Corporate Governance, Science and Technology</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>John L. LaMattina, Ph.D.</B>, age 73, has served as a member
of the Board since October&nbsp;2017. Dr.&nbsp;LaMattina has served as a director at PureTech Health (LSE: PRTC, Nasdaq: PRTC) since
November&nbsp;2010 and Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) since February&nbsp;2011, both of which are public
companies, as well as Vedanta Biosciences since February&nbsp;2012. He has served as a scientific advisor to Frequency Therapeutics
since August&nbsp;2017. He served on the board of directors of Zafgen, Inc. from January&nbsp;2014 until May&nbsp;2020 and Gelesis
Inc. (NYSE: GLS) from October&nbsp;2009 to February&nbsp;2019. Dr.&nbsp;LaMattina was previously President of Pfizer Global Research
and Development and Senior Vice President of Pfizer,&nbsp;Inc., having held previous positions at Pfizer, including Vice President
of US Discovery Operations, Senior Vice President of Worldwide Discovery Operations and Senior Vice President of Worldwide
Development. Dr.&nbsp;LaMattina received his B.S. in Chemistry from Boston College and a Ph.D. in Organic Chemistry from the
University of New Hampshire. Dr.&nbsp;LaMattina completed his postdoctoral studies as a National Institutes of Health Postdoctoral
Fellow at Princeton University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications</I></B>: Dr.&nbsp;LaMattina&rsquo;s
experience as a member of the board of directors of several biotechnology companies and his comprehensive understanding of the industry
qualifies him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Mike Rapp</b></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Director Since:</B> 2015</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Committee Memberships:</B> None</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Mike Rapp</B>, age 55, has served as of the Chairman of the Board
since December&nbsp;2015. Mr.&nbsp;Rapp has served as a Managing Member of Broadband Capital Investments, LLC, since January&nbsp;2017
and has served as Chairman of and held various leadership roles at Broadband Capital Management LLC and its affiliates since March&nbsp;2000.
He was the Chief Executive Officer and Chairman of Committed Capital Acquisition Corporation II from 2014 to 2017. Mr.&nbsp;Rapp was
Managing Member of HF Investments and its affiliates from April&nbsp;2017 to November&nbsp;2020. Mr.&nbsp;Rapp has served as a board
member of Hudson Equity Partners LLC since May&nbsp;2012 and of Hydrofarm Inc. from April&nbsp;2017 until November&nbsp;2020. Mr.&nbsp;Rapp
received his B.A. in Psychology from the University of Michigan-Ann Arbor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications</I></B>: Mr.&nbsp;Rapp&rsquo;s
extensive experience as a venture capital investor, financial executive and board member qualifies him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Purnanand D. Sarma, Ph.D.</b></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Director Since:</B> 2019</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Committee Memberships:</B> None</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purnanand D. Sarma, Ph.D</B>., age 58, has served as our President
and Chief Executive Officer and as a member of the Board since June&nbsp;2019. Prior to joining us, Dr.&nbsp;Sarma served as President,
Chief Executive Officer and a member of the board of directors at TARIS Biomedical LLC from July&nbsp;2010 to December&nbsp;2018. He
has also previously served as Vice President and General Manager of World-Wide Drug Delivery Technologies at Cephalon Corporation and
served in several roles at Nektar Therapeutics and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline). Dr.&nbsp;Sarma received
a B.Pharm. from Andhra University in Visakhapatnam,&nbsp;India, and a Ph.D. in Pharmaceutics from the University of Minnesota.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications</I></B>: Dr.&nbsp;Sarma&rsquo;s
extensive experience in the pharmaceutical industry and executive leadership experience qualify him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>CLASS&nbsp;II DIRECTORS&thinsp;&mdash;&thinsp;TERMS EXPIRING
AT THE 2025 ANNUAL MEETING OF STOCKHOLDERS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Michael Lefenfeld</b></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Director Since:</B> 2017</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Committee Memberships:</B> Audit, Compensation, Nominating and Corporate
Governance (Chair)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Michael Lefenfeld</B>, age 42, has served as a member of the
Board since October&nbsp;2017. Mr.&nbsp;Lefenfeld has served as President and Chief Executive Officer of Hexion Inc. and on the
board of directors of Hexion Inc. since January&nbsp;2023. Mr.&nbsp;Lefenfeld previously served as President and Chief Executive
Officer and on the board of directors of Cyanco from March&nbsp;2018 to September&nbsp;2022. He also previously served on the board
of directors of SiGNa Chemistry from 2007 to 2020 and as President and Chief Executive Officer of SiGNa Chemistry from 2007 to 2018.
Mr.&nbsp;Lefenfeld received his B.S. in Chemical Engineering at Washington University in St. Louis, his M.S. in Chemistry at
Columbia University and an executive education certificate at Stanford University&rsquo;s Graduate School of Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications: </I></B>Mr.&nbsp;Lefenfeld&rsquo;s
corporate management experience and industry knowledge qualify him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Franklyn G. Prendergast, M.D., Ph.D.</b></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Director Since:</B> 2021</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; width: 32%"><B>Committee
    Memberships:</B> Nominating and Corporate Governance, Science and Technology</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Franklyn G. Prendergast, M.D., Ph.D.</B>, age 78, has served as
a member of the Board since June&nbsp;2021. Dr.&nbsp;Prendergast is a renowned medical and academic research professional who received
the 2019 Mayo Distinguished Alumni award and the 2021 Mayo Doctor of Medical Science, <I>honoris causa</I>, and has over 45 years of
association with the Mayo Foundation. Dr.&nbsp;Prendergast has served as a director of Perimeter Medical Imaging AI,&nbsp;Inc. (OTC:PYNKF)
since 2017, Neubase Therapeutics,&nbsp;Inc. (Nasdaq: NBSE) since July&nbsp;2019 and Lantern Pharma Inc. (Nasdaq: LTRN) since June&nbsp;2020.
Dr.&nbsp;Prendergast served as a director of Eli Lilly and Co. (NYSE: LLY) from 1995 until 2017, and a director of Vyant Bio,&nbsp;Inc.
(Nasdaq: VYNT) from 2014 until 2020. Dr.&nbsp;Prendergast received his medical degree with honors from the University of the West Indies
in 1968 and after an internship attended Lincoln College, University of Oxford, as a Rhodes Scholar where he obtained a B.A. with First
Class&nbsp;Honors in 1971 and M.A. in 1979. He commenced a residency in Internal Medicine at the Mayo Clinic in 1971 and subsequently
obtained a Ph.D. in biochemistry from the joint Mayo Graduate School/University of Minnesota program in 1977.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Skills&nbsp;&amp; Qualifications: </I></B>Dr.&nbsp;Prendergast&rsquo;s
significant medical experience and life science industry experience qualify him to serve on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_07"></A><B>CORPORATE GOVERNANCE AND RISK MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We are committed to good corporate governance
and integrity in our business dealings. We believe that strong corporate governance practices that provide meaningful rights to our stockholders
and ensure Board and management accountability are key to our relationship with our stockholders. We strive to have regular, constructive
conversations with our stockholders to better understand our stockholders&rsquo; priorities and perspectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our governance practices are documented in our
Amended and Restated Certificate of Incorporation, or Certificate, our Bylaws, our Code of Business Conduct and Ethics, or the Code of
Conduct, our Corporate Governance Guidelines and the charters of the committees of the Board, or the Committees. Aspects of our governance
documents are summarized below. You can find our charters for each Committee, our Code of Conduct and our Corporate Governance Guidelines
on our website at <U>www.immunome.com</U> under &ldquo;Investors&thinsp;&mdash;&thinsp;Governance&thinsp;&mdash;&thinsp;Governance Documents.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD INDEPENDENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As required under Nasdaq listing standards, a
majority of the members of a listed company&rsquo;s board of directors must qualify as &ldquo;independent,&rdquo; within one year of
listing, as affirmatively determined by the Board. The Board consults with the Company&rsquo;s counsel to ensure that the Board&rsquo;s
determinations are consistent with relevant securities and other laws and regulations regarding the definition of &ldquo;independent,&rdquo;
including those set forth in pertinent listing standards of Nasdaq, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board has determined that, with the exception
of Dr.&nbsp;Sarma and Mr.&nbsp;Wagenheim, each of our directors is an &ldquo;independent director,&rdquo; as defined under the rules&nbsp;of
Nasdaq. In making this determination, the Board considered the relationships that each such non-employee director has with the Company
and all other facts and circumstances that the Board deemed relevant in determining their independence, including the beneficial ownership
of our common stock by each non-employee director. Our independent directors generally meet in executive session at each regularly scheduled
Board meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD LEADERSHIP STRUCTURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Currently, our leadership structure separates
the offices of Chief Executive Officer, or CEO, and Chairman of the Board with Dr.&nbsp;Sarma serving as our CEO and Mr.&nbsp;Rapp serving
as Chairman of the Board. The Board believes that the current separation of the positions of CEO and Chairman of the Board reinforces
the independence of the Board from management, creates an environment that encourages objective oversight of management&rsquo;s performance
and enhances the effectiveness of the Board as a whole. While the Board does not have a formal policy with respect to the separation
of the offices of CEO and Chairman of the Board, the Board believes it is important to retain its flexibility to allocate the responsibilities
of the officers of Chairman of the Board and CEO in any way that is in the best interest of the Company at a given point in time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD COMMITTEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board has established the following Committees
to assist in discharging its duties: the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee
and the Science and Technology Committee. Each member of our Committees is an independent director as that term is defined by the SEC
and Nasdaq. The primary responsibilities of each of the Committees and the Committee memberships are provided below under the section
entitled &ldquo;Board Attendance, Committee Meetings and Committee Membership.&rdquo; Each of the Committees has the authority, as its
members deem appropriate, to engage legal counsel or other experts or consultants in order to assist the Committee in carrying out its
responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>RISK MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">One of the key functions of the Board is to oversee
our risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function
directly through the Board as a whole, as well as through various standing committees of the Board that address the risks inherent in
their respective areas of oversight. In particular, the Board is responsible for monitoring and assessing strategic risk exposure and
the Audit Committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has
taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management
is undertaken. In addition, the Board meets with certain members of our executive team, including the heads of our business, compliance
and regulatory functions, who discuss the risks and exposures involved in their respective areas of responsibility as well as any developments
that could impact our risk profile or other aspects of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">While the Board has the ultimate oversight responsibility
for the risk management process, its Committees oversee risk in certain specified areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The Audit Committee oversees management of financial reporting,
                                            approval of related-party transactions, compliance and litigation risks, including risks
                                            related to our insurance, information technology, cybersecurity, human resources, regulatory
                                            matters, internal controls, as well as the steps management has taken to monitor and control
                                            such exposures.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The Compensation Committee is responsible for overseeing the
                                            management of risks relating to our executive compensation policies, plans and arrangements
                                            and the extent to which those policies or practices increase or decrease risk for the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>The Nominating and Corporate Governance Committee manages risks
                                            associated with the independence of the Board, potential conflicts of interest that could
                                            impact independence and the effectiveness of the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EVALUATING BOARD EFFECTIVENESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Board, led by the Nominating and Corporate
Governance Committee, is committed to continuous improvement, and annual self-evaluations are an important tool for evaluating effectiveness.
It has established and conducts an annual self-evaluation of the Board, which is presented by the Chair of the Nominating and Corporate
Governance Committee to the Board for discussion. In addition, each committee conducts an annual self-assessment in a review process
similar to that used by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CODE OF CONDUCT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a written Code of Conduct that applies
to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions. The Code of Conduct covers fundamental ethical and compliance-related
principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection
and use of our property and information and compliance with legal and regulatory requirements. The Code of Conduct and any amendments
thereto, or any waivers of its requirements, are disclosed on our website at <U>www.immunome.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CORPORATE GOVERNANCE GUIDELINES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have a written set of corporate governance
guidelines that are designed to help ensure effective corporate governance of the Company. Our corporate governance guidelines cover
topics including, but not limited to, the size and composition of the Board, Board membership criteria, director qualifications and duties,
Board committees, director compensation and director communications with third parties. Succession planning for the Board is critical
to our success. Our goal is to achieve a Board that provides effective oversight of the Company through the appropriate balance of diversity
of perspectives, experience, expertise and skills. Our corporate governance guidelines are reviewed at least annually by the Nominating
and Corporate Governance Committee and amended by the Board when appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD INDEPENDENCE; COMMITTEE MEMBERSHIP AND MEETINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information regarding each director&rsquo;s
independence and roles on the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 34%; font-size: 10pt; font-weight: bold">Director</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">Independent</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">Board</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">AC</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">CC</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">NCGC</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; font-weight: bold; text-align: center">STC</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Richard A. Baron</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Yes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John L. LaMattina, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Yes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Michael Lefenfeld</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Yes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Mike Rapp</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Yes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">C</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Purnanand D. Sarma, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">No</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Philip Wagenheim</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">No</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Franklyn G. Prendergast, M.D., Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Yes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">M</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC = Audit Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">C = Chair</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CC = Compensation Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">M = Member</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NCGC = Nominating and Corporate Governance Committee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">STC = Science and Technology Committee</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During 2022, the Board held ten meetings, the
Compensation Committee held five meetings, the Audit Committee held seven meetings, the Nominating and Corporate Governance Committee
did not hold any meetings and the Science and Technology Committee held three meetings. The Board and each Committee also acted by written
consent on various matters throughout the year. Each director attended at least 75% of the aggregate of the number of meetings of the
Board and the number of meetings of each Committee on which the director served in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Audit Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Audit Committee assists the Board by providing
oversight of our financial management, independent auditor and financial reporting procedures, as well as such other matters as directed
by the Board or the Audit Committee Charter. Among other things, the Audit Committee&rsquo;s responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>selecting a firm to serve as the independent registered public
                                            accounting firm to audit our consolidated financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>helping to ensure the independence and performance of the independent
                                            registered public accounting firm;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>discussing the scope and results of the audit with the independent
                                            registered public accounting firm, and reviewing, with management and that firm, our interim
                                            and year-end operating results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>establishing procedures for employees to anonymously submit concerns
                                            about questionable accounting or audit matters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>considering the adequacy of our internal controls and internal
                                            audit function;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>monitoring compliance with the code of business and conduct and
                                            ethics for financial management;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing material related party transactions or those that require
                                            disclosure; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>approving or, as permitted, pre-approving all audit and non-audit
                                            services to be performed by the independent registered public accounting firm.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The members of the Audit Committee are Messrs.&nbsp;
Baron (Chair) and Lefenfeld and Dr.&nbsp;LaMattina. The Board has determined that all members of the Audit Committee are &ldquo;independent&rdquo;
and all members are financially literate under the applicable rules&nbsp;and regulations of the SEC and Nasdaq. The Board also has determined
that Mr.&nbsp;Baron qualifies as an &ldquo;audit committee financial expert&rdquo; within the meaning of SEC regulations. This designation
does not impose any duties, obligations or liabilities that are greater than those that are generally imposed on members of the Audit
Committee and the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Nominating and Corporate Governance Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
identifies qualified individuals for membership on the Board, recommends to the Board the director nominees to fill vacancies on the
Board and to stand for election at the next annual meeting of stockholders, develops and recommends to the Board a set of corporate governance
guidelines for the Board and provides oversight of the corporate governance affairs of the Board, as well as such other matters as directed
by the Board or the Nominating and Corporate Governance Charter. Among other things, the Nominating and Corporate Governance Committee&rsquo;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>identifying and recommending candidates for membership on the
                                            Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing and recommending our corporate governance guidelines
                                            and policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing proposed waivers of the code of conduct for directors
                                            and executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>overseeing the process of evaluating the performance of the Board;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>assisting the Board on corporate governance matters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Nominating and Corporate Governance Committee
is responsible for identifying individuals that the Nominating and Corporate Governance Committee believes are qualified to become Board
members, as described above in the section entitled &ldquo;Board Structure and Composition.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The members of the Nominating
and Corporate Governance Committee are Mr.&nbsp;Lefenfeld (Chair), Dr.&nbsp;LaMattina and Dr.&nbsp;Prendergast. The Board has determined
that all Nominating and Corporate Governance Committee members are independent under the listing standards of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Compensation Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Compensation Committee reviews the performance
and development of our management in achieving corporate goals and objectives and assures that our executive officers (including our
CEO) are compensated effectively in a manner consistent with our strategy, competitive practice and stockholder interests, as well as
such other matters as directed by the Board or the Compensation Committee Charter. Among other things, the Compensation Committee&rsquo;s
responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing and approving, or recommending that the Board approve,
                                            the compensation of our executive officers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing and recommending to the Board the compensation of our
                                            directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>administering our stock and equity incentive plans;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing and approving, or making recommendations to the Board
                                            with respect to, incentive compensation and equity plans; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing our overall compensation philosophy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Compensation Committee has the authority
to form and delegate authority to one or more subcommittees as it deems appropriate from time to time under the circumstances. The Compensation
Committee annually reviews the performance of each of the executive officers, including the CEO. In accordance with the authority granted
to it, the Committee then either determines the compensation of each executive officer or makes recommendations regarding such compensation
to the Board for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The members of the Compensation Committee are
Dr.&nbsp;LaMattina (Chair) and Messrs. Baron and Lefenfeld. The Board has determined that all Compensation Committee members are
independent under the listing standards of Nasdaq and are &ldquo;non-employee directors&rdquo; for purposes of Rule&nbsp;16b-3 under
the Securities Exchange Act of 1934, or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Science and Technology Committee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Science and Technology Committee reviews
and discusses the Company&rsquo;s research and development activities on behalf of the Board. Among other things, the Science and Technology
Committee&rsquo;s responsibilities include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing, evaluating and advising the Board regarding goals
                                            and objectives for the Company&rsquo;s research and development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>evaluating trends in regulatory regimes and relation to the Company&rsquo;s
                                            proposed regulatory path;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>reviewing and recommending strategic approaches to acquiring,
                                            divesting and maintaining technology positions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>identifying and discussing significant emerging trends and issues
                                            in science and technology and the competitive landscape, and recommending to the Board and
                                            management emerging technologies for the Company to pursue; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>consulting with management regarding the Company&rsquo;s intellectual
                                            property portfolio and the prosecution, maintenance and protection of the same in support
                                            of the Company&rsquo;s new product development and lifecycle management efforts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Science and Technology Committee has the
authority to form and delegate authority to one or more subcommittees as it deems appropriate from time to time under the circumstances.
The members of the Science and Technology Committee are Dr.&nbsp;Prendergast, Messrs. Baron and LaMattina. The Board has determined
that all Science and Technology Committee members are independent under the listing standards of Nasdaq and are &ldquo;non-employee directors&rdquo;
for purposes of Rule&nbsp;16b-3 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>BOARD DIVERSITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As presently constituted, the Board represents
a deliberate mix of members who have a deep understanding of our business as well as members who have different skill sets and points
of view. The matrix below summarizes the self-identified gender and demographic background statistics for our Board. Each of the categories
listed in the matrix below has the meaning given to it in Nasdaq Listing Rule&nbsp;5605(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Board Diversity Matrix (As of April&nbsp;20, 2023)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold"><B>Total Number of Directors</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center">7</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt; font-size: 10pt; vertical-align: top"></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Female</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Male</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Binary</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Did Not</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Disclose</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Gender</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Part&nbsp;I:&nbsp;&nbsp;Gender Identity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; font-size: 10pt">Directors</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">7</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: center">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Part&nbsp;II:&nbsp;&nbsp;Demographic Background</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">African American or Black</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Alaskan Native or Native American</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Asian</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Hispanic or Latino</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Native Hawaiian or Pacific Islander</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">White</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Two or More Races or Ethnicities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">LGBTQ+</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD COLSPAN="13" STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Did Not Disclose Demographic Background</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD COLSPAN="13" STYLE="font-size: 10pt; text-align: center">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FAMILY RELATIONSHIPS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There are no family relationships among any of
our directors or executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the fiscal year ended December&nbsp;31,
2022 and as of the date of this Proxy Statement, none of the members of the Compensation Committee was or is one of our officers or employees,
and none of our executive officers has served or serves on the compensation committee or board of any company that employed or employs
any member of the Compensation Committee or the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>STOCKHOLDER ENGAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Engaging with our stockholders is an integral
component of maintaining strong corporate governance practices. We make considerable effort to ensure that the views of stockholders
are heard by the Board or individual directors or executive officers, as applicable, and that appropriate responses are provided to stockholders
in a timely manner. We believe our responsiveness to stockholder communications to the Board has been excellent. Our goal is to continue
to communicate with our stockholders through various platforms, including via our website at <U>www.immunome.com</U>, in print and in
person at investor presentations or stockholder meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>STOCKHOLDER AND OTHER INTERESTED PARTY COMMUNICATIONS WITH THE
BOARD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stockholders and other interested parties who
wish to communicate with the non-management or independent members of the Board may do so by letters addressed to the attention of our
Chief Legal Officer. All such communications will be reviewed by the Chief Legal Officer and routed to the appropriate member(s)&nbsp;of
the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">The address for these communications is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Immunome,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">665 Stockton Drive, Suite&nbsp;300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Exton, Pennsylvania 19341</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Attn: Chief Legal Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_08"></A><B>DIRECTOR COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have designed and implemented our compensation
program for our non-employee directors to attract, motivate and retain individuals who are committed to our values and goals and who
have the expertise and experience that we need to achieve those goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On June&nbsp;15, 2022, the Board adopted a second
amended and restated non-employee director compensation policy, the material terms of which are summarized in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Compensation Elements&thinsp;&mdash;&thinsp;Non-Employee
Director Compensation Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Annual Board Member Retainer</I></B></FONT></TD>
    <TD STYLE="text-align: left; width: 70%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director Retainer</FONT></TD>
    <TD STYLE="text-align: left">$35,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman Additional Retainer</FONT></TD>
    <TD STYLE="text-align: left">$35,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
  <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Annual Committee Chair Retainer </I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>(inclusive
  of Annual Committee Member </I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Retainer
  below)</I></B></FONT></TD>
  <TD STYLE="text-align: left">&nbsp;&nbsp;&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit</FONT></TD>
    <TD STYLE="text-align: left">$15,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT></TD>
    <TD STYLE="text-align: left">$10,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance</FONT></TD>
    <TD STYLE="text-align: left">$8,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Science and Technology Committee</FONT></TD>
    <TD STYLE="text-align: left">$8,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Annual Committee Member Retainer</I></B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit</FONT></TD>
    <TD STYLE="text-align: left">$7,500</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT></TD>
    <TD STYLE="text-align: left">$5,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance</FONT></TD>
    <TD STYLE="text-align: left">$4,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Science and Technology Committee</FONT></TD>
    <TD STYLE="text-align: left">$4,000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Equity Awards</I></B></FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Equity Award</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each non-employee director received, upon his initial election or appointment to the Board, an option to purchase 13,000 shares of our common stock under the 2020 Equity Incentive Plan, or the 2020 Plan. Each of these options will vest in equal quarterly installments until all shares are vested on the third anniversary of the date of grant, subject to the non- employee director&rsquo;s continued service as a director.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual Equity Award</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the date of each annual meeting of stockholders, each non-employee director will receive an option to purchase 6,500 shares of our common stock under the 2020 Plan, or a pro-rated amount based on the full months such director has served as a director if such director has not served on the Board for 12 months prior to the applicable annual meeting of stockholders. Each of these options will vest in equal quarterly installments over the four quarters following the date of grant such that the option is fully vested on the first anniversary of the date of grant, subject to the non-employee director&rsquo; continued service as a director. For each non-employee director who remains in continuous service until immediately prior to the closing of a change in control (as defined in the 2020 Plan), the shares subject to his or her then outstanding initial grant and annual grants that were granted under the director compensation policy will become fully vested immediately prior to the closing of such change in control. All options issued to our non-employee directors under our director compensation policy will be issued at exercise prices equal to the fair market value of our common stock on the date of grant and will have a term of ten years.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The cash retainers above are payable in arrears
in four equal quarterly installments within 30 days after the end of each calendar quarter in which the service occurred, provided that
the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the Board. We also reimburse
our non-employee directors for reasonable travel and other expenses incurred in connection with attending meetings of the Board and any
committee of the Board on which they serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>DIRECTOR COMPENSATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table below sets forth information
for the fiscal year ended December&nbsp;31, 2022 regarding the compensation of our non-employee directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Fees Earned</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>or Paid in</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Awards</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cash ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">($)(1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 67%; font-size: 10pt; text-align: left">Mike Rapp (2)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">70,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">12,142</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">82,142</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Richard A. Baron</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">59,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">71,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">John L. LaMattina, Ph.D.&nbsp;&nbsp;(2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">72,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Michael Lefenfeld (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">67,642</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Franklyn G. Prendergast, M.D., Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Philip Wagenheim (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">47,142</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Amounts shown in this column do not reflect dollar amounts actually received
                                            by our directors. Instead, these amounts reflect the aggregate grant date fair value of each
                                            stock option granted in 2022 determined in accordance with the provisions of Financial Accounting
                                            Standards Board Accounting Standards, Codification Topic 718, Compensation&thinsp;&mdash;&thinsp;Stock
                                            Compensation, or FASB ASC Topic 718. The assumptions made in the calculation of these amounts
                                            are included in Note 12 of the Notes to the Consolidated Financial Statements included in
                                            our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Mr.&nbsp;Rapp, Lefenfeld and Wagenheim and Dr.&nbsp;LaMattina elected
                                            to receive their 2022 compensation in the form of a stock grant pursuant to the Company&rsquo;s
                                            second amended and restated non-employee director compensation policy in lieu of the Board
                                            and committee cash retainers owed for service on the Board in 2022. The number of shares
                                            issued to each such director is as follows: 17,500 shares of common stock were issued to
                                            Mr.&nbsp;Rapp; 13,875 shares of common stock were issued to Mr.&nbsp;Lefenfeld; 8,750 shares
                                            of common stock were issued to Mr.&nbsp;Wagenheim; and 15,125 shares of common stock were
                                            issued to Dr.&nbsp;LaMattina.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_09"></A><B>EQUITY COMPENSATION PLAN INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table provides certain aggregate
information with respect to all of the Company&rsquo;s equity compensation plans in effect as of December&nbsp;31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(a)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(b)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(c)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Plan category</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number
of securities to <BR>
be issued upon exercise <BR>
of outstanding options,<BR>
warrants and rights</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average<BR>
 exercise price of <BR>
outstanding options, <BR>
warrants and rights</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of securities <BR>
remaining available<BR>
 for future<BR>
issuance under</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>equity compensation<BR>
 plans (excluding <BR>
securities reflected in <BR>
column (a))</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 67%; font-size: 10pt; text-align: left">Equity compensation plans approved by security holders (1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">2,519,405</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">9.60</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">1,677,637</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Equity compensation plans not approved by security holders</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">2,519,405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">9.60</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,677,637</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Consists of the 2008 Equity Incentive Award Plan (&ldquo;2008 Plan&rdquo;),
                                            the 2018 Equity Incentive Plan (&ldquo;2018 Plan&rdquo;), the 2020 Equity Incentive Plan
                                            (&ldquo;2020 Plan&rdquo;) and the 2020 Employee Stock Purchase Plan (&ldquo;ESPP&rdquo;).
                                            The 2020 Plan supersedes the 2008 Plan and 2018 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Summary Description of the Company&rsquo;s 2018 Equity Incentive
Plan and 2008 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In June&nbsp;2018, the Company adopted the Immunome,&nbsp;Inc.
2018 Equity Incentive Plan, which was most recently amended and restated in March&nbsp;2020 (the &ldquo;2018 Plan&rdquo;). The terms
of the 2018 plan provide for the grant of incentive stock options, or ISOs, within the meaning of Section&nbsp;422 of the Code, nonstatutory
stock options, or NSOs, and other stock awards. Stock options granted under the 2018 Plan were required to have an exercise price not
less than 100% of the fair market value of the common stock on the date of grant (or at least 110% of the fair market value per share
of our common stock on the grant date in the case of ISOs granted to our stockholders that own more than 10% of the total combined voting
power of all our classes of stock). The 2018 Plan was terminated prior to our initial public offering. However, the 2018 Plan continues
to govern the terms and conditions of the outstanding awards previously granted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July&nbsp;2008, the Company adopted the Immunome,&nbsp;Inc.
2008 Equity Incentive Plan, which was most recently amended and restated in January&nbsp;2017 (the &ldquo;2008 Plan&rdquo;). The 2008
Plan was terminated upon the effectiveness of the 2018 Plan. However, the 2008 Plan continues to govern the terms and conditions of the
outstanding awards previously granted thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Summary Description of the Company&rsquo;s 2020 Equity Incentive
Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In September&nbsp;2020, the Company adopted the
Immunome,&nbsp;Inc. 2020 Equity Incentive Plan (the &ldquo;2020 Plan&rdquo;). The terms of the 2020 Plan provide for the grant ISOs,
within the meaning of Section&nbsp;422 of the Code, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards,
performance awards, and other forms of equity compensation. Stock options may be granted under the 2020 Plan with an exercise price not
less than 100% of the fair market value of the common stock on the date of grant. Stock options under the 2020 Plan may be granted with
terms of up to ten years. The total number of shares of the Company&rsquo;s common stock initially reserved for issuance under the 2020
Plan was equal to the sum of (i)&nbsp;1,701,723 shares plus (ii)&nbsp;the number of shares reserved, and remaining available for issuance,
under our 2018 Plan at the time our 2020 Plan became effective and (iii)&nbsp;the number of shares subject to stock options or other
stock awards granted under our 2018 Plan and 2008 Plan that would have otherwise returned to our 2018 Plan (such as upon the expiration
or termination of a stock award prior to vesting). Additionally, the number of shares of our common stock reserved for issuance under
our 2020 Plan will automatically increase on January&nbsp;1 of each calendar year, beginning on January&nbsp;1, 2021 and continuing through
and including January&nbsp;1, 2030, by 4% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding
calendar year, or a lesser number of shares determined by our board of directors. The maximum number of shares that may be issued upon
the exercise of ISOs under the 2020 Plan is 10,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Summary Description of the Company&rsquo;s 2020 Employee Stock
Purchase Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The 2020 Employee Stock Purchase Plan (&ldquo;ESPP&rdquo;)
was adopted by the Company in 2020 and allows eligible employees to purchase shares of the Company&rsquo;s common stock at a discount
through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP generally provides
for set offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair
market value of the Company&rsquo;s common stock on the first trading day of the offering period or on the first trading day of the offering
period. The ESPP will authorize the issuance of 125,000 shares of our common stock pursuant to purchase rights granted to our employees
or to employees of any of our designated affiliates. The number of shares of our common stock reserved for issuance will automatically
increase on January&nbsp;1 of each calendar year, from January&nbsp;1, 2021 through January&nbsp;1, 2030, by the lesser of (1)&nbsp;1%
of the total number of shares of our common stock outstanding on December&nbsp;31 of the preceding calendar year, and (2)&nbsp;1,000,000
shares; provided, that prior to the date of any such increase, our board of directors may determine that such increase will be less than
the amount set forth in clauses (1)&nbsp;and (2). The Company&rsquo;s executive officers are eligible to participate in the ESPP. No
employee may purchase shares under the ESPP at a rate in excess of $25,000 worth of our common stock, based on the fair market value
per share of our common stock at the beginning of an offering for each year such a purchase right is outstanding. Finally, no employee
will be eligible for the grant of any purchase rights under the ESPP if immediately after such rights are granted, such employee has
voting power over 5% or more of our outstanding common stock measured by vote or value pursuant to Section&nbsp;424(d)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_10"></A><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee works with our management
in order to negotiate appropriate fees with Ernst&nbsp;&amp; Young LLP (&ldquo;Ernst&nbsp;&amp; Young&rdquo;) and is ultimately responsible
for approving those fees. The following is a summary and description of fees for services provided by Ernst&nbsp;&amp; Young LLP in 2022
and Deloitte and Touche LLP (&ldquo;Deloitte&rdquo;), our former auditors, in 2022 and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Service</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2022</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2021</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Audit Fees (1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">446,861</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">(2)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">625,388</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Audit-Related Fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Tax Fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">All Other Fees (3)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">34,250</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Total</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">481,111</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">625,388</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>&ldquo;Audit fees&rdquo; represented the aggregate fees for professional
                                            services rendered for the audit of our financial statements and the review of our quarterly
                                            financial statements on Form&nbsp;10-Q that are customary under the standards of the Public
                                            Company Accounting Oversight Board (United States). Also included are the fees related to
                                            our Registration Statements on Form&nbsp;S-1, Form&nbsp;S-3 and Form&nbsp;S-8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>This amount consists of the aggregate audit fees for Deloitte and Ernst&nbsp;&amp;
                                            Young in 2022. Deloitte audit fees in 2022 were $201,861 and Ernst&nbsp;&amp; Young audit
                                            fees in 2022 were $245,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>&ldquo;All other fees&rdquo; in 2022 consists of fees paid
                                            to Deloitte for professional services rendered for the transition of audit services from
                                            Deloitte to Ernst&nbsp;&amp; Young in 2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AUDIT COMMITTEE PRE-APPROVAL POLICIES AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee is responsible for appointing,
retaining, setting compensation for, and evaluating and overseeing the work of the independent registered public accounting firm. The
Audit Committee Charter establishes a policy that all audit and permissible non-audit services provided by the independent registered
public accounting firm will be pre-approved by the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All such audit and permissible non-audit services
were pre-approved in accordance with this policy during the fiscal year ended December&nbsp;31, 2022. These services may include audit
services, audit-related services, tax services and other services. The Audit Committee considers whether the provision of each non-audit
service is compatible with maintaining the independence of our independent registered public accounting firm. The responsibility to pre-
approve audit and non-audit services may be delegated by the Audit Committee to one or more members of the Audit Committee; provided
that any decisions made by such member or members must be presented to the full Audit Committee at its next scheduled meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_11"></A><B>AUDIT COMMITTEE REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The primary purpose of the Audit Committee is
to assist the Board in its general oversight of the Company&rsquo;s financial reporting process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Management is primarily responsible for the preparation,
presentation, and integrity of the Company&rsquo;s consolidated financial statements, accounting and financial reporting principles,
internal controls and procedures designed to ensure compliance with accounting standards, applicable laws and regulations. The Company&rsquo;s
independent registered public accounting firm for the fiscal year ended December&nbsp;31, 2022, Ernst&nbsp;&amp; Young, is responsible
for performing an independent audit of the consolidated financial statements and expressing an opinion on the conformity of those consolidated
financial statements with generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee has reviewed and discussed
the audited consolidated financial statements contained in the Company&rsquo;s 2022 Annual Report with management and Ernst&nbsp;&amp;
Young. The Audit Committee has discussed with Ernst&nbsp;&amp; Young the matters required to be discussed by the applicable requirements
of the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) and the SEC. In addition, Ernst&nbsp;&amp; Young has provided
the Audit Committee with the written disclosures and the letter required by the applicable requirements of the PCAOB regarding Ernst&nbsp;&amp;
Young&rsquo;s communications with the Audit Committee concerning independence, and the Audit Committee has discussed with Ernst&nbsp;&amp;
Young its independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Audit Committee also considered whether the
independent registered public accounting firm&rsquo;s provision of non-audit services to the Company is compatible with the auditor&rsquo;s
independence. The Audit Committee has concluded that the independent registered public accounting firm is independent from the Company
and its management. Based on the considerations and discussions referred to above, the Audit Committee recommended to the Board that
the audited consolidated financial statements be included in the Company&rsquo;s 2022 Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: italic 10pt Times New Roman, Times, Serif">Members of the Immunome,&nbsp;Inc. Audit Committee</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Richard Baron (Chair)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">John LaMattina, Ph.D.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Michael Lefenfeld</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_12"></A><B>EXECUTIVE OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth the name, age
and position of each of our executive officers as of the date of this Proxy Statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1pt solid"><B>Name</B></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: black 1pt solid; text-align: center"><B>Position</B></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"><B>Age</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Purnanand D. Sarma, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>President, Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Corleen M. Roche</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">57</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Sandra G. Stoneman</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Legal Officer and General Counsel</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">50</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dennis H. Giesing, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Development Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">70</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Matthew K. Robinson, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Technology Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">54</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Purnanand D. Sarma</I>&thinsp;&mdash;&thinsp;For
biographical information for <I>Purnanand D. Sarma</I>, see &ldquo;Information Regarding Our Directors &thinsp;&mdash;&thinsp;Continuing
Directors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Corleen M. Roche </I>has served as our Chief
Financial Officer since April&nbsp;2021. Ms.&nbsp;Roche served as the Chief Financial Officer, U.S. of Biogen Inc. from 2019 until April&nbsp;2021,
and served as the Chief Financial Officer U.S. Biopharma for Sandoz, a division of Novartis, from 2015 to 2019. Ms.&nbsp;Roche began
her career at PricewaterhouseCoopers and has served as Chief Financial Officer at other companies including IoGenetics,&nbsp;Inc. and
the Global Vaccines business unit at Wyeth Pharmaceuticals. Ms.&nbsp;Roche received her B.A. in Accountancy from Villanova University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Sandra G. Stoneman </I>has served as our Chief
Legal Officer and General Counsel since October&nbsp;2020. In this role, Ms.&nbsp;Stoneman serves as Corporate Secretary to the Board
and leads the legal, corporate governance, intellectual property and human resources functions of the Company. Prior to her role at Immunome,
Ms.&nbsp;Stoneman was a corporate partner at the law firm of Duane Morris LLP from 2002 to 2020, where she was co-lead of the firm&rsquo;s
Life Sciences interdisciplinary practice group and was a co-chair of the firm&rsquo;s emerging companies division and was an associate
at the Dechert law firm from 1997 to 2002. Ms.&nbsp;Stoneman is a 1997 graduate of Temple University School of Law, where she was an
articles editor for the Temple Law Review, and received her B.A. in Sociology and Spanish from the State University of New York at Binghamton.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Dennis H Giesing, Ph.D. </I>has served as
our Chief Development Officer since March&nbsp;2021. Prior to joining us, Dr.&nbsp;Giesing was with Johnson&nbsp;&amp; Johnson from 2019
to 2021. Previously he served as Chief Scientific Officer at Taris Biomedical for nearly 12 years, heading the development of innovative
treatments for bladder diseases including overactive bladder and bladder cancer, leading to its acquisition by Johnson&nbsp;&amp; Johnson
in 2019. Prior to TARIS, Dr.&nbsp;Giesing was Head of Pharmaceutical Development at Medivector, leading the development of treatments
to combat infectious diseases, including pandemic influenza and hemorrhagic viruses. Previously to that, he served as Senior Vice President
of Lead Optimization at Aventis Pharmaceuticals, advancing novel therapies into late-stage clinical development. Dr.&nbsp;Giesing received
his Ph.D. in Biochemical Pharmacology from the University of Missouri&ndash; Kansas City.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Matthew K. Robinson, Ph.D. </I>has served
as our Chief Technology Officer since June&nbsp;2022. Dr.&nbsp;Robinson has been with the Company since March&nbsp;2016, most recently
serving as Senior Vice President of Research&nbsp;&amp; Development until June&nbsp;2022. Prior to joining the Company, Dr.&nbsp;Robinson
was a faculty member in the Developmental Therapeutics Program at Fox Chase Cancer Center in Philadelphia from 2002 through 2016, focusing
on the development of antibody-based molecules for the detection and treatment of cancer. Dr.&nbsp;Robinson earned a B.S. degree in biology
from Allegheny College as well as a M.S. in biochemistry and Ph.D. in genetics from the University of Rochester School of Medicine&nbsp;&amp;
Dentistry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_13"></A><B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This section discusses the material components
of the executive compensation program for our named executive officers. For 2022, our named executive officers are Dr.&nbsp;Sarma, our
President and Chief Executive Officer, Corleen M Roche, our Chief Financial Officer, and Dennis H. Giesing, Ph.D., our Chief Development
Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SUMMARY COMPENSATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth information concerning
the compensation of our named executive officers during the fiscal years ended December&nbsp;31, 2021 and 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Salary</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Bonus</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Option <BR>
Awards</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Non-Equity
<BR>
Incentive Plan<BR>
Compensation</B></P></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">All Other<BR>
 Compensation</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name and Principal Position</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">($)(1)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">($)(2)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">($)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; font-size: 10pt; font-weight: bold; text-align: left">Purnanand D. Sarma, Ph.D. (3)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: right">2022</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">540,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">221,333</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">216,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 7%; font-size: 10pt; text-align: right">12,976</TD><TD STYLE="width: 1%; font-size: 10pt">(4)</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right">990,309</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">President, Chief Executive Officer and Director</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">540,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,371,370</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">189,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">11,914</TD><TD STYLE="font-size: 10pt"> (4)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,112,284</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Corleen M. Roche (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">412,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">40,000</TD><TD STYLE="font-size: 10pt; text-align: left">(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">127,226</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">164,800</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">16,253</TD><TD STYLE="font-size: 10pt"> (7)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">760,279</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Chief Financial Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">282,051</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,670,236</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">89,775</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">3,905</TD><TD STYLE="font-size: 10pt"> (7)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,095,967</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Dennis H. Giesing, Ph.D.&nbsp;&nbsp;(8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2022</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">385,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">(9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">108,930</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">115,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">6,193</TD><TD STYLE="font-size: 10pt"> (10)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">715,623</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Chief Development Officer</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2021</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">306,971</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">(9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,055,236</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84,318</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">2,969</TD><TD STYLE="font-size: 10pt"> (10)</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,499,494</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(1)</TD><TD>Amounts in this column represent the aggregate grant date fair value
                                            of stock awards for the year indicated in accordance with FASB ASC Topic 718. The assumptions
                                            made in the calculation of these amounts are included in Note 12 of the Notes to the Financial
                                            Statements included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
                                            2022.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(2)</TD><TD>This column reflects the amount of performance-based cash incentive compensation
                                            earned by our named executive officers for 2021 and 2022. For more information, see below
                                            under &ldquo;&mdash;Non-Equity Incentive Plan Compensation.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(3)</TD><TD>Dr.&nbsp;Sarma was a member of Board in 2021 and 2022 but did not receive
                                            additional compensation in his capacity as a director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(4)</TD><TD>For 2022, this amount consists of $7,290 in matching contributions to
                                            Dr.&nbsp;Sarma&rsquo;s 401(k)&nbsp;plan and $5,686 for use of a corporate apartment. For
                                            2021, this amount consists of $7,516 in matching contributions to Dr.&nbsp;Sarma&rsquo;s
                                            401(k)&nbsp;plan and $4,398 for use of a corporate apartment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(5)</TD><TD>Ms.&nbsp;Roche&rsquo;s employment commenced on April&nbsp;19, 2021. The
                                            salary reported for 2021 reflects the pro rata portion of Ms.&nbsp;Roche&rsquo;s annual salary
                                            of $400,000 from commencement of her employment through December&nbsp;31, 2021. Ms.&nbsp;Roche&rsquo;s
                                            Non-Equity Incentive Plan Compensation was pro-rated commensurate with the portion of 2021
                                            during which she was employed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(6)</TD><TD>In 2022, Ms.&nbsp;Roche was awarded a cash retention bonus of $40,000
                                            in accordance with her employment agreement. In 2021, Ms.&nbsp;Roche was awarded cash retention
                                            bonuses of $50,000 in the aggregate in accordance with her employment agreement. For more
                                            information, see below under &ldquo;&mdash;Cash Bonus Compensation.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(7)</TD><TD>For 2022, this amount consists of $16,253 in matching contributions to
                                            Ms.&nbsp;Roche&rsquo;s 401(k)&nbsp;plan. For 2021, this amount consists of $3,905 in matching
                                            contributions to Ms.&nbsp;Roche&rsquo;s 401(k)&nbsp;plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(8)</TD><TD>Dr.&nbsp;Giesing&rsquo;s employment commenced on March&nbsp;23, 2021.
                                            The salary reported for 2021 reflects the pro rata portion of Dr.&nbsp;Giesing&rsquo;s annual
                                            salary of $375,000 from commencement of his employment through December&nbsp;31, 2021. Dr.&nbsp;Giesing&rsquo;s
                                            Non-Equity Incentive Plan Compensation was pro-rated commensurate with the portion of 2021
                                            during which he was employed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(9)</TD><TD>In 2022, Dr.&nbsp;Giesing was awarded a cash retention bonus of $100,000
                                            in accordance with his employment agreement. In 2021, Dr.&nbsp;Giesing was awarded a signing
                                            bonus of $50,000 in accordance with his employment agreement. For more information, see below
                                            under &ldquo;&mdash;Cash Bonus Compensation.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(10)&nbsp;</TD><TD>For 2022, this amount consists of $6,193 in matching contributions to
                                            Dr.&nbsp;Giesing&rsquo;s 401(k)&nbsp;plan. For 2021, this amount consists of $2,969 in matching
                                            contributions to Dr.&nbsp;Giesing&rsquo;s 401(k)&nbsp;plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Elements of Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In 2022, the Compensation Committee engaged Aon
plc/Radford, a compensation consultant, to assist the Compensation Committee in reviewing and adjusting our compensation strategy and
practices, including the various elements of compensation noted below. As part of this engagement, the compensation consultant recommended
updates to our list of comparative group of companies and performed an analysis of competitive performance and compensation levels among
that group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is a discussion of each of the
primary elements of compensation that our named executive officers are eligible to receive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Base Salaries</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Annual base salaries are intended to provide
a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities,
and are typically reviewed on an annual basis. Base salaries for our named executive officers have generally been set at levels deemed
necessary to attract and retain individuals with superior talent and were set based on feedback from our compensation consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth the annual base
salaries for each of our named executive officers for 2022 and 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">NAME</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2021
BASE<BR>
SALARY ($)</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2022
BASE<BR>
SALARY ($)</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Purnanand D. Sarma, Ph.D. <BR><I>President, Chief
    Executive Officer and Director</I></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">540,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">540,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Corleen M. Roche <BR><I>Chief Financial Officer</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">400,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">412,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dennis H. Giesing, Ph.D. (2) <BR><I>Chief Development Officer</I></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">375,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">385,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Cash Bonus Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">From time to time the Board or Compensation Committee
may approve discretionary cash bonuses for our named executive officers based on individual performance, Company performance or as otherwise
determined appropriate. In 2021, (i)&nbsp;Ms.&nbsp;Roche, in accordance with her employment agreement, received a retention bonus of
$25,000 on the 90-day anniversary of her employment start date and an additional retention bonus of $25,000 upon the 180-day anniversary
of her employment start date and (ii)&nbsp;Dr.&nbsp;Giesing earned a $50,000 signing bonus upon execution of the employment agreement.
In 2022, (i)&nbsp;Ms.&nbsp;Roche, in accordance with her employment agreement, received a $50,000 retention bonus on the 365-day anniversary
of her employment start date and (ii)&nbsp;Dr.&nbsp;Giesing, in accordance with his employment agreement, received a $100,000 retention
bonus on the 365-day anniversary of his employment start date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Non-Equity Incentive Plan Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We seek to motivate and reward our executives
for achievements relative to corporate and individual goals and expectations for each fiscal year. Drs.&nbsp;Sarma and Giesing and Ms.&nbsp;Roche
are eligible to receive an annual performance bonus based on the achievement of individual and Company-wide performance goals as determined
by the Compensation Committee and/or the Board, pursuant to the terms of their employment agreements and the Company&rsquo;s bonus policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For 2021 and 2022, the annual performance goals
included research, development and corporate objectives. Each of Drs.&nbsp;Sarma and Giesing and Ms.&nbsp;Roche were assigned a target
bonus expressed as a percentage of their respective base salary. The target bonus amounts for Drs.&nbsp; Sarma and Giesing and Ms.&nbsp;Roche
for 2021 and 2022 were set pursuant to their employment agreements at 50%, 40% and 40%, respectively. Dr.&nbsp;Sarma&rsquo;s bonus is
based entirely on achievement of corporate goals and Dr.&nbsp;Giesing&rsquo;s and Ms.&nbsp;Roche&rsquo;s bonuses are based 75% on achievement
of corporate goals and 25% on achievement of individual goals. Accordingly, for 2022, the Board approved annual performance bonuses in
the respective amounts of $216,000 for Dr.&nbsp;Sarma, $115,500 for Dr.&nbsp;Giesing and $164,800 for Ms.&nbsp;Roche, based on 89% achievement
of corporate goals as well as, for Dr.&nbsp;Giesing and Ms.&nbsp;Roche, their achievement of individual goals. For 2021, the Board approved
annual performance bonuses in the respective amounts of $189,000 for Dr.&nbsp;Sarma, $84,318 for Dr.&nbsp;Giesing and $89,775 for Ms.&nbsp;Roche,
based on a 70% achievement of corporate goals as well as, for Dr.&nbsp;Giesing and Ms.&nbsp;Roche, their achievement of individual goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Equity-Based
Incentive Awards</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We believe that equity grants provide our executives
with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our
stockholders. In addition, we believe that equity grants with a time-based vesting feature promote executive retention because this feature
incentivizes our executive officers to remain in our employment during the vesting period. Accordingly, the Board periodically reviews
the equity incentive compensation of our named executive officers and from time to time may grant equity incentive awards to them in
the form of stock options. We typically grant stock option awards at the start of employment to each executive and our other employees.
We also maintain a practice of granting additional equity on an annual basis based on individual and Company performance, and we retain
discretion to provide additional targeted grants in certain circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We award stock options on the date the Board
approves the grant. We set the option exercise price based on the fair market value of our common stock on the date of grant. Time vested
stock option grants to our executives typically vest over four years with a one-year cliff and monthly thereafter over the next three
years for initial grants and monthly over four years for follow-on grants. All stock options have a term of ten years from the grant
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Other Benefits</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We currently provide broad-based welfare benefits
that are available to all employees, including our named executive officers, including health, dental, life, vision and disability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, we maintain a 401(k)&nbsp;plan intended
to qualify as a tax-qualified plan under Section&nbsp;401 of the Internal Revenue Code of 1986, as amended, or the Code, with the 401(k)&nbsp;plan&rsquo;s
related trust intended to be tax exempt under Section&nbsp;501(a)&nbsp;of the Code. The 401(k)&nbsp;plan provides that each participant
may contribute up to the lesser of 92% of their compensation or the statutory limit, which was $20,500 for calendar year 2022. We match
100% of employee contributions up to 3% of their eligible compensation. Employees&rsquo; pre-tax contributions are allocated to each
participant&rsquo;s individual account and are then invested in selected investment alternatives according to the participant&rsquo;s
directions. Employees are immediately and fully vested in their contributions. As a tax-qualified retirement plan, contributions to the
401(k)&nbsp;plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k)&nbsp;plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, our eligible employees (including
our named executive officers), may participate in the Company&rsquo;s 2020 Employee Stock Purchase Plan, or 2020 ESPP, as determined
by the Board. The 2020 ESPP provides eligible employees with the opportunity to acquire our common stock through periodic payroll deductions,
at a discounted price. The 2020 ESPP is structured as a qualified employee stock purchase plan under Section&nbsp;423 of the Code. We
do not maintain any defined benefit pension plans or nonqualified deferred compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PLEDGING AND HEDGING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the terms of our Insider Trading Policy,
our executive officers and directors are prohibited from: trading in call or put options involving our securities and other derivative
securities; engaging in short sales of our securities; holding our securities in a margin account, all forms of hedging or monetizing
our transactions, such as zero-cost collars and forward sale contracts and pledging company securities to secure margin or other loans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth information regarding
the number of shares of common stock underlying outstanding plan awards held by each of our named executive officers as of December&nbsp;31,
2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="15" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Option Awards</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Name</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Grant Date</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underlying</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unexercised</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options (#)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercisable</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Underlying</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unexercised</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options (#)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Unexercisable</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exercise</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Price ($)</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Expiration</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date</B></P></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; font-size: 10pt; font-weight: bold; text-align: left">Purnanand D. Sarma, Ph.D.</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">3/03/2020</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">294,402</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">34,233</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">(1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.54</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 10%; font-size: 10pt; text-align: center">3/02/2030</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">8/04/2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">63,140</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">28,700</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.40</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">8/03/2030</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">8/04/2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">51,205</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(3)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.40</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">8/03/2030</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/28/2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,952</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">56,402</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(4)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20.92</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/27/2031</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/16/2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">121,000 </TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/16/2032</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Corleen M. Roche</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">4/19/2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">52,083</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">72,917</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27.53</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">4/18/2031</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/28/2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,574</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,035</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20.92</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/27/2031</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6/16/2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(8)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6/16/2032</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6/16/2022</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">(9)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.42</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6/16/2032</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Dennis H. Giesing, Ph.D.</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">11/3/2020</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,812</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,688</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(10)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">11.38</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">11/2/2030</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3/25/2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">54,687</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,313</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31.83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">3/24/2031</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/28/2021</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,574</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10,035</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(12)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20.92</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5/27/2031</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/16/2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,000</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(13)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/16/2032</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">6/16/2022</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">30,000</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">(14)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.42</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">6/16/2032 <BR></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(1)</TD><TD>On March&nbsp;3, 2020, Dr.&nbsp;Sarma was granted an option to purchase
                                            328,635 shares of common stock, which vests in equal monthly installments over forty-eight
                                            months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(2)</TD><TD>On August&nbsp;4, 2020, Dr.&nbsp;Sarma was granted an option to purchase
                                            91,840 shares of common stock, which vests in equal monthly installments over forty-eight
                                            months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(3)</TD><TD>On August&nbsp;4, 2020, Dr.&nbsp;Sarma was granted an option to purchase
                                            51,205 shares of common stock, which vests in full on the four-year anniversary of the grant
                                            date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(4)</TD><TD>On May&nbsp;28, 2021, Dr.&nbsp;Sarma was granted an option to purchase
                                            93,354 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(5)</TD><TD>On June&nbsp;16, 2022, Dr.&nbsp;Sarma was granted an option to purchase
                                            121,000 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(6)</TD><TD>On April&nbsp;19, 2021, Ms.&nbsp;Roche was granted an option to purchase
                                            125,000 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(7)</TD><TD>On May&nbsp;28, 2021, Ms.&nbsp;Roche was granted an option to purchase
                                            16,609 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(8)</TD><TD>On June&nbsp;16, 2022, Ms.&nbsp;Roche was granted an option to purchase
                                            40,000 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(9)</TD><TD>On June&nbsp;16, 2022, Ms.&nbsp;Roche was granted an option to purchase
                                            30,000 shares of common stock, with 50% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 50% vesting on the two-year anniversary of the grant
                                            date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(10)</TD><TD>On November&nbsp;3, 2020, Dr.&nbsp;Giesing was granted an option to
                                            purchase 4,500 shares of common stock which vests in equal monthly installments over forty-eight
                                            months. This option was granted in consideration of Dr.&nbsp;Giesing&rsquo;s consulting services
                                            to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(11)</TD><TD>On March&nbsp;25, 2021, Dr.&nbsp;Giesing was granted an option to purchase
                                            125,000 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(12)</TD><TD>On May&nbsp;28, 2021, Dr.&nbsp;Giesing was granted an option to purchase
                                            16,609 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(13)</TD><TD>On June&nbsp;16, 2022, Dr.&nbsp;Giesing was granted an option to purchase
                                            30,000 shares of common stock, with 25% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 75% vesting in equal monthly installments over the following
                                            36-month period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(14)</TD><TD>On June&nbsp;16, 2022, Ms.&nbsp;Roche was granted an option to purchase
                                            30,000 shares of common stock, with 50% of the shares vesting on the one-year anniversary
                                            of the grant date and the remaining 50% vesting on the two-year anniversary of the grant
                                            date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EMPLOYMENT ARRANGEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into agreements with each of
our named executive officers. Below are written descriptions of our employment agreements with Dr.&nbsp;Sarma, Ms.&nbsp;Roche and Dr.&nbsp;Giesing.
Each of our named executive officers&rsquo; service may be terminated at any time by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Purnanand D. Sarma, Ph.D. </I>We entered into
an amended and restated employment agreement dated September&nbsp;24, 2020, which took effect upon our initial public offering, setting
forth the terms of Dr.&nbsp;Sarma&rsquo;s employment as President and Chief Executive Officer. The employment agreement superseded the
employment offer with the Company dated May&nbsp;30, 2019, as amended August&nbsp;5, 2020. Pursuant to the employment agreement, Dr.&nbsp;Sarma
is entitled to an initial annual base salary of $540,000 and an annual target bonus of up to 50% of his base. Receipt of an annual bonus
is subject to achievement of Company-wide annual performance goals, as set by the Company and confirmed by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of Dr.&nbsp;Sarma&rsquo;s
employment agreement, until the earlier of the date he relocates to Exton, Pennsylvania or we open a location in the Boston, Massachusetts
area, Dr.&nbsp;Sarma is entitled to reimbursement for reasonable costs incurred in commuting between his home in Massachusetts and our
offices in Pennsylvania, including out-of-pocket costs for coach airfare, hotel, temporary accommodations and car rental or other transportation
costs. Dr.&nbsp;Sarma has agreed to relocate to within a 45-mile radius of the Company&rsquo;s headquarters within a reasonable period
of time following our request (provided that such relocation shall not be required if we establish an additional location in the Boston,
Massachusetts area), and we have agreed to reimburse Dr.&nbsp;Sarma or pay directly any reasonable out-of-pocket relocation costs for
Dr.&nbsp;Sarma and his immediate family and reimburse. Dr.&nbsp;Sarma for the reasonable commission paid to his realtor on the sale of
his home in Massachusetts, in a combined maximum amount of $200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Dr.&nbsp;Sarma&rsquo;s employment agreement,
if he resigns for &ldquo;good reason&rdquo; or we terminate Dr.&nbsp;Sarma&rsquo;s employment without &ldquo;cause&rdquo; (each as defined
in the employment agreement, and excluding a termination on account of Dr.&nbsp;Sarma&rsquo;s death or disability), and if such termination
or resignation is not in connection with a &ldquo;change in control&rdquo; (as defined in the Company&rsquo;s 2020 Equity Incentive Plan,
as may be amended), then Dr.&nbsp;Sarma will be eligible to receive (i)&nbsp;continued payment of his base salary for 12 months following
the termination (less applicable tax withholdings), (ii)&nbsp;COBRA premium coverage for up to 12 months, (iii)&nbsp;a prorated bonus
for the year of termination paid in a lump sum, and (iv)&nbsp;24 months&rsquo; of accelerated vesting of Dr.&nbsp;Sarma&rsquo;s unvested
time-based equity awards. As a condition to receiving the foregoing severance benefits, Dr.&nbsp;Sarma must sign and not revoke a general
release contained in a separation agreement in the form presented by the Company, return all Company property and confidential information
in his possession, comply with his post-termination obligations, and resign from any positions held with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If Dr.&nbsp;Sarma resigns for good reason or
we terminate his employment without cause (excluding a termination on account of Dr.&nbsp;Sarma&rsquo;s death or disability), and if
such termination or resignation occurs within three months prior to or within 12 months following the effective date of a change in control,
then Dr.&nbsp;Sarma will be eligible to receive (i)&nbsp;continued payment of his base salary for 18 months following the termination
(less applicable tax withholdings), (ii)&nbsp;COBRA premium coverage for up to 18 months, (iii)&nbsp;150% of his target bonus for the
calendar year of termination paid in a lump sum, and (iv)&nbsp;full acceleration of the vesting of Dr.&nbsp;Sarma&rsquo;s unvested equity
awards. As a condition to receiving the foregoing severance benefits, Dr.&nbsp;Sarma must sign and not revoke a general release contained
in a separation agreement in the form presented by the Company, return all Company property and confidential information in his possession,
comply with his post-termination obligations, and resign from any positions held with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If payments and benefits payable to Dr.&nbsp;Sarma
in connection with a change in control are subject to Section&nbsp;4999 of the Code, then such payments and benefits will be reduced
to an amount determined by us in good faith to be the maximum amount that may be provided to Dr.&nbsp;Sarma so that the Section&nbsp;4999
excise tax does not apply or Dr.&nbsp;Sarma receives the greater economic benefit notwithstanding that some or all of the payment or
benefit may be subject to excise tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Corleen M. Roche</I>. We entered into an employment
offer letter agreement dated March&nbsp;17, 2021, with Ms.&nbsp;Roche setting forth the terms of Ms.&nbsp;Roche&rsquo;s employment as
Chief Financial Officer beginning on April&nbsp;19, 2021. Pursuant to the employment agreement, Ms.&nbsp;Roche is entitled to an initial
annual base salary of $400,000, subject to annual review by the Board. Ms.&nbsp;Roche&rsquo;s employment agreement also provides for
an annual target bonus of up to 40% of her base salary, pro-rated for her first year of employment. Receipt of an annual bonus is subject
to achievement of individual and company-wide annual performance goals. Ms.&nbsp;Roche is also entitled to the following one-time retention
bonuses: (i)&nbsp;a retention bonus of $25,000, contingent upon her remaining employed by the Company for 90 consecutive days; (ii)&nbsp;an
additional retention bonus of $25,000, contingent upon her remaining employed by the Company for 180 consecutive days; and (iii)&nbsp;an
additional retention bonus of $40,000, contingent upon her remaining employed by the Company for 365 consecutive days. To be eligible
to receive, and to be deemed to have earned, each retention bonus (in addition to the other criteria specified above) Ms.&nbsp;Roche
must remain continuously employed by the Company through the scheduled date of the bonus payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Ms.&nbsp;Roche&rsquo;s employment agreement,
if she resigns for &ldquo;good reason&rdquo; or we terminate Ms.&nbsp;Roche&rsquo;s employment without &ldquo;cause&rdquo; (each as defined
in the employment agreement, and excluding a termination on account of Ms.&nbsp;Roche&rsquo;s death or disability), and if such termination
or resignation occurs at or within 12 months following the effective date of a change in control, then Ms.&nbsp;Roche will be eligible
to receive (i)&nbsp;continued payment of her base salary for 12 months following the termination (less applicable tax withholdings),
(ii)&nbsp;COBRA premium coverage for up to 12 months, (iii)&nbsp;a lump sum cash payment in an amount equal to one times the target bonus
for the year in which the termination occurs and the retention payment if not then paid, and (iv)&nbsp;full acceleration of the vesting
of Ms.&nbsp;Roche&rsquo;s unvested equity awards. As a condition to receiving the foregoing severance benefits, Ms.&nbsp;Roche must sign
and not revoke a general release contained in a separation agreement in the form presented by the Company, return all Company property
and confidential information in her possession, comply with her post-termination obligations, and resign from any positions held with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Ms.&nbsp;Roche&rsquo;s employment agreement,
if we terminate Ms.&nbsp;Roche&rsquo;s employment without cause (other than in circumstances specified in the prior paragraph), then
Ms.&nbsp;Roche will be eligible to receive continued payment of her base salary for nine months following the termination (less applicable
tax withholdings). As a condition to receiving the foregoing severance benefits, Ms.&nbsp;Roche must sign and not revoke a general release
contained in a separation agreement in the form presented by the Company, return all Company property and confidential information in
her possession, comply with her post-termination obligations, and resign from any positions held with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If payments and benefits payable to Ms.&nbsp;Roche
in connection with a change in control are subject to Section&nbsp;4999 of the Code, then such payments and benefits will be reduced
to an amount determined by us in good faith to be the maximum amount that may be provided to Ms.&nbsp;Roche so that the Section&nbsp;4999
excise tax does not apply or Ms.&nbsp;Roche receives the greater economic benefit notwithstanding that some or all of the payment or
benefit may be subject to excise tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the employment agreement,
Ms.&nbsp;Roche was awarded a stock option to purchase 125,000 shares of our common stock. The option vest over four years, with 25% of
the shares subject to the option vesting on the first anniversary of the start date and the remaining 75% vesting in substantially equal
monthly installments over the next 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>Dennis H. Giesing, Ph.D. </I>We entered into
an employment offer letter agreement dated March&nbsp;4, 2021, with Dr.&nbsp;Giesing setting forth the terms of Dr.&nbsp;Giesing&rsquo;s
employment as Chief Development Officer beginning on April&nbsp;7, 2021. Pursuant to the employment agreement, Dr.&nbsp;Giesing is entitled
to an initial annual base salary of $375,000, subject to annual review by the Board. Dr.&nbsp;Giesing&rsquo;s employment agreement also
provides for an annual target bonus of up to 40% of his base salary, pro-rated for his first year of employment. Receipt of an annual
bonus is subject to achievement of individual and company-wide annual performance goals. Dr.&nbsp;Giesing is also entitled to a $50,000
signing bonus and a one-time retention bonus of $100,000, contingent upon his remaining employed by the Company for 365 consecutive days.
To be eligible to receive, and to be deemed to have earned, the retention bonus (in addition to the other criteria specified above) Dr.&nbsp;Giesing
must remain continuously employed by the Company through the scheduled date of the bonus payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Dr.&nbsp;Giesing&rsquo;s employment agreement,
if he resigns for &ldquo;good reason&rdquo; or we terminate Dr.&nbsp;Giesing&rsquo;s employment without &ldquo;cause,&rdquo; (each as
defined in the employment agreement and excluding a termination on account of Dr.&nbsp;Giesing&rsquo;s death or disability), and if such
termination or resignation occurs at or within 12 months following the effective date of a change in control, then Dr.&nbsp;Giesing will
be eligible to receive (i)&nbsp;continued payment of his base salary for 12 months following the termination (less applicable tax withholdings),
(ii)&nbsp;COBRA premium coverage for up to 12 months, (iii)&nbsp;a lump sum cash payment in an amount equal to one times the target bonus
for the year in which the termination occurs and the retention payment if not then paid, and (iv)&nbsp;full acceleration of the vesting
of Dr.&nbsp;Giesing&rsquo;s unvested equity awards. As a condition to receiving the foregoing severance benefits, Dr.&nbsp;Giesing must
sign and not revoke a general release contained in a separation agreement in the form presented by the Company, return all Company property
and confidential information in his possession, comply with his post-termination obligations, and resign from any positions held with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under Dr.&nbsp;Giesing&rsquo;s employment agreement,
if we terminate Dr.&nbsp;Giesing&rsquo;s employment without cause (other than in circumstances specified in the prior paragraph), then
Dr.&nbsp;Giesing will be eligible to receive continued payment of his base salary for nine months following the termination (less applicable
tax withholdings). As a condition to receiving the foregoing severance benefits, Dr.&nbsp;Giesing must sign and not revoke a general
release contained in a separation agreement in the form presented by the Company, return all Company property and confidential information
in her possession, comply with his post-termination obligations, and resign from any positions held with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If payments and benefits payable to Dr.&nbsp;Giesing
in connection with a change in control are subject to Section&nbsp;4999 of the Code, then such payments and benefits will be reduced
to an amount determined by us in good faith to be the maximum amount that may be provided to Dr.&nbsp;Giesing so that the Section&nbsp;4999
excise tax does not apply or Dr.&nbsp;Giesing receives the greater economic benefit notwithstanding that some or all of the payment or
benefit may be subject to excise tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the terms of the employment agreement,
Dr.&nbsp;Giesing was awarded a stock option to purchase 125,000 shares of our common stock. The option vest over four years, with 25%
of the shares subject to the option vesting on the first anniversary of the start date and the remaining 75% vesting in substantially
equal monthly installments over the next 36 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Each of the named executive officers has also
executed our standard form of employee confidential information, inventions, non-solicitation and non-competition agreement, whereby
each of them agrees to maintain confidentiality of confidential information regarding the company, assigns to the Company all intellectual
property pertaining to the Company and agrees to be bound by the restrictive covenants included in those agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For additional information regarding equity awards
to the named executive officers, see &ldquo;&mdash;Summary Compensation Table&rdquo; and &ldquo;&mdash;Equity-Based Incentive Awards,&rdquo;
and &ldquo;&mdash;Outstanding Equity Awards at Fiscal Year-End&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_14"></A><B>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since January&nbsp;1, 2021,
we have engaged in the following transactions with our directors, executive officers, holders of more than 5% of our voting securities,
and affiliates or immediate family members of our directors, executive officers, and holders of more than 5% of our voting securities.
We believe that all of these transactions were on terms as favorable as could have been obtained from unrelated third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Broadband Capital Management Services Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We and Broadband Capital Partners LLC, or Broadband
Capital, were parties to a management services agreement, or the Broadband MSA, initially entered into in November&nbsp;2015, and as
subsequently amended and/or restated in July&nbsp;2016, January&nbsp;2017, June&nbsp;2018, March&nbsp;2020 and August&nbsp;2020. Pursuant
to the Broadband MSA, we engaged Broadband Capital as a consultant for advice in connection with senior management matters related to
our business, administration and policies in exchange for a cash fee of $20,000 per month. From January&nbsp;1, 2021 through expiration
in June&nbsp;2022, we made aggregate payments to Broadband Capital of $0.4 million under the Broadband MSA. Mr.&nbsp;Wagenheim is a member
of the Board and the managing member of Broadband Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>April&nbsp;2021 Private Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April&nbsp;26, 2021, we entered into a Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) with certain accredited investors (the &ldquo;Purchasers&rdquo;) to issue (a)&nbsp;an
aggregate of 1,000,000 shares of our common stock and (b)&nbsp;warrants (the &ldquo;Series&nbsp;B Warrants&rdquo;) to purchase an aggregate
of 500,000 shares of common stock, at a combined purchase price of $27.00 per unit (the &ldquo;Offering&rdquo;). Each unit consists of
one share of common stock and a Series&nbsp;B Warrant to purchase one half of a share of common stock. The Series&nbsp;B Warrants initially
had an exercise price of $45.00 per share (subject to adjustment), and expire on April&nbsp;26, 2024. Alpine Global Management, LLC,
a holder of more than 5% of our voting securities, purchased 130,185 shares of common stock and Series&nbsp;B Warrants to purchase up
to 65,093 shares of common stock in the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">By letter dated September&nbsp;2, 2022, at any
time prior to the expiration date of the Series&nbsp;B Warrants, we are permitting the holders of the Series&nbsp;B Warrants to exercise
the Series&nbsp;B Warrants at an exercise price of $10.00 per share (reduced from the previous exercise price of $45.00 per share), subject
to adjustment as set forth in the Series&nbsp;B Warrants, and eliminated the provision permitting us to redeem the Series&nbsp;B Warrants
if the closing price of shares of our common stock exceeds $55.00 per share for any 20 trading days during any 30 trading day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors&rsquo; Rights, Voting and Co-Sale Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In connection with our convertible
preferred stock financings, we entered into investors&rsquo; rights, voting and right of first refusal and co-sale agreements containing
registration rights, information rights, voting rights and rights of first refusal, among other things, with certain holders of our convertible
preferred stock and certain holders of our common stock, including Broadband Advisory, Mr.&nbsp;Morris, Cotswold Foundation, Mr.&nbsp;Rapp,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Dr.&nbsp;Widlitz, Mr.&nbsp;Lefenfeld, and the
John LaMattina Revocable Trust. These agreements with our stockholders terminated upon completion of the IPO, except for the registration
rights granted under our investors&rsquo; rights agreement. Broadband Advisory does not have registration rights with respect to the
shares of our common stock owned by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered into employment agreements or
offer letter agreements with certain of our executive officers. For more information regarding these agreements with our named executive
officers, see &ldquo;Executive and Director Compensation&thinsp;&mdash;&thinsp;Employment Agreements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have entered indemnification agreements with
each of our directors and executive officers. The indemnification agreements and our Bylaws require us to indemnify our directors and
executive officers to the fullest extent permitted by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Executive Officer and Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have granted stock options to certain of our
executive officers and directors. See the sections titled &ldquo;Director Compensation&rdquo; and &ldquo;Executive Compensation&rdquo;
for a description of these stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Transaction Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Board has adopted a written related party
transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related
party transactions. For purposes of our policy only, a related party transaction is a transaction, arrangement or relationship, or any
series of similar transactions, arrangements or relationships, in which we and any related party are, were or will be participants and
in which the amount involved exceeds the lesser of $120,000 and one percent of the average of our total assets at year-end for the last
two completed fiscal years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Transactions involving compensation for services
provided to us as an employee or director are not covered by this policy. A related party is any executive officer, director or beneficial
owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or
controlled by such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Under the policy, if a transaction has been identified
as a related party transaction, including any transaction that was not a related party transaction when originally consummated or any
transaction that was not initially identified as a related party transaction prior to consummation, our management must present information
regarding the related party transaction to the Audit Committee, or, if Audit Committee approval would be inappropriate, to another independent
body of the Board, for review, consideration and approval or ratification. The presentation must include a description of, among other
things, the material facts, the interests, direct and indirect, of the related parties, the benefits to us of the transaction and whether
the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to
or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive
officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions
and to effectuate the terms of the policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In addition, under our Code of Conduct our employees
and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give
rise to a conflict of interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The policy requires that, in determining whether
to approve, ratify or reject a related party transaction, the Audit Committee, or other independent body of the Board, must consider,
in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders,
as the Audit Committee, or other independent body of the Board, determines in the good faith exercise of its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">All of the transactions described above were
entered into prior to the adoption of the written policy, but all were approved by the Board considering similar factors to those described
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_15"></A><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table sets forth certain information
regarding the beneficial ownership of common stock as of April&nbsp;1, 2023 by (a)&nbsp;each person known by us to be the beneficial
owner of more than 5% of the outstanding shares of common stock, (b)&nbsp;each executive officer, (c)&nbsp;each director and nominee
for director, and (d)&nbsp;all executive officers and directors as a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The percentage of common stock outstanding is
based on 12,215,018 shares of our common stock outstanding as of April&nbsp;1, 2023. For purposes of the table below, and in accordance
with the rules&nbsp;of the SEC, we deem shares of common stock subject to options that are currently exercisable or exercisable within
60 days of April&nbsp;1, 2023 to be outstanding and to be beneficially owned by the person holding the options for the purpose of computing
the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership
of any other person. Except as otherwise noted, each of the persons or entities in this table has sole voting and investing power with
respect to all of the shares of common stock beneficially owned by them, subject to community property laws, where applicable. Except
as otherwise noted below, the street address of each beneficial owner is c/o Immunome,&nbsp;Inc., 665 Stockton Drive, Suite&nbsp;300,
Exton, Pennsylvania 19341.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Beneficially Owned</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Name of Beneficial Owner</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares</B></P></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">5% or Greater Stockholders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Alpine Global Management, LLC (1)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">783,328</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">6.4</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Longboat Family Office, LP (2)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">660,479</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5.4</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Executive Officers and Directors</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Purnanand D. Sarma, Ph.D.(3)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">458,518</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.6</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Sandra G. Stoneman (4)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">109,982</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Corleen Roche (5)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">73,408</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Dennis H. Giesing, Ph.D.&nbsp;&nbsp;(6)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79,293</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Matthew K. Robinson, Ph.D.&nbsp;&nbsp;(7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">66,082</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Mike Rapp (8)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,207,753</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9.7</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Richard A. Baron (9)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,979</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">John L. LaMattina, Ph.D.(10)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">116,976</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Michael Lefenfeld(11)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">101,881</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Philip Wagenheim(12)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">421,126</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.4</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Franklyn G. Prendergast, M.D., Ph.D.(13)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,510</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">*</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">All executive officers and directors as a group (11 persons)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,659,508</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20.0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">* Represents beneficial ownership
of less than 1% of the outstanding shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(1)</TD><TD>Consists of (a)&nbsp;718,235 shares of common stock included in the most
                                            recently available Schedule 13G filed with the SEC on January&nbsp;17, 2023 by Alpine Global
                                            Management, LLC (&ldquo;Alpine&rdquo;) and (b)&nbsp;65,093 shares of common stock issuable
                                            upon the exercise of a warrant to purchase shares of common stock held by Alpine Partners
                                            (BVI), L.P. Alpine Partners (BVI), L.P. also owns the shares of common stock indirectly and
                                            is a beneficial owner. The address for Alpine listed in the Schedule 13G is 140 Broadway,
                                            38th Floor, New York, NY 10005.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(2)</TD><TD>Based solely on the information included in the most recently available
                                            Schedule 13G filed with the SEC on August&nbsp;23, 2021 by Longboat Family Office, LP (&ldquo;Longboat&rdquo;).
                                            The address for Longboat listed in the Schedule 13G is 500 Mamaroneck Avenue, Suite&nbsp;213,
                                            Harrison NY, 10528.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(3)</TD><TD>Consists of (a)&nbsp;10,500 shares of common stock and (b)&nbsp;448,018
                                            shares of common stock issuable upon the exercise of stock options exercisable within 60
                                            days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(4)</TD><TD>Consists of (a)&nbsp;5,555 shares of common stock and (b)&nbsp;104,427
                                            shares of common stock issuable upon the exercise of stock options exercisable within 60
                                            days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(5)</TD><TD>Consists of 73,408 shares of common stock issuable upon the exercise
                                            of stock options exercisable within 60 days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(6)</TD><TD>Consists of 79,293 shares of common stock issuable upon the exercise
                                            of stock options exercisable within 60 days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(7)</TD><TD>Consists of 66,082 shares of common stock issuable upon the exercise
                                            of stock options exercisable within 60 days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(8)</TD><TD>Consists of (a)&nbsp;817,366 shares of common stock, (b)&nbsp;208,742
                                            shares of common stock held by Broadband Capital Investments LLC (&ldquo;Broadband&rdquo;),
                                            (c)&nbsp;166,666 shares of common stock issuable upon the exercise of a warrant to purchase
                                            shares of common stock and (d)&nbsp;14,979 shares of common stock issuable upon exercise
                                            of stock options exercisable within 60 days hereof. Mr.&nbsp;Rapp is a managing member of
                                            Broadband and has voting and investment power with respect to shares held by Broadband.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(9)</TD><TD>Consists of (a)&nbsp;2,343 shares of common stock and (b)&nbsp;12,636
                                            shares of common stock issuable upon exercise of stock options exercisable within 60 days
                                            hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(10)</TD><TD>Consists of (a)&nbsp;66,953 shares of common stock and (b)&nbsp;11,111
                                            shares of common issuable upon the exercise of a warrant to purchase shares of common stock
                                            held by the John LaMattina Revocable Trust, and (c)&nbsp;38,912 shares issuable upon the
                                            exercise of stock options exercisable within 60 days hereof. Dr.&nbsp;LaMattina is the trustee
                                            of the John LaMattina Revocable Trust and has voting and investment power with respect to
                                            shares held by the John LaMattina Revocable Trust.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(11)</TD><TD>Consists of (a)&nbsp;40,747 shares of common stock (b)&nbsp;11,111 shares
                                            of common stock issuable upon the exercise of a warrant to purchase shares of common stock
                                            and (c)&nbsp;50,023 shares of common stock issuable upon the exercise of stock options exercisable
                                            within 60 days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(12)</TD><TD>Consists of (a)&nbsp;406,147 shares of common stock and (b)&nbsp;14,979
                                            shares of common stock issuable upon exercise of stock options exercisable within 60 days
                                            hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.3in">(13)</TD><TD>Includes 9,510 shares of common stock issuable upon exercise of stock
                                            options exercisable within 60 days hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_16"></A><B>OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>OTHER MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Annual Meeting is called for the purposes
set forth in the Notice. The Board does not know of any other matters to be considered by the stockholders at the Annual Meeting other
than the matters described in the Notice. However, the enclosed proxy confers discretionary authority on the persons named in the proxy
card with respect to matters that may properly come before the Annual Meeting and that are not known to the Board at the date this Proxy
Statement was printed. It is the intention of the persons named in the proxy card to vote in accordance with their best judgment on any
such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>REQUIREMENTS FOR SUBMISSION OF STOCKHOLDER PROPOSALS FOR NEXT YEAR&rsquo;S
ANNUAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stockholders intending to present a proposal
to be considered for inclusion in the proxy statement for our 2024 Annual Meeting of Stockholders, stockholder proposals must be received
by us no later than December&nbsp;23, 2023. If we change the date of the 2024 Annual Meeting of Stockholders by more than 30 days from
the anniversary of this year&rsquo;s Annual Meeting, stockholder proposals must be received no later than the close of business on the
tenth day following the day on which notice of the meeting was mailed or public disclosure of the date of the meeting was made, whichever
occurs first in order to be considered for inclusion in our proxy statement. Proposals must be sent via registered, certified, or express
mail (or other means that allows the stockholder to determine when the proposal was received by the Secretary) to our Secretary at Immunome,&nbsp;Inc.,
665 Stockton Drive, Suite&nbsp;300, Exton, PA 19341. Proposals must contain the information required under our Bylaws, a copy of which
is available upon request to our Corporate Secretary, and also must comply with the SEC&rsquo;s regulations regarding the inclusion of
stockholder proposals in Company-sponsored proxy materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Stockholders intending to present a proposal
or nominate a director for election at our 2024 Annual Meeting of Stockholders without having the proposal or nomination included in
our Proxy Statement must comply with the requirements set forth in our Bylaws. Our Bylaws require, among other things, that the Secretary
of the Company receive the proposal or nomination no earlier than the close of business on the 120th day, and no later than the close
of business on the 90th day, prior to the first anniversary of the preceding year&rsquo;s Annual Meeting. Accordingly, for our 2024 Annual
Meeting of Stockholders, our Secretary must receive the proposal or nomination no earlier than February&nbsp;8, 2024, and no later than
the close of business March&nbsp;9, 2024. However, if we change the date of the 2023 Annual Meeting of Stockholders by more than 30 days
before or 30 days after the anniversary of this year&rsquo;s Annual Meeting, stockholder proposals must be received no later than the
close of business on the later of the 90th day prior to the scheduled date of the meeting and the tenth day following the day on which
public notice of the meeting was first made. Proposals must contain the information required under our Bylaws, a copy of which is available
upon request to our Secretary. If the stockholder does not meet the applicable deadlines or comply with the requirements of SEC Rule&nbsp;14a-4,
we may exercise discretionary voting authority under proxies we solicit to vote, in accordance with our best judgment, on any such proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>AVAILABILITY OF MATERIALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our 2022 Annual Report, including the financial
statements and financial statement schedules, has been filed with the SEC and provides additional information about us, which is incorporated
by reference herein. It is available on the internet at <U>www.immunome.com</U> and is available in paper form (other than exhibits thereto)
by first class mail or other equally prompt means to beneficial owners of our common stock, without charge, upon written request to Chief
Financial Officer,&nbsp;Immunome,&nbsp;Inc., 665 Stockton Drive, Suite&nbsp;300, Exton, PA 19341.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="ja_002"></A>Appendix
A &ndash; Text of Amendment to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Amended
and Restated Certificate of Incorporation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMUNOME,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">It is hereby certified that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><U>FIRST</U>:</TD><TD>The name of the corporation is Immunome,&nbsp;Inc. (the &ldquo;Corporation&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><U>SECOND</U>:</TD><TD>The Amended and Restated Certificate of Incorporation of the
                                            Corporation is hereby amended by adding new Article&nbsp;IX as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IX.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">A.</TD><TD>The liability of the officers for monetary damages shall be eliminated
                                            to the fullest extent under applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">B.</TD><TD>If applicable law is amended after approval by the stockholders of this
                                            Article&nbsp;IX to authorize corporate action further eliminating or limiting the personal
                                            liability of officers, then the liability of an officer to the Corporation shall be eliminated
                                            or limited to the fullest extent permitted by applicable law as so amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">C.</TD><TD>Any repeal or modification of this Article&nbsp;IX shall only be prospective
                                            and shall not affect the rights or protections or increase the liability of any director
                                            under this Article&nbsp;IX in effect at the time of the alleged occurrence of any act or
                                            omission to act giving rise to liability or indemnification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><U>THIRD</U>:</TD><TD>The amendment of the Certificate of Incorporation herein certified
                                            has been duly adopted in accordance with the provisions of Section&nbsp;242 of the General
                                            Corporation Law of the State of Delaware.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">IN WITNESS WHEREOF, the Corporation has caused
this Certificate of Amendment to be signed by to be signed by its duly authorized officer this ____ day of _______, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">IMMUNOME,&nbsp;INC.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%">Purnanand D. Sarma, Ph.D.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President and CEO</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"></P>

<!-- Field: Page; Sequence: 42; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 1pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in">&nbsp;</P>

<div align="center"><IMG SRC="tm232159d1_pre14aimg04.jpg" ALT=""><div style="position:absolute; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;"></div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date
TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
KEEP THIS PORTION FOR YOUR RECORDS
DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.
V10799-P92715
! ! !
For
All
Withhold
All
For All
Except
For Against Abstain
! ! !
! ! !
To withhold authority to vote for any individual
nominee(s), mark "For All Except" and write the
number(s) of the nominee(s) on the line below.
IMMUNOME, INC.
665 STOCKTON DRIVE
SUITE 300
EXTON, PA 19341
IMMUNOME, INC.
01) Richard A. Baron
02) Philip Wagenheim
1. Election of Two Class III Directors for a Three-Year Term
Expiring in 2026
2. To approve a proposed amendment to the Company's Amended and Restated Certificate of Incorporation to reflect new Delaware law provisions
regarding officer exculpation.
3. To ratify the appointment of Ernst &amp; Young LLP as the Company&#x2019;s independent registered public accounting firm for the year ending December 31, 2023.
Nominees:
The Board of Directors recommends you vote FOR the
following:
The Board of Directors recommends you vote FOR the following proposals:
Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint
owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer.
NOTE: In their discretion, the proxies are authorized to vote upon such other matters which may properly come before the annual meeting or any adjournments
or postponements thereof.
THE VOTES ENTITLED TO BE CAST BY THE UNDERSIGNED WILL BE CAST AS DIRECTED.
IF THIS PROXY IS EXECUTED BUT NO DIRECTION IS INDICATED, THE VOTES ENTITLED TO BE CAST BY THE UNDERSIGNED WILL BE CAST FOR EACH DIRECTOR
NOMINEE, FOR PROPOSAL 2 AND FOR PROPOSAL 3.
SCAN TO
VIEW MATERIALS &amp; VOTEw VOTE BY INTERNET
Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above
Use the Internet to transmit your voting instructions and for electronic delivery of information
up until 11:59 p.m. Eastern Time the day before the meeting date. Have your proxy card in
hand when you access the web site and follow the instructions to obtain your records and to
create an electronic voting instruction form.
During The Meeting - Go to www.virtualshareholdermeeting.com/IMNM2023
You may attend the meeting via the Internet and vote during the meeting. Have the information
that is printed in the box marked by the arrow available and follow the instructions.
VOTE BY PHONE - 1-800-690-6903
Use any touch-tone telephone to transmit your voting instructions up until
11:59 p.m. Eastern Time the day before the meeting date. Have your proxy card in hand when
you call and then follow the instructions.
VOTE BY MAIL
Mark, sign and date your proxy card and return it in the postage-paid envelope we
have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way,
Edgewood, NY 11717.</font></p></td></tr></table></div><!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 1pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page --><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><IMG SRC="tm232159d1_pre14aimg03.jpg" ALT=""></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">V10800-P92715
Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting:
The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com.
PROXY CARD
IMMUNOME, INC.
PROXY FOR 2023 ANNUAL MEETING OF STOCKHOLDERS
June 7, 2023
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
The undersigned stockholder of Immunome, Inc. hereby appoints Purnanand D. Sarma, Ph.D. and Sandra G. Stoneman,
and each of them, with full power of substitution, as proxies to vote the shares of stock which the undersigned could vote
if personally present at the 2023 Annual Meeting of Stockholders of Immunome, Inc. to be held virtually via the internet
at www.virtualshareholdermeeting.com/IMNM2023 on June 7, 2023, at 1:00 p.m. Eastern Time, and at any adjournment
or postponement thereof, as hereinafter specified and, in their discretion, upon such other matters as may properly come
before the meeting. The undersigned hereby revokes all proxies previously given. If the undersigned holds any of the shares
of common stock in a fiduciary, custodial or joint capacity or capacities, this proxy is signed by the undersigned in every such
capacity as well as individually.
When properly executed, this proxy will be voted in the manner directed herein. On matters for which you do not
specify a choice, the shares will be voted in accordance with the recommendation of the Board of Directors. If no
direction is made, this proxy will be voted &#x201C;FOR&#x201D; each of the nominees listed in Proposal 1, &#x201C;FOR&#x201D; Proposal 2 and
 &#x201C;FOR&#x201D; Proposal 3.
(Continued and to be signed on the reverse side)</font></p></td></tr></table></div><!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm232159d1_pre14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232159d1_pre14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 1 # 2(  A$! Q$!_\0
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MFV@'.>:_2K]CC]B;QQ!X]\)_$+QCI#>%]#\(ZC8:[9:=?(EM>7FHV]W'>6[
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M-8U&TG9=>Y_6&74<D\?WL':!SDEL;0!@Y). < D$C*QS1YQN^\P53@X=BKL
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M^&_ GA[6="T)_".FG6M2N#'J#R^)/#>A:E+=((VVREVU>U/S9$;-@8*S"/\
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M*;?-VLI-*RO=:*^K:_)'MY=H_C_F?U8+*C[-K9\S=L&&!.TX8E2 5"G 8L
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M$7@C2#K>B:AX7U5HM#LY6U'0;VZ!>RN#YBDP216L$A4%7Q*J,<QR+7T40#U
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MRR[5**Q._)("[QZ100#U /UK%PNXMRE>+NM5WOKH6E;0\U\#?##P5\.-(NM
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M5,JD*C'L47!=BN"3MSD$LJYVDX[G)////(J3 '0 44FVW=[LI*RL0R !HR
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm232159d1_pre14aimg02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232159d1_pre14aimg02.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  @ *T# 2(  A$! Q$!_\0
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M']:\1BTU&_L]7U;^P-!U22-E,>EZ)XGUX'0O"&O:M+I^C>+M9_XE7AJ_U6_
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M([%\W_A_6+:T^V?.B !9U3< P$A\ML'U5]K#IR" 0>"!7YC> _\ @EY^R_\
M#+4?"\_PW@^/7P_T[X<V?C2U\ ^#?"?[4_[06C> OA]%\3=1M-:\;6'A3P)I
M_P 0[7PEHFG:SJY^U:H=$LK)IX;.>V@LW6\N#JGZ"^!?!&F_#[1_[$TF\\6Z
HG:F=[CS_ !9XX\4^/-15G/\ JUUCQEJ^IZFL2\D1"?9DY8LP& #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm232159d1_pre14aimg04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232159d1_pre14aimg04.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS#P[KZ^3+,KJ&5[=R LR,#D%<$CG:* />J*** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0#GW?P)\13G0X'O;"ZT_2=UK!;O.1BU$JR)D/!(I<[$#;E(P ,\9(![Q17
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFTL"0O." <>N#Z&@#M:*\F\)_M/> /%_B :5!K,%D\UI:WEE+?2+"+M)HWD
M0$Y!41MD''3C-=%/\:/!B>!-6\86VNVVI:#I:DW-Q8-YQ5@ 0@5>2S;EVCON
M7'!% ';T5X=K_P"UQX9\*J\.L^'O$>EZO'-'')I%U#;)<(CPRS),3Y_EE"D,
MO1RV5*E0>*V_B#^TAX7^'/A+PQXCOK74[O3_ !"AEM!;11I(J" SEG662/&$
M!^498G@ F@#U:BN%;XX^ X([AKKQ1I]@]M;1W=Q%>2B%X(GV!2X;&WF2,'T+
M '&:CD^/GPZBM;FY?QEI M[9XXI9/M(VJ[J75,]VV@DJ.0 2<8H [ZBO,]5_
M:)\#:=XPT;PY#KMC?WNH>8TCVUU&T=I$MLUQYLK;L!#&H.1_>4G@@UT=I\4O
M"6H>%)_$UMXAL+C08'\J2^CE#1H^0-IQSNRR\=?F'J* .IHKS'2OVC/ FJ^,
M[CPXNO6,$_V>UN;.YENHQ#?).CNIB.><",YSCV[ULZ7\:_ 6MP)-8>+M(NHF
M>2,/'=*062(RL.O_ #S!?W49&10!VM%<OX>^)_A+Q9K$FE:/XAT_4=2CA6X:
MUMYPT@C(4AL?1T)]-RYQD5U% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<GXLTSPI?ZA$GB"[A6X>&3RK:YU%HEV;&5W
M2/> "%9AO R,]1765QNN>!K[5/%-UK$&L):";3UL%A:WD?RQN<NV/-$;DA^
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M#SW"QJJM=0P.ZN(EB,@E$8D!*K@C=M^9N.:[4W4(NEMC-&+AD,@A+#>5! +
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MPU(-&TF32!"?"EULNT=)%,L^-3!>4>=,0X*X,K''3'U6L\;3O"'4RHH=D!Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV83&(>>HV8P XX'3DXXH [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** *VIASIUT(]QD\I]NSKG!QCWKQ%O&/Q!\+>%M.LETZ\
MU/48[:VE6<Z7,RM^X4R0OM#MNW9 )QT.Y@1S[A?W1L;&XN1$\YAC:3RHQEGP
M"<#W->/WGQRU.WTR*^M[/2-2@:TANI6M+W*VYEF2)8W9L*-F_<[,5X7&!G(
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MO#[P?3'7K6)!\:]932EN_P"R[%X&C"1O/?"-S(+>"9F<L%3&)F &1DJ.1NX
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M!P>M/MO&7C^YNYOL]O+/86L(G6>?0YH'NGW0;H=C$%<>9-@@9.T==K$^S44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-H (P,'J,=:&
M8*I8G  R2:\]\/\ Q;6_O]&MM5TU=,&N0&YTMX;@S^;&#_RT&Q?+;:5;'S#&
M>>* /0MH]!TQ0% Z "O.[GXZ>'(UBDA:ZFMV>-&E^R2X;?$LBK& I+N0\?RC
M^^!G. ;\7Q>\/SSVT*?;6>6X2T?;9R$03/*T2QR$#"DNCCTP,DX() .U  &
M,"C SG'/K7G7BOXGZIX;UK5K5=#M;JSL4M")X[V1II'N)3'&@A$/WLKD@/T(
M/M5_0?C+X5\2>(;?1+&_9]2FW#R'C*LCJI=HV!Z,%!/IQUY&0#MBJD'(!SUX
MZT  9XZ]:\JO_CY:66BZA=C2VDNX-8.EV]H;@+YZ!T7[06V_(F'ST/.!G)%6
M;?\ :-\!74D4<6LAGED5%4(<E6V;7_W3YB>_/3@X /3  !@<"C SG SZUYI;
M?'C197S-:7]NI65EB-N[S%$:7]YA00$*P2-DMG@#&2,]#I/Q-T+6]66PM9;A
MB\<TL=R]LZ02+"P64B0@#Y68 Y[],X- '58!(..10  , 8'M7+ZWX[M[>STJ
M31?LNMRZI*\=JZ786V(1&=W:55? "HW16.<#'4BKH7Q4T;69K.W6>.6>=UMW
MGL2\]FEP5+"'SBB@MA3U [ X) (!T%IX<L++6+C5(TF>^G4HTL]Q)+M4D$JB
MNQ$:D@$A0 <#T%:1 (P1D'L:X:7XOZ/9W^K6MW:ZA;OIT\L<K"V,@\J-(VDG
M^7.(U\U,D\\\ U7\8?'GP;X#\1KH6MZA+9:BT]I J&W=E8W)D$3!@,;,Q.&;
MHN.<9H ]!P,DXY/>C:, 8''3CI7C\/[6/PWE:T5]7GMC<R^5'Y]G(@QY(F60
MY'$;(RX8\$L!UXIO_#6GPW18O.U6ZMI)(KF;R9K*5700Q+*P88X8HP*@\MSC
M.* /8MH  P,#IQ2UYUXW^.OAGP)//9:C/+#J@M(;J"UD@D_?"9V1,%5).&4[
M\ E1R17)6_[6?AJ=] M8-,U;4[W4;NRL;A].L9GM;::XMQ<*/-=%WC80< ;L
M<D"@#W' SG'/K2UY->_M/^ K'0VU9[V\>S6Q@U$LEG(2()7D1&(QQS#)P?0>
MHKGK7]K?PW<ZSK>EK&TMXGF2Z,L*N5OH%LH+KS6)4",?OU&.3CG'7 ![U17A
MND?M>>")/ -OXDUEK_2"B6OVZWDL)LVS30"96Y4%HRI)# <XX&>*NZQ^US\-
M=!NI8+[5;NW$5Y+9&9M/F$1>(@2LK[<,J;DW%<XWK0![+17AWAK]K'PQ>PZC
M%K<%[I6J6MY<VT-I%93S?;1'>FT3R&"?O79S&"JYP7Z\$AB?M:>&7U^]M5@N
MY[$6UM]B^SVDTEY/=227226[6X3<IC^R2%L],-Z#(![I17SYX9_;7^'][X=T
MZYUN]DTO5IM+34;JR@MY9UA+1"8Q!@OS,(R'QCI[\5N:K^UMX!T6[N;:]_MV
M">V5VF1M$N?W92%)Y%;Y.&6*178'H,YYXH ]GHKQ;4/VPOA;IU[JEI)K[O<6
M$GE,D=K(?.?S!&RQG'S;6(!Z =>G-41^USX8O]=CM-.MKF33<V<G]JW,,L<,
MT-Q!-,IBVHQ+A83\K[0?FY!7! /=Z*\83]KCX>2:;]K6XU<MM\W[(-'N?M!A
M^SBX,_E[-WE>40V_ISZUUFL?&OPMHCZ&L]Q=2-J]@VJ0^1:22"&S559[B8@8
MCC7>N2V.OUH [NBO&+S]KCX>:?8BYN)]7B;:93;-H]R)Q#Y!G$QCV9\LQ!G#
M=,*1U&*K>(_VJ]!L_#=UJV@Z;=ZVUG'?37=K<J]C+!';0+*S%70G#>; !Q_R
MUSV(H ]PHKY?U[]N.RT&P\7,_A&>74M$U1+"VLA?J#?Q?O/,N%;R_D"""4E<
M'H.?FJQ=?MLV-JNN0MX4N%U#3+K58OLTEZ%\^&SBF=9T;9]V1K>1,8^4J<Y[
M@SZ8HKYU\._M>?\ "8^(_#NA:+X3\W4=4T>;4+C[9J8@BL+F,N&M9'\MN1Y3
MDOC@ ':<TW2OVO6U9-#:+P>^V\6W^U2?VB-D)N+N6UMFA)B'G1N\1;>0F$96
M /2@1]&45\]:E^U5?:1X6FUFZ\)V>+77WT&=(-9:2.:0&,;K:7[/ME.792'\
MI0T;#>:^A: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH BN;:.\MI8)03%*A1P&*D@C!Y'(^HKCE^#7A1+2*W%G
M>$0JL<4S:I=--$BHR!$E,N]4VNXV@@?,>,UV4\RV\,DK[MD:EFVJ6. ,\ <G
MZ"LFP\9Z)J>#;:E!*A@BN/,SA DN?+)8\ M@X7.?:@#/M_A=X8M4L5BTL*ME
M*)H%\^4A'!C(.-W./)BZYX7'0G.2GP@L8?%]EJT$PM;*UF^TBRA,X,TP$F&E
M)F*/AI78'RPWW1NP*[S[1%S^\3@$GYAQC@_E58:SIY5V%];%44NQ\Y<*H."3
MSP >,T 5)O".DW%]->26F^YEN8;MW,C\RQ+MC.,XPH[=,\XSS5;P]X#T7PI<
MRSZ5;SVID&'B%W,T1. -VQF*[L* 6QDXZUMQW<$JJR31NK="K@@\9X_#GZ5D
MZEXX\/:0B/>ZU8VRO%).K/.H#1H0'8<\@%@#]: ,Q?A+X360O_8Z,QCAB)::
M1LK$Q9 <MSR<G^]A=V=HQ8T_X<Z)IEQ8SVZ7RS62^7$[:E<L=F00C9D.]00,
M*V0.?4YVVU>P1)':]MU6/&]C*H"Y&1GGC(YJ&?Q'IUOJT.FO=)]LEB>81@YV
MHFTL6/\ #PPZ]: ,&V^$OA6T258]-<B6VDLV+W<S'R7&&0$OP,<<<CG&,FH?
M"'PSB\+^)+_6&NEE>>-X8+:!9DAMT>4R2;4DED +-M)V;%^7[M;.B>-]#\1R
MRIINI6]WLC27=&XVNC+N#*>XP>2.G>M0ZE9K;1W!NH!;R8V2F0;&STP<X- %
M37/#6G^(K:""]BDQ!()H9+>9X)8GP1N1XRK*<$@X/()!X-8VD_"SPUH=Y!<V
M=E-'+#+]H >]GD1IOF_>NK.0[_.WSL">G/ QTB:E9RF()=0.92RQA9 =Y7[P
M'/)&.?2J;^*M(2]@LQJ%O)=SKOB@B<.[KO"%@!G@,P!/;OT- &3J?PN\.:O?
M7EY<VD[3WA8W!CO9XUD#*BNI57 VL(TRN,':,BO/?C)^RWI?QH\5-KFH^)=6
MTV0Z9)I(M[*&U*""3F0!GA9MQ/1LY7)VE<G/L+:S8+$9#?6PC#B(N9EP'/1<
MYZ^U/NM1M[.%I))!M5@I"#<<GH,#GW^G- 'S=KO[#.C>)1(-1\<:_.'TRWT<
M[;33T_T2!U>*,;;<8VLB_,/F(&"2.*GUO]B73/$>LWFJZAXZU^XO[R>TN9Y1
M9Z>FZ2U!$!VK; #:#@@ !APP:OH&\\1Z5I]DUY<ZC:PVJS+;F9I5VB1F"A"<
M]2Q Q[U'I7BG2M9TL:A;7L)M2=I=V"[3G # ]"?0^HH'<\/U7]D%==U/3=1U
M+XD^*+^_TW[7]DN+F&QD>(7((F )MSD$,< Y"?P;<"H;;]C:&RTR*PMOB1XI
MMK>*]MM1C\F*Q21+B"%88G5Q;[AB-%4@'##.X')S[VWB'34U&XL7O(H[JW6-
MI(Y#MP)"P3D\')4\#THL/$>E:HN;34;6X'G20?NY5.9(R0Z]>JD'- 'S2/V
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MB,0%[>UA#J-W!'V7=QC[^,C&3R>F_!#QA%97EO=7]E)/<J1)>G4[B1I5^QB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M57;M!P.@VKCTVCT%;=% %&?0M-NO.\[3[6;SI%FE\R!6\QU "LV1RP  !/(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI4$3E0K[AABQ 7!]R0!]: ):**K1ZG:37AM8[F)[D)YOE*P+;=Q7/TR"/J*
M+-%%% !139)$B +NJ D*"QQDG@"G4 %%%% !156YU2SL[:[N)[F**"T!-Q(S
M "+"ACN]."#]#5J@ HHJ"[OK>P2-KB9(5DD6%"YQN=CA5'N20!0!/1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)&SG&Q<$ $MC->M>&;F=[#[)<FYENK'9;375Q%L%S((U+2)ZJ2V,X R"!TH
MUZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117!7'Q<MK#4=<MK_0-8L8](6,SW,@MG1S(<0K&L<S.S2'A1MZD9Q0!WM%<
MOH_CR+5'U2VFTG4M,U33H%N9=,NUB,SQ,&V,ACD=&#%&7AN"I!Q5+4/BYH.G
MV&FW0^TW::C9+>VR6T09W5WC2),9'SN\JJH]0V2 ": .UHKSW4_C)!I-G>23
M^&=<%Y930PW>GC[)YT F8+"Y)G",CL< HS8*MG&#6SX>\=-XBUR^TV/0-4M/
ML+K%=75PUMY44IB23RSMF9B=LB\JI7.>: .IHKF];\>Z9H'B[0/#MV)UO=:6
M9K:54!B!B"DJ[9R"=PQP<D8XXSC7/QGT"WT_Q3>+%?7$?AZ\6PG2"$,]Q,0N
M%@&[Y^6V\XY4]AF@#O:*X;6OB]I&C:A80?9+Z]M;NVM[PW]J(C!#%-*(HF;=
M('.6(X16/.:O>%_B3I7C'4)+32X[JX:#S1<R>6/+MF21HPDC9X9BI(49.W!(
M (R =717G=S\<-%L;O48;JPU.WCM&N42=HXF2Y-O(D<WEA9"PPSK]\+GMFMG
MQ)\0[?P_J<]A#I.IZU<VML+R\738XV^RPDL%9][KDG8^$3<QVGY>F0#JZ*Y'
M3OB19Z_J26^AZ=?Z[:@1&?4;/R5MK?S$61=QDD1F.QE8A%8@,,\G%9<?QP\/
MW.C76J6L%]=VEK&AG>*- (Y7D$<<#,SA1(Q8'&<*I!8J",@'H5%<WK?C4>'O
M"\.L7NCZA'++-#;KIJF!KCS)95C1<B7R^68<[\8/6LK0_BQ9^)-4L[#3=&U6
MYDEC:6X?$"+9A9W@;S-TH+8>-Q^[#Y R,Y% '<T5QI^*%A/I.A7>GZ?J&JW.
MM(TMGI]JD8G9%&7=C(ZHJKD9)<<L ,D@5FR_'/P[!HFK:D\.H*-,@2:>U, \
M\LTSPF)5W<NLL;(1G&<8)!!H ]$HKFG^(&E"SUV[3SIK;1[-+VXEC4$,C1&4
M*G/+; #CC[R\\UD:=\:/#VIRZE#$+M9]/U"UTZ6*2(*Q:X9%C=?FY3<^">Q5
MN..0#O**XO5_BIINB^*VT.XL;\E'@B>^18S LDP<Q)C?YA)V'D(0.Y%:&E>/
M=-U@^'/(2X']O6;WUIO0#$:JC$/SP<2+P,]Z .DHKB= ^*=IXHUB"PTO1]3N
ME:!;B6ZQ D5NC22Q@ONE#'YH7^XK<8]:D\0_%"P\/7^HPMINI7]MI2))J=]9
MQQM#8JPW#?N=7;"8<B-7(4@D#(H [*BN,T'XI:;X@\42:+%97T#>9<107DPB
M,%RT!42[-LC.,;UY=5!SQFL_4OC;HVD:AJUM=V&I0Q:>;E/M7EQ-'.\$2RRK
M&!(6R%8'+JH/0&@#T.BN;\6>/]*\&+I!U$S8U.Y2VB\I-WE[O^6C\_*@)4%N
MVX4D'C=+_P 0W&EZ?I&HZC%:S"VN]1@\E;:WDVABI+R*[D KGRU;&<=00 #I
M:*Y3P?\ $G2O'4I72([J>../?/.8P(X&S@1.V?\ 6$?-M&<#!.-RYQ8/COX:
MGU+5[#;>QW&FV-QJ#B2$ 2QPRRQR+&=W+ PL=IQP0?7 !Z+17'^'OBCH_BC6
M#IFFQW=Q>1R2)<*(QBV5>-\AW84,>%'WFP<#"L1=U'QYIFF>,M,\,S>=_:%_
M$TL;JF8DP&*J[9X9@DA48Y\MO3D Z.BN:\*^.(/%ME>7]KIU[!IL#ND5Y.8=
MESL9E8HJR,XP5/$BH?:L>P^+D.I:7I%U!X;UI[C6$\[3[#_1?/N(0@=IL^?L
M1 &7.]E.6 P210!WM%<?HOQ2T;7EN_LZ7:26EDU[<131!7B"R21O&PS]]7B<
M$=.!@D&GWOQ&M(;?138Z;J&LWNKVOVVVL+)8A,( JEI',DB(H&]!RV26 &:
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M44 %%%% !1110 445C^+]1O]'\,:G?Z7;I=WUK T\=O)G$NWDIP1R0"![D4
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MC ZUR3?M):%)HEI=V8M+^^DL;R]N-.M]0C>:V^SKDJX )&3QD@8H ]?HKD/
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M2R^,$U_X@TW1AI%O87LL\UK=?VE?F&-)HV4-% RQL)W*L)%4["5P>#D#TN@
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M5_\ D>O29/&EA%X('BHV^HG3C9"_\A=/F-YY97=M^S[?-WX/W-N[/&,UOT4
M>+_\-9>#O^@)XZ_\(K5?_D>NJ^'GQIT+XF:E<V.E:?XBM)K>'SG;6= O-/C*
M[@,*\\2!CD] <XR:[ZB@#S7QQ\?O#G@#Q!+HVI:9XINKJ)%=I-+\-7][ 0PR
M,2PQ,A/J >.]8/\ PUEX._Z GCK_ ,(K5?\ Y'KVBB@# \4^-+#PAX3F\17M
MOJ,]C$D;M#8:?-=7)#LJC$$:M(3EAD!>!DG !KS;_AK+P=_T!/'7_A%:K_\
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MD)P>0#P>#78:=XW\.:OX>EUZPU_2[W0X@S2:G;WL<EL@7[Q,H8J,=^>*M_\
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M[+&)!:[4^<;LA@F><YKZ+_X:;^#W_15_ _\ X4=G_P#'*/\ AIOX/?\ 15_
M_P#X4=G_ /'*!GRG\8OA)\1S<^-EOFU?QQ+=_#J"TM+FUT(PA91J,+_95$0(
M>0*K-C[V,G&!7HD^CZGX-_:Y>]\(Z)JVM0>(M3C?Q"FL>&7%M8(MOM^UVFIE
M0H  "^5ELDMC%>T?\--_![_HJ_@?_P *.S_^.4?\--_![_HJ_@?_ ,*.S_\
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MC2ZT/QGX*\47&C^)/ GAS1':+P[>7%MYBVS1SQ32)&5B*%P&WD;>^,5]"_\
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MX"MM<_9%\ Z3K\7B'3+W3+'1YT&E:))J=S:W<,*8\^S",9$5@0Z%?KBO3?\
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MPH]['X8\.SWES-JNHR6<$-_.72T6.X$,JS26L>"5'0D98<9^O/\ AIOX/?\
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M]NQRR.78[\D<ELGWKCO^&F_@]_T5?P/_ .%'9_\ QRC_ (:;^#W_ $5?P/\
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M\P8$AO,?@G )! !48Q?^&F_@]_T5?P/_ .%'9_\ QRC_ (:;^#W_ $5?P/\
M^%'9_P#QR@9U6D^ ]'T5M.:WCNY9-/\ ,^RR7E_<7+Q!U"L TKL<84#!X';&
M370UB>%/''ASQY8-?>&=?TOQ%9*VQKG2;V.ZC#>A:-B,^U;= @HHHH ****
M"BBB@ K\_M ^'-O^W1^U9\4+CX@W5W=> _AUJ!T33/#D-PT,4LH>2-Y&*$-A
MC [$@ACO09VIBOT!KXP_8(_Y+/\ M2?]CM-_Z4WE T=EK?[&/[+WAHS+J_A3
M0-*,,(N91?:S/#LB+!!(VZ<87<0NX\9..M)=?L9?LO6-Y;V=SX5T"WN[FW:\
M@@EUF=9)8%!+2JIGRR  DL. !UJ/]IOX'>*?B?XVU.?2]$&IZ1=^'++3'9KF
M&,.ZZM#/*F'<'B%7;.,'& 2>*\[T/]F?XFCQ19ZKK.E)=S:5INJ>&+"9;V D
MZ<EA)%9R'+Y!FDE.1U7 +8'- 'H8_8^_96;3],OQX<\.&QU.406%R-<F\J[D
M)("1-Y^';((PN3Q5B']BW]F&X@LYHO"6A20WAD%M(FL3E9S&"9 A\_YMH5BV
M.@4YZ5Y!X?\ V4?B58KX1TJYT2,^'_"E]IFIZ7$+Z E)IIK:34.-_'D^3-C^
M\)3MS7?>"?A'\0;7_A"_#5]X2DLK/PA)K\SZT]_;-;ZA]KAN([=8%60R GSP
M6\Q$"[>IH Z"Q_8P_9?U2.RDL_"F@W:7L+W%JT&L3N+B),!WC(G^95R,D9 S
MS6?:_LH_LE7NDWVJ6^C>%;C3+!@EW>Q>()&AMV)P!(XN,(2>,$BO*]+_ &0_
MBA8:'IGAFSM(['1O^$+O(5EEOHO] U*Y2W^T6;;7+&-W@=MZ!E'G/STKJOB'
M\!/%_P 5/M-S8_#9?!5C'HECHEQH\EY9;M2*W\$KL/)E9/*BCCDVER';>0%'
M2@#N+K]C+]EZQO+>SN?"N@6]W<V[7D$$NLSK)+ H):55,^60 $EAP .M'AC]
MC3]EWQM;S3^'?"WA_7H(&"2R:9K,URL;$9 8I.0#CL:\WT/]F?XFCQ19ZKK.
ME)=S:5INJ>&+"9;V DZ<EA)%9R'+Y!FDE.1U7 +8'->N_LV1^*/AAX5\*>$-
M?\)^*DU"["V\USJ2Z6UO9K#; LPDL,CR]P"+YQ,C%NIP< &5/^QE^R]:ZB-/
MF\*Z!%?M<+:"UDUF=93.R[UBVF?.\K\P7&2.<8J#4_V0/V5=$TM]3U'P[X;L
M--2=K5KRZUR6.%9E)#1EVG #@@@KG((-8'Q-_9F\7?$+XM:Q>BP>RTFY\3IJ
MMKJT=U"&M_+TCR8;@+OW92Y5!MQDXSC;S5#X:?"#XE>#M6\->,?%O@!?%%Q!
M/K9O/#ME>V;RVDUW="5+N#SI5A;<H*D%U< CCJ* /2K7]@C]GB^MHKFV^'NG
MW%O,@DCEBO[ID=2,A@1-@@CG(J3_ (=_?L_?]$XL_P#P-N__ ([7M'A/5-0U
M*UG6^\.7'AM+=UC@@N)X)/,3RU.0(78* 2R8)ZH2.""=V@#YZ_X=_?L_?]$X
ML_\ P-N__CM'_#O[]G[_ *)Q9_\ @;=__':^A:* N?/7_#O[]G[_ *)Q9_\
M@;=__':/^'?W[/W_ $3BS_\  V[_ /CM?0M% 7/GK_AW]^S]_P!$XL__  -N
M_P#X[1_P[^_9^_Z)Q9_^!MW_ /':^A:* N?/7_#O[]G[_HG%G_X&W?\ \=H_
MX=_?L_?]$XL__ V[_P#CM?0M% 7/GK_AW]^S]_T3BS_\#;O_ ..T?\._OV?O
M^B<6?_@;=_\ QVOH6B@+GSU_P[^_9^_Z)Q9_^!MW_P#':/\ AW]^S]_T3BS_
M / V[_\ CM?0M% 7/GK_ (=_?L_?]$XL_P#P-N__ ([1_P ._OV?O^B<6?\
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M .!MW_\ ':^A:* N?/7_  [^_9^_Z)Q9_P#@;=__ !VC_AW]^S]_T3BS_P#
MV[_^.U]"T4!<_.[]IOX,:/\ L*Z]X1^-'PF-UH%BFJQ:9KGA];IY;>\MW#.0
M/,+$ B-@020"49=I6OT0!R 1T-?&?_!5_P#Y->M?^QAM/_14]?947^J3Z"@!
M]%%% @HHHH **** "OC#]@C_ )+/^U)_V.TW_I3>5]GU\8?L$?\ )9_VI/\
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M>,/VH_B%J!\6:5H4^A6>K1PZVBZ3!I\LVJ:&MDK&*YN,S;6$X'R9C0 NA'F
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MUEW/[4_A);>1K>.YFE2%F*>;;Y24([",J)2S9\O&^-73YE.[!H&6;C6;ZT^
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MQAAB"".1TKB? _Q=L]!TR>+4?#]YHV@Q"W*2YBDCM?.M!<LDC>:7?)+X*@@
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M6)9B3\C$<\<YZ\UFCX'>"P9!_9,C02*BR6KWUPUO)LB\I"T1DV,0G )&>_4
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M:#:25^4<9%=C10!Q\7PE\+P:@+R/3Y8Y#<"[>-;R<0RS"1I%DDBW['8.Q(+
MXXQ]U<-L_A!X2T]K)[32VM9+(W)MI(+N='B-P<RD,'SD]!S\HX7:.*[*B@!
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M^$_J/_R;1_9G[0__ $,GPQ_\)_4?_DV@#VBBO%_[,_:'_P"AD^&/_A/ZC_\
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MTM% "$!@01D'L:6BB@ I"H)!(!(Z>U+10 @4+G  SR<4,H8$$ @]0:6B@!,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD\C<22<5ZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XR_X*O_\ )KUK_P!C
M#:?^BIZ^RHO]4GT%?&O_  5?_P"37K7_ +&&T_\ 14]?947^J3Z"@?0?1110
M(**** "BBB@ KXP_8(_Y+/\ M2?]CM-_Z4WE?9]?&'[!'_)9_P!J3_L=IO\
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M.M<G-^RI\,)[*.U/AZ=5!F\Z9-6O%GNUF*F5+F43;[A'*+E968' XH Q]?\
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MWE%8?CS]M"WE\#W-YX-\.ZS)JT4-M/=2WMO 8-+\R^-J4N )\EBT4P'E!P,
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M04444 %%%% !7QA^P1_R6?\ :D_[':;_ -*;ROL^OC#]@C_DL_[4G_8[3?\
MI3>4#Z'V?1110(**Q+KQCI5CXAM=$N)9X+^Z)6#S+280R-M+[%FV>67V@G;N
MS@'CBMN@ HHKG-;^(&C^'M<LM(O?[0%_>\6Z6^EW4Z28&3B2.-DX R>>!R<4
M ='12 YHW#&<C% "T4F><=Z,CUH 6BD)QUH) ')Q0 M%(2 ,G@4$@=3B@!:*
M3(XYZT9'//3K0 M%)GG'>J-AK=IJ=_J5G;N7GT^1(IP5("LT:R#![_*XH OT
M4FX8SD8HR/6@!:*3/..]4+#7+34K[4K2"0M-I\J0W *D!69%D&#W^5UH T**
M3(]:9-/';Q22RNL<<:EV9C@*!U)H DHJD^M6$>GV]\]W$MG<&,13EOE<R$"/
M![[BR@?45<S0 M%9$GBO2TUF#2A=*][+*\/EISL=8Q(58]CL93SZBM;/..]
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M^E #J*P+'QOI5[X>L=;,DEMI]])%';O/&5,AD<)$<#) 8LN,XZC.*WLCGVH
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M#Z'V?1110(X2^T#Q)JGQ,M-2O+72Y_#6G+FP07\BSI,R%9)WB\@JS8)11Y@
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MQ(")(9&)5 1N!&234WB3]GS4+QO(T_\ LZ+1_M!E.EQND49W6D4+2?/;3*)
MZ.00F<.3N!X.I'\9]<U:XMEM]&MK2".[O;2^$D\\<H$5FMPC1K+;(P)#C[Z#
MD=P<U)-\=[JPT%]6.@K<Z7 WV0ROJ&+I[@6GVC!C$6W8?N[]V?XMF* *.J_
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MY;/-:VJ?"[5]97Q!'<Z[9+%K]NB7XCTY]RR(FQ&B)F.$P$RC!LX;D;N/2:*
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M [6BN)L_C+X2OH)YH[^Y584+$2Z=<QLY$HB945HP7<2,J%%RP8@$9I\/Q?\
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M'&4 V*QZDD=0#BL"\\":#:^*IFNM7O!>:T+P06.8]J^;%$D[)B/=@".,Y8D
MM[@5PJ^"OB)!>:X?MNKR0K.ZQPPWI N[3[5&RK%*]XQCE%NK(&$<1R6+.3AC
MM>$_!FNV?C.V\0WUCK+6EG!J*65E=:MYT\<;M;F*)\SE'9BDQ!9F !0,PVC
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M4GT%?&O_  5?_P"37K7_ +&&T_\ 14]?947^J3Z"@?0?1110(**** "BBB@
MKXP_8(_Y+/\ M2?]CM-_Z4WE?9]?&'[!'_)9_P!J3_L=IO\ TIO*!]#[/HHH
MH$%(1FEHH *.M%% !THHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1,?ND,LC#FMK4?&%I>?!:VOHKZYTBRCUFULKJ]77)IU*?;8XY6COF<.\3 L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUI:* "BBB@ HHHH **** "D"A<X &>3BEHH 0J"02 2.A]*6BB@!",C!Y%
M4  8 X %+10 4444 )M&[.!GIFEHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XR_P""K_\
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M)PRK]X<9''=^'/$6MV+^*;#7KZ[/B&UMI+V&!XX/L?D;G$<ENR('*\ ,LI+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4G_8[3?^E-Y7V?7QA^P1_P EG_:D_P"QVF_]*;R@?0^SZ***!!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#'ROEK/$?4^4_'!K<\0:I\2?#LD.E6%WJ5Q8*$_XFLE@"\;&V4K'B&SES&)
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M!G2-2T:YTM;R[L[2XNX[QQ;Q6P*ND4<2^7F(^5@1*04VLIS@@8 B?X):3-)
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MH \KU#]GG1M8O_[0U35]1U;4MZD7-_!93@*(Q'L$;6YCP0 <[<Y&<]0=B_\
M@_I5[H]MIB7MY:V<&H/J06%(-PD:3S,*QB)C .0#'M8 D9KO** .9G\ :=<:
MXVJM-<BX;4(]2*AEV>8EN8 ,;<[=ASC.<]\<5SMK\#=-T\VB6FMZQ;6UL\$P
MMU:W9'EAB,22-NA))VXR,A25''7/I%% '#^%_A/8>$KO3+BRU*^+61NOW;+
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M** "BBB@ HHHH **** /C+_@J_\ \FO6O_8PVG_HJ>OLJ+_5)]!7QK_P5?\
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M'_\ !E>?_(]'VOXQ?] OP/\ ^#*\_P#D>O2Z* /-/M?QB_Z!?@?_ ,&5Y_\
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MA=_X,M1_^1Z]LHH \'TGXG_%3PY\7O!/A+QUH_@];#Q.M]Y-SX>O+J66%K:
M2G<)HU&#D#CWKWBO#_BU_P G-_ 7ZZ]_Z1)7N% @HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ^,O^"K_ /R:]:_]C#:?^BIZ^RHO]4GT%?&O_!5__DUZ
MU_[&&T_]%3U]E1?ZI/H*!]!]%%% @HHHH **** "OC#]@C_DL_[4G_8[3?\
MI3>5]GU\8?L$?\EG_:D_[':;_P!*;R@?0^SZ***!'FGP6_X_OB/_ -C;=?\
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M\2_^Q9U/_P!)9*[31_\ D$6/_7!/_010!<HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S3PW_R<7X__P"Q:T#_ -*-
M6KTNO-/#?_)Q?C__ +%K0/\ THU:O2Z "BBB@ HHHH \/^+7_)S?P%^NO?\
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M?LE_!SP[X8G\0:SH'Q#TK2XW@19)]==GD$LBHK"-)V< ;@2&"L!GC(Q7NY^
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M>+@#(/7.,9I6_P"R]\"&DU(7=OXXTZ&SCNI5GN-=F9;E;>802F,1RLV?,*J
MP4MN& :^C_"/P63PAXHT'5K?5R\6GZ1_9UQ:?9]JW,VR)!<@[CL.R%5*X;.%
MY&WG&L?V=8K>\U^9]5M+<:F+H^;INF"VG=Y;G[1&]Q(9&$YB8 )E5P"W][%
M7/$'_9-^"M@+E=7TKQ[H4ULL,TT5]KTA,=O(Q07!:.9U\M6&&YW)U90.:N>'
MOV-O@UXFUV"RLK;Q:;*YM9[JVOW\17(2=8I4C9E7=DH3("K?Q $XQ@GW^_\
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M@#QK_AWC\)?[WBC_ ,*&Z_\ BJ/^'>/PE_O>*/\ PH;K_P"*KZ:HH"Y\R_\
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M^B@+L^,/^'5?PS_Z'?XB?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ*
MNSXP_P"'5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/C
M#_AU7\,_^AW^(G_@VMO_ )%H_P"'5?PS_P"AW^(G_@VMO_D6OL^B@+L^,/\
MAU7\,_\ H=_B)_X-K;_Y%H_X=5_#/_H=_B)_X-K;_P"1:^SZ* NSXP_X=5_#
M/_H=_B)_X-K;_P"1:/\ AU7\,_\ H=_B)_X-K;_Y%K[/HH"[/C#_ (=5_#/_
M *'?XB?^#:V_^1:/^'5?PS_Z'?XB?^#:V_\ D6OL^B@+L^,/^'5?PS_Z'?XB
M?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ* NSXP_P"'5?PS_P"AW^(G
M_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/C#_AU7\,_^AW^(G_@VMO_
M )%H_P"'5?PS_P"AW^(G_@VMO_D6OL^B@+L^,/\ AU7\,_\ H=_B)_X-K;_Y
M%H_X=5_#/_H=_B)_X-K;_P"1:^SZ* NSXP_X=5_#/_H=_B)_X-K;_P"1:/\
MAU7\,_\ H=_B)_X-K;_Y%K[/HH"[/C#_ (=5_#/_ *'?XB?^#:V_^1:/^'5?
MPS_Z'?XB?^#:V_\ D6OL^B@+L^,/^'5?PS_Z'?XB?^#:V_\ D6C_ (=5_#/_
M *'?XB?^#:V_^1:^SZ* NSXP_P"'5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^
M(G_@VMO_ )%K[/HH"[/C#_AU7\,_^AW^(G_@VMO_ )%H_P"'5?PS_P"AW^(G
M_@VMO_D6OL^B@+L^,/\ AU7\,_\ H=_B)_X-K;_Y%H_X=5_#/_H=_B)_X-K;
M_P"1:^SZ* NSXP_X=5_#/_H=_B)_X-K;_P"1:/\ AU7\,_\ H=_B)_X-K;_Y
M%K[/HH"[/C#_ (=5_#/_ *'?XB?^#:V_^1:/^'5?PS_Z'?XB?^#:V_\ D6OL
M^B@+L^,/^'5?PS_Z'?XB?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ*
MNSXP_P"'5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/C
M#_AU7\,_^AW^(G_@VMO_ )%H_P"'5?PS_P"AW^(G_@VMO_D6OL^B@+L^,/\
MAU7\,_\ H=_B)_X-K;_Y%H_X=5_#/_H=_B)_X-K;_P"1:^SZ* NSXP_X=5_#
M/_H=_B)_X-K;_P"1:/\ AU7\,_\ H=_B)_X-K;_Y%K[/HH"[/C#_ (=5_#/_
M *'?XB?^#:V_^1:/^'5?PS_Z'?XB?^#:V_\ D6OL^B@+L^,/^'5?PS_Z'?XB
M?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ* NSXP_P"'5?PS_P"AW^(G
M_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/C#_AU7\,_^AW^(G_@VMO_
M )%H_P"'5?PS_P"AW^(G_@VMO_D6OL^B@+L^,/\ AU7\,_\ H=_B)_X-K;_Y
M%H_X=5_#/_H=_B)_X-K;_P"1:^SZ* NSXP_X=5_#/_H=_B)_X-K;_P"1:/\
MAU7\,_\ H=_B)_X-K;_Y%K[/HH"[/C#_ (=5_#/_ *'?XB?^#:V_^1:/^'5?
MPS_Z'?XB?^#:V_\ D6OL^B@+L^,/^'5?PS_Z'?XB?^#:V_\ D6C_ (=5_#/_
M *'?XB?^#:V_^1:^SZ* NSXP_P"'5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^
M(G_@VMO_ )%K[/HH"[/C#_AU7\,_^AW^(G_@VMO_ )%H_P"'5?PS_P"AW^(G
M_@VMO_D6OL^B@+L^,/\ AU7\,_\ H=_B)_X-K;_Y%H_X=5_#/_H=_B)_X-K;
M_P"1:^SZ* NSXP_X=5_#/_H=_B)_X-K;_P"1:/\ AU7\,_\ H=_B)_X-K;_Y
M%K[/HH"[/C#_ (=5_#/_ *'?XB?^#:V_^1:/^'5?PS_Z'?XB?^#:V_\ D6OL
M^B@+L^,/^'5?PS_Z'?XB?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ*
MNSXP_P"'5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/C
M#_AU7\,_^AW^(G_@VMO_ )%H_P"'5?PS_P"AW^(G_@VMO_D6OL^B@+L^,/\
MAU7\,_\ H=_B)_X-K;_Y%H_X=5_#/_H=_B)_X-K;_P"1:^SZ* NSXP_X=5_#
M/_H=_B)_X-K;_P"1:/\ AU7\,_\ H=_B)_X-K;_Y%K[/HH"[/C#_ (=5_#/_
M *'?XB?^#:V_^1:/^'5?PS_Z'?XB?^#:V_\ D6OL^B@+L^,/^'5?PS_Z'?XB
M?^#:V_\ D6C_ (=5_#/_ *'?XB?^#:V_^1:^SZ* NSXP_P"'5?PS_P"AW^(G
M_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH"[/ O@/^Q%\,/V?-<;7M#LK_
M %CQ(594UG7;D7%Q$K<,$"JJ*2.-P7=@D9P2*]]HHH$%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm232159d1_pre14aimg03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm232159d1_pre14aimg03.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN<U#X\WT^K^$K71O"FH7']H:S/H^JV]RUND]C+%!)(T?,X7=\J/N4NI0\')
MK;TGXW:;JVO65HFDZE%I.H7\VF6.N2>3]FN;F/?N55$AD"DQ2!69 &*'U4D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4*',0DC_ 'B8^5LG&YACG(I?#'X*'X<W.B3'61J)TW3+O3B%LQ )//NQ<;P
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M!\#MHNH^,O$+PWMO::KJ4B:3;:C;/;RV]BKO(%\MP'0---<. P!VE>*]BHH
M\Z^(?P\\1?$.632KG7M+MO",L]O/);1Z4[7X\ITDVK<&?8I+(/F\K*@X'.&&
M!XF^!&I:\-;MUUS37TN]UV/7XM/U#2FN(GD"!7@N5\]1-$2H8 !2& )W8P?9
M** /&=*^ FH:#H$<%AKVFQ:I#XF_X22%TT?RK*-C#Y30"!)@0FTM@A\CC.<'
M,OA/]GRT\(>,+C4[>W\+WEE+J,VIK+>>'5?4X9)6,C*EV)1P'8E24) ^7G@U
M[#10!YUX:^$/_".VG@*#^UOM'_"+?:/F^S;?M7FQNG]\[,;\_P 6<=JXV[_9
M>M_[7M]6AN- U6^47D4T?B3P^M_;M%-=R7*[$\U61T,K+N#88=0.,>[T4 >=
M#X0QK;^,(8KVWM(_$&C0:0L-I8B*&T\N*6/<B!_NGS<A,C 7&3UJUX?^'=_X
M;\;QZS;:K;RV$FCVNE7=I+9MYKM;^9Y<D<@DP@/FME2K=!@BN[HH \5^*_[/
M$_Q*UW7KU=6TN"/6--33C)J6B_;KG3PH<%K20RJ(M^_+#:>5!STQOZE\&O[1
M\-^.M)_MCR_^$HECE\[[+G[-MMX8<8W_ #Y\G=U7[V.V3Z710!XWXF^!>MZM
M;:[I&F>++?2_#6L:LFL3VSZ69KE)1+'+)&DOG*HC=X\G*$C<P!Y&.Q^(?PSL
M_B7<:'!K$WFZ'I]RUY/INUA]JE"%8B75@5"%BV,')"G(QSV=% 'CFI_LV:3'
M>:JWAV]_X1^QU6VMHKVS\I[A99;>Y2:*4%I 00HDC([AP?X<'=\7_"#_ (2O
MQ)J&K?VM]E^UC2AY/V;?L^Q7;7'7>,[]VWI\N,_-TKT:B@#S/Q?\'9O$6L:W
MJ]IK26.H7DVF75H9;3S8[>:R=W4N ZF17WX(!4@=#Z<]JWP UGQ#!K5QJWB7
M3M1U+4]6M-5EMI]'8Z:P@A\H6\D!GW21D -R^0R@\XQ7MM% 'D?P^^ S^"-?
ML]5DUFUN'@OK^]-K8Z8+2 ?:HH$\N-!(VQ4\C(ZD[N>1D]/X@^&%GXG\77VK
M:A,)[&]T&30I]/:+AT>3>S[\^G&,>^:[6B@#PD_LSN-5M-4N;WPWXDU$Z;;:
M;?3^)_#2WWF^1N$<T?[Y3&Y5L.-S!B ?EZ&O%\)O$OB76?BAI(U6+0_"FN:G
M%#-;2Z4S22VXLK='-K+YBJ@8*T>2CA2IQR,5[]10!Y!J7P,U&XLM=\/67B.W
MM/!6N7S7MYI[:>SW:!V5IHHKCS0JI(P)RT;%=S 'D;=C4/A ;WX?^,?#2ZL$
MDU^]N[Y+LVV1;M-)YBJ4W_.%(&>5S[5Z/10!QOC?P/J'C[X:WGAR^U2"VU&[
MA1)KRVM6\AF5U8J83)N,;;=K)OR58C<,UP^@?L[2:9?7=Y+JNE6K7.I:5J'V
M/1=%%E:PBR9F\M$\UC\^[EB2003@C 'M5% 'D"_L^V=I\0]4\106WAB]MM4U
M!-2G76?#RW=[#*%17$-SYJE0=@(W*VUB2,@X&Y\5/A9-\0]0\/7L5UIF=)DF
M?[#KFFG4+*8R*%#F(21_O$Q\K9.-S#'.1Z'10!XG#^S3$GAKP5I+^("PT&YF
M:\DCL5C74;66X^T-;% ^(U\Q8N1GA",#=PV?]G*>X\;'6FUC2S'_ ,)#'K_V
MA]%WZF^QPPMFNC-_JAC:N$&!M'.#N]NHH \8F_9T>30KK3T\2R0/-I&H:4)X
MK3:5^TWGVG>?WG(7[A7(W DY7I6./V8=06>YO;/Q%HV@7[S:9/;Q:'X=%O9V
M[64LDBCRO/);>9,-E@<#CMCW^B@#RI/@O?:E>W6JZWKUO=ZW=ZOIVI3RV=@T
M-N(K-LQVZ1M*[#.7)<L>7/& !57X7_L_6?PQU:!K6W\,7-A:-*;6Z'AY8]65
M7+$*]V)<,5#%=WE@L.#SDGU^B@#QWXL? .;XEZ_J.H)JFEPI?Z0=)(U71OM\
MEB,OF6T8RH(G;S/FRK9V(>V*Z;P]\.[_ ,-^-HM9M]6MY;"31K72KNUELV\U
MVM_,\N2.0280'S6RI5N@P17>44 >>^(/A#;Z_P#%+2_%TE^4M;:V\JZTHP!D
MNY5$BP2,^[C8L\PQM.=R\C;SSND_L[G2/A?K'A>/Q'(^J75W'=V>MO: O9M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/@NX_P :]7^)/C^/X:^&FUF30=?\2*)4A^P^&].>^NSNS\PC7G:,<GM7544
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MVVH+Y;,N# ?FRVW*CN&4]ZZFB@#Y^_X;#M?^B/?&'_PBY_\ &NC^'W[1UO\
M$+Q5::$GPY^(WAY[A78:AXA\,36=G'M0MAY6.%)Q@9ZD@=Z]>HH \Q^*7QU@
M^%FLVNG2>!O'7BEKBW%Q]I\+>'Y=0@C&YEV.ZD!7^7.WK@@]ZXS_ (;#M?\
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MU_Z(]\8?_"+G_P :^@:* .5\4>/X_"_P_?Q6V@Z_JD:P0S_V1I>G//J1\QD
M46X^;<N_+#^$*Q/2O*/^&P[7_HCWQA_\(N?_ !KZ!HH \\^%'QFA^*\NII%X
M-\9>%/L*QL6\5Z))IPGW[N(BY.\C;SCIN7UKF_&G[3EMX+\4:AHC?#+XFZTU
MG((S?Z+X5FNK2;@',<H.''.,CN#7L]% '@$7[8%I+*B?\*A^+Z;F W/X+N !
M[GGI7J7Q-^(D?PQ\.)J\GA[Q#XF5IUMQ9>&=,>_N@6#'>8UY"#;RW0$CUKK:
M* /G[_AL.U_Z(]\8?_"+G_QKTCX5_%:+XJZ??7<7A7Q5X5^R2K$8/%6D2:?+
M+D9W1J_WE[$CH:[FB@#P[Q%^U7;>'?$&IZ4WPJ^*NHM8W4MJ;S3O",\]M/L<
MKYD4@.'1L95AU!![T>'?VJ[;Q%X@TS2E^%?Q5TYKZZBM1>:CX1G@MH-[A?,E
MD)PB+G+,>@!->XT4 <-\5/BM%\*K"QNI?"OBKQ5]KE:(0^%=(DU"2+ SND5/
MNKV!/4UYO_PV':_]$>^,/_A%S_XU] T4 <E\,_B''\3?#C:O'X>\0^&56=H#
M9>)M,>PNLJ%.\1MR4.[ANAP?2O+9?VP+2*5T_P"%0?%]]I(W+X+N"#[CGI7O
M]% 'C'@O]INV\:^*-/T1?AG\3=$:\<H+_6O"LUK9P_*3F24G"#C&3W(KH_BM
M\9H?A1-IL<O@WQGXK-\LC!O"FAR:BL&S;Q*4(V$[N,]<-Z5Z)10!\_?\-AVO
M_1'OC#_X1<_^->K^&/'\?B?X?IXK70=?TN-H)I_[(U/37@U(>6S@J;<_-N;9
ME5_B#+CK7544 ?/W_#8=K_T1[XP_^$7/_C73?#K]HJW^(OBB'1$^'?Q$\.-+
M&[B_\1^&IK*T7:,X:5B0">@!ZGBO6Z* /+_BC\>8/A;KUMI<G@3QYXI:>V%S
M]K\+>'I=0MT!9EV-(IP'^3)7KAE/>N._X;#M?^B/?&'_ ,(N?_&OH&B@#EI?
M'T<7PY'B_P#L'7VC-B+[^Q5TYSJF"H;R?LWWO-YP4]:\G_X;#M?^B/?&'_PB
MY_\ &OH&B@#S#X6_'>#XIZW=:;'X%\=^%F@MS<?:O%/A^73[>0!E78DC$@O\
MV=O7 8]JH_$/]HVW^'GBFYT-_AU\1O$30*C&_P##WAF:]LWW*&PLJG#$9P<=
M"".U>NT4 ?/W_#8=K_T1[XP_^$7/_C7O.G7HU'3[6[6&:W6>)91%<1F.5-P!
MVNIY5AG!!Z&K%% !1110 4444 %%%% !116;X@\2Z1X2TN74]<U6RT;38L>9
M>:A<)!"GU=R /SH TJ*\T_X:;^#W_15_ _\ X4=G_P#'*/\ AIOX/?\ 15_
M_P#X4=G_ /'* /2Z*\T_X:;^#W_15_ __A1V?_QRC_AIOX/?]%7\#_\ A1V?
M_P <H ]+HKS3_AIOX/?]%7\#_P#A1V?_ ,<H_P"&F_@]_P!%7\#_ /A1V?\
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MW_15_ __ (4=G_\ '* /2Z*\T_X:;^#W_15_ _\ X4=G_P#'*/\ AIOX/?\
M15_ _P#X4=G_ /'* /2Z*\T_X:;^#W_15_ __A1V?_QRC_AIOX/?]%7\#_\
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M%'9__'*/^&F_@]_T5?P/_P"%'9__ !R@#TNBO-/^&F_@]_T5?P/_ .%'9_\
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M<H_X:;^#W_15_ __ (4=G_\ '* /2Z*\T_X:;^#W_15_ _\ X4=G_P#'*/\
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M '*>(/&GQ(\*Z)?:K?C6(M/M8'N-/,EK8RSW4@\O$5X8LI&A._:8]A((R=V
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M (=_?L_?]$XL_P#P-N__ ([7T+10%SYZ_P"'?W[/W_1.+/\ \#;O_P".T?\
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M .!MW_\ ':^A:* N?/7_  [^_9^_Z)Q9_P#@;=__ !VC_AW]^S]_T3BS_P#
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M?_@;=_\ QVC_ (=_?L_?]$XL_P#P-N__ ([7T+10%SYZ_P"'?W[/W_1.+/\
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M (=_?L_?]$XL_P#P-N__ ([7T+10%SYZ_P"'?W[/W_1.+/\ \#;O_P".T?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'QE_P5?_Y->M?^QAM/
M_14]?947^J3Z"OC7_@J__P FO6O_ &,-I_Z*GK[*B_U2?04#Z#Z***!!1110
M 4444 %?&'[!'_)9_P!J3_L=IO\ TIO*^SZ^,/V"/^2S_M2?]CM-_P"E-Y0/
MH?9]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^3/VLO^3G/
MV9?^PY=_^@1U\QZ;<'X8^-?&'QGAC=D\(?%6]M=4\H99M/NE$<GUPP7'NU?I
MQJWA'0M?U33-2U/1=.U'4=+<RV%Y=VD<LUHYX+1.P)0G R5(Z50?X8>#9-,U
MC37\):&VG:S.;G4[0Z;"8;Z4D$R3IMQ(Q(!W,">!0.Y^>'P0\/7<?Q_^ ?C3
M58RNM>.[W7_$=R6^\$EC(A7Z"-5(_P!ZN8\#:N?@I=R_&Z*%Y+;0_B)K>BZN
ML2Y+VERHV9]ED7\V%?I^/ ?AD7VC7H\.Z2+S18C!I=Q]AB\RPC*[2D#;<Q*5
M&,+@8XJF_P *O!,NA:AHC^#] ?1M1N#=WFG-ID!M[F<D$RR1[=KN2 =S G('
M- 7/S^_9R\&7GA[]HSX(ZQJJG^W_ !=H>M>([]F^\9+DR,@/TCV5O_LT_%KP
MC\.OV3_B]X;\2Z_8:+XAT[4-:CETJ]N%BN6:1"L82-B&?+97Y0>17WC_ ,(3
MX=_MC3=6_L'3/[5TV VMC??8X_/M82,&.)]NY$(XVJ0*P?$/P,^'/BWQ -=U
MOP'X;U?600WV^]TJ"68D="7923CMGI0%S\][3X?6_BCX7_L<^%?$=DWV'5I]
M2AG@D7#&*8$JPST.U@P/T-:'PPU?Q&G[7/PY^&WB!Y#XG\"Z7K&AI?2 @75N
M86:SG!]XRH_X#7Z,:EX.T#6;[2KW4-#TV^O-)<R:=<7-I'))9,0 6A8@F,X
M&5QTJ&7P%X9G\61>*9?#FDR>)HH_)CUI[&(WJ1X(V";;O"X)&,XY- 7/CO\
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M_P"QAM/_ $5/7V5%_JD^@KXU_P""K_\ R:]:_P#8PVG_ **GK[*B_P!4GT%
M^@^BBB@04444 %%%% !7QA^P1_R6?]J3_L=IO_2F\K[/KXP_8(_Y+/\ M2?]
MCM-_Z4WE ^A]GT444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ!XA^V:A/K%WG) 5GB5, D87 '4]:^P:* N?(GQ%^!'QR^/_ (@\*6'CVX\
M:)X9T'5XM6-_X=^URW\QC;(1/-4!,CKSUP><8KZ[HHH$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?&7_  5?_P"37K7_ +&&T_\
M14]?947^J3Z"OC7_ (*O_P#)KUK_ -C#:?\ HJ>OLJ+_ %2?04#Z#Z***!!1
M110 4444 %?&'[!'_)9_VI/^QVF_]*;ROL^OC#]@C_DL_P"U)_V.TW_I3>4#
MZ'V?1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^>XBM8C+/*D,8QEY&"@9.!R?>I*^;/BUXL\5^+O!7C&^M[G2;;PWIFOP:/\
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M@H'T'T444""BBB@ HHHH *^,/V"/^2S_ +4G_8[3?^E-Y7V?7QA^P1_R6?\
M:D_[':;_ -*;R@?0^SZ***!&9J/AO3M6U?2=4N[?S;[2GDDLY=[#RFD0QN<
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MI65C;K((PS!B20H.3N^]S4MU\)/"=XFHI)I6(]1LHM/O$CN98UN(8\",.%<
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MS7B_C'QWXYN=*\=K?6MF\6D^+M)M-.BT^^82,K2V3>2284^5O,)+$L?G9<$
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M9A>"PUB[LX9HSU62.&15<'_:!."1T.*P)_B^T/AS4=5_LH$VGB5?#_E?:/O
MW:6_FYV\??W;<=L9[UC#XUZ\+Z\O)/#%G'X8L_$?_".2W1U)C=.QG6%9TB\K
M;L#NF5+@_>QT&X W]9^ G@C7I+C[5I4Z6US%##<6-IJ%S;6LRPJ%BWP1R*C%
M%50"5R J_P!T8W[GX>>'[O3]6L9=/WVNJWJZC>1^=(/-N%,9#Y#97F*/@8'R
M].3GQ_Q?\3?$?BRR\.ZC9Z+!9^%9_&%GI\-]%J+?:W6*]\II)(?+"B-VC=<!
MR<%21R0M[0/VH;#Q!XJM+*WCT:;3[[4+C3;:.WU@2:DCQ>9B6:U$?R1L8F'W
MR5W(2/FPH,[CQ!\#/!OBG4[J]U+3KF4W=Q%>7%K'J5S%:S7$>W9,\"2"-G&Q
M?F*Y^49S@5J:A\,?#>IZ#J.CS6#BQO[UM2F$5S+')]I,@D\U)%8/&P<!@4(P
M1QBO,;;]H#Q++X4\*:]>^&M&T.R\2$26UUJ>KRK;6J%%*+<2K;D))(S$(/NX
M'+;L*=K5_BI)X>U[Q%:6.B_;==DU33M+MH9=3D^SSSSVX<-DJPA1%#$[$);;
MG&30!W/@_P"'NA^!9-2ETB"X6YU*5)KVYN[R:ZEN)%4(K.\KL20H Z] /2D\
M7?#K0O&\UG<:G;SI?V>X6VH:?>36=U"&^\JS0NCA3@97.TX&0<5YO<_'/Q3I
MVH7^BW/@^P?7[?6[/18T@U9C;3?:+=IEGWF ,JJ%P5VD]<9P,NUK]H>7PMI5
MQ;ZW8:3IGB*+71H6+G53%IV\VXN!,UPT894\HYV[,[OE&<YH$=]H'PNT#PU9
MBWL4U ?Z>-4DFFU2ZEFGN=H7?+(TA:0;0!L8E>!\O KHM5TR'6=-N;&X:=(+
MB,QNUM.\$H![K)&5=#[J01V->0>'_P!H"_\ &QTO3/#>CZ7J&OW5Q>Q3.=58
MZ<D=MY>^:.=(6:17\Z(* @Y9LXV\[G[/>K7VK^ ;V[U2*2VO3KFJK+!)-YOD
ME;V4; _=1C .!P!P.E &K:?!?PK;:1KFG2VM[J":W"MO?W.HZE<W5U-&H.Q/
M/DD,BA<DJ%8 $DCDDTS5?@CX4ULAKR'4I7:U2RN776+M&OH5SM2Y*RCSP-S?
MZS=PQ'0D' M?C5JDG@G4/'D^@VD7@N.WEGLV6_=M0NE5ML1\KR@B>8V, R$@
M$$\Y K^(_C=KW@&*]C\4^&+&VOO[*EU6Q33M4>>*81/&LL+LT*%'7S4((#!A
MGIB@#T)_ &@2#61_9RJNL6<>GWJI(ZK) B.B( #A %D<97!Y]A6=_P *D\-Q
MZVFJVT-_IUX$ACD_L_5;JV2X6(!8O.2.15E*@ 9<$D#!)'%<9\>O'4]OX>\9
M^'K>)[>6W\.IJB7T4Q5P6G:/8 !QC9G.>_2L'XN_$WQ'K7A+Q2^C:+ GA[3=
M8M](EU(:BT=XTJW,*RR)$(]OEJS%#F0$@,<< $&>P#X>>'Q!Y/\ 9_[K^U/[
M:V^=)_Q^;]_F_>_O<[?N^V*S]9^$/A?6[N6\FM+JVOI+XZB;RQU"XM9UG,*P
MLRR1R*R@QJJE00IQR,\U=\>>,6\$6.FWSV8N;*?4;>RNI?,V?9DF?RQ+C!W
M.R CCAB<\8/&+\:-4UW7UT/PYH-K>7UQ=WT=M/?7S0V[6UHT<<L[%8G.3,YC
M5 #G:6+#I0(ZWPY\+/"_A(:5_96F&V_LMKI[0FYED,;7#;YR2S'<6;GYLX[8
MJ*R^&]MI/B;2]0TV]N+#3++[=,VE12.8[BYNI [S2$N<X/F84C ,AQC %>>W
MGQ?\7:WJW@B+1]+TZP>?Q!=Z+K=E=7S';+!!,S(CB!MR'8LBN-I/R@@9.'^%
M_P!IRP\3^,M/TV!=&DT[4=3GTNW2VU<2ZE&\?F 2S6H3Y(V,3#[Y(RA(^;"@
M'N%%%% 'QE_P5?\ ^37K7_L8;3_T5/7V5%_JD^@KXU_X*O\ _)KUK_V,-I_Z
M*GK[*B_U2?04#Z#Z***!!1110 4444 %?&'[!'_)9_VI/^QVF_\ 2F\K[/KX
MP_8(_P"2S_M2?]CM-_Z4WE ^A]GT444"/,?&/P&T_P 8ZAXAF?Q#K>F67B 0
M_P!IV%@UN([AHE"HV]X6D7A5!56"G'3EL[6J_"C2-8TOQA837%ZL/BB99[UH
MW0-&PBCB CRIP-L2GYMW)/T'G/QR\6ZI!H'Q3LM!M?*U"QTZP\Z[GU6:(&*;
MS03$JJPC8;<97&[=DG*BO8-"M#X=\)VL!LK:Q-I;<VEI*TD,9 SM5V521[E0
M?:@#A_$GP TWQ'+J</\ PD6NZ;HVIW\6J7>CV,D"P27*,C[]S0M( S1J64.%
M)&<<G/9>./!5EX]T+^S;V>YLS'/%=V]Y9.$GMIXG#QRH6#+D,!PP(/((()%>
M6Z3^T5J=MX=\-^)_%/AFVT7PWX@LI;NVEM=1:YN8&CMGN=LL9B5<-''(058X
M( (YXI:3^U3'>Z3K5VUCHM_-:Z!/K]O;Z'K8O2JQ!2UO<$1@12?.N"-P/S8^
M[D@SO]4^$]QK*:-<7?C+7)-:TBZDNK35A#9"6/S(S&\?E_9_**E2>2A8$\-V
MK-T[X Z?H,&FR:-XCUW2]8L7O&76%>WEN)TN9C--'*LD+1NIDPP^0%2!@]<T
MS\7?$UEXC\.:/J^A:'HDVKQ"X26]U:589-SX6VAD^S[7N GS,AQU 7<,L"#X
MWZI)9VOB-O#MJO@>YU8:5'?#4&-Z,W'V=;@P>5M\LRX&/,W!2&_V0".GNOA-
MINH:7XNL[O4-0N6\46R6VH7#-$LGRP"#>FV,*K%1D_*1D\ #BMOQ1X.T[Q?X
M4NO#VHK(]A<1+$6C?9(A4@HZL.C*RJP/8@5YSI?QKUZ\NK:]NO#%G:^&I_$4
MOAP7"ZDSW7F+.\"3>5Y07870 C?D9)YQR^_^.D</Q)A\)%]"O([V:XLD;2]5
M:XN[:5(7E'GQ>4JID1L"H<E3CKG@&;D/P:M;A=;DUKQ!K'B'4-4TM]&:^OC;
MI);VKYW)$L42("20Q8J22JYX %=UIUA'IFG6ME$6:*WB6%2YRQ50 ,X[\5\T
M?#/XAWWA'3[#6+L3:G91^%/#AO/-N&'DQRSW$<MQR#DJ"&;ID*>>*]Z\&^,3
MXPN_$/E6@BL-,U%].@NO,W?:6C5?-8# VA9"Z=3DH30(Q?"WP<L/"\?AR,:O
MJ=_%X>N)YM-CN3"!$DL;1^42D:EE57."3NSC+&H+CX(Z<FHQZII6MZMHFLQW
MMY>)J%HT#OBZ96FA*21,C1EE0@%2P*@ANN</Q'\;?$&CW?CBZMO"MI<^'?!]
MRD5_=2ZFT=Q/&8(II'AB$1!*+)G#.-V, \\5]9_:%O-$M?%^KW&AV,'AW0K]
M-(@N[G4S$]Y=2>3Y9(,>V*+]^-SLQ(P<*<4#.^'PXM)=1N=0N]2U"_O[K1QH
ML]Q,8E,D6YV\S"1JH<EST 7I\M9>J_"^2PTBSE\,ZA):^(-)\/S:'I5Q>,IB
M3>L6V64!"2RF%#P,=>.>.(7]I:67P_JUQ;V6B7]SIM];6MSJ.GZJ]SI$$,R,
MPN)+A(=RJI0JP*?*2I)"G(/&7[3T/A*^GLBOAF6ZT[2X=3ODE\0"+[2) S+'
M8YBS.Q5"P)" ED7^+(!'MVG6LMKIMM;W-PUY-'$L<D\@ :5@ "Q  &2>>!WK
MRX_LR^$SX);PO]IU3["=5_M7SO/3S@<;/(#;,>3Y7[G;C/E\9SS5'5/CQK<#
M>*-2LO#%I/X8\.7%LEW=SZBT=S/'+##*6BB$1&468$AG&<8!]-_P=XJ\6:G\
M8O&VC:C#IX\/:=#9O:>3<LTR>8LAR5\E<[MN3ESMP ,Y- &CXF^$6E>)E\2F
M2\OK.;78K..26V:/-NUJY>%X@R$9#')#!@<#CKF9OA?8W$?B4W>HW]W<>(=-
MBTR^N',2L42.1-Z!4"JY$K$\$9Q@ <56^+'Q)/PZTZUFCN/#\=Q.7V0ZWJC6
MC2E0#MB5(I&D)[X V\'FN5\(?%/Q-XV^)7A@V5G8P>$-8\,+K/DRW1^T(S/'
M\V!#RP+;<;P""6X/% 'I>H>$K/4O!5SX8EDG6PGT]M-:1& E$;1^62#C&[!Z
MXQGM6#KWPJAU2[T>]T_7]5\/ZAIMB^FK=Z?Y#/-;-LW(XEB=<YC4AE (/L<5
M0^-?BCQ5X6M/##^%XK!WO=<M+*Y^W7!BS'(X&P8BDX;D%N"O;-<1H?Q'\2>$
MM2\>W\^CV]]X>M/%B6MS<3:BXGC$J6L?[B/RR&5&D!(9DSEL 8Y .MM/V=?#
M=GX:;1$OM5:T;14T'>\\;2>0LK2AMQCY?<Y&3QC'&>:UOCEX/O?'OPSU+0M/
MCDDN;J>TXBF$3JBW,3NRN2 "%5B/IQS7%3_M.:>GCF;28ET:6P@UM=!DB.K@
M:HTQ<1M*MILYB61L'+@[0S8P #Z_XBTE-<T>XLY+Z[TV*0#?<V,Y@E50<G$@
MY7(&"1@X)P1UH X6?X$:;JBZE<:QKVM:SK-W]F$6LW#01W-E]GD,D'DB.)8U
M*NQ8ED;<2=V1Q5AO@IIU_I7B>WUC6-5UO4/$-LEI=:M<M#'<111@^4L(CB6-
M-C,SCY#\QR<UY?I?B#79?#$EGIGB#5F\,>(/%T&DZ)J]U<M+>BP,8,[QS/ER
MKO%,L<C$MA@P/W379^&M.E;6/'O@F^\1ZR-%TDV5];W[ZDXO((9HW9X6N2?,
M*AHF.XMN ?&[@4#-ZS^!GARQUKP9J<<E]Y_A6T-I:H95V7 *[0\XV_.ZDNP(
M*X9V..>+?AGX6KX1N[A--\1ZO%H4LT\XT)Q;/;1M,69PKF'S0NYV8+YG!/\
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M:221RIHEU+$\1*N#Y+$$'L: .A\-^$[3PO/K4MK)/(VK7[ZC.)F!"R,B(0N
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M=,T+47TZSUN_NI)K"XMX]-N;=;JVEM8TBAD@:<JF0JY82,P;+ @@XKS/P/\
M$&_\'Z7H.N3I/JUM:^ ]+NKR*2X8$1M=,LT_(.65"6/<A<9%>\>$_&@\6ZSX
MEM[>V"Z?I%VEC'>B3<+F7RE>7 QP$+JN<G)#=,4#/.?AO\&[V;5-6\0>)IM8
MAO+G7;?6+:+4;FVDNR8+8P+Y_D*85!W/\D6  %YSFNMUOX,:5J]W?7T6HZGI
MNJW&K1ZU#?VCQ^9:7*6ZV_[L-&RE#&I#*X8'<WMBJWQ@D74YM'.D#^VT\1+H
M:VGVCAHC&)_M.=O3R,OMQ]X;<]ZY:?XXQ>%OA7X<UFT31+,WEI+<1Z;KVOS"
MYD"$_)$3%(\Q/=CC;D9SG@$=QJGPMDU8:-=R>*]:C\0Z49A!KD4=H+AHY<>9
M$R>1Y10[5XV9!13G.<ZGP[\ 67PU\-#1;"[O;^'[3<7;W&HR+)-))-*TLA9E
M51]YSVJYI>OR^(_!EEK>DV\;2W]C'>6L%W(8UR\8=5=E5B.HR0I^AKP70_'?
MCO7]&^"VJW=K97NO:G<W>Z..^:*WF3['*1),1"-N,$[51N0N#SD 'IMG\#M.
MM-&U+P\=;U:?P?>QSQ#P[*8#;VXE)8B*01"90K$E1YAVGIP !'+\"M/U>+4!
MXBU_6O$\USIDFD17&H/ CVMNY!?R_)BC&]BJ$NP8G8O;BN6U/]I<:9%IFGW=
MMH6C^(KBZO[:Y76=:^S6$/V201R,LYB+/O+IM78#@DG&WGU#X;^-H/B-X)TK
MQ%;P?9DOHRQA\P2!&5BC .  R[E.& Y&#WH Y*3X!66IG79=;\3Z]KMYK&F1
MZ3/<W+VR%($D+J$6.%5#99LD@YSSVPOB7X Z;XDFU2(^(M=TW1M3OX]4N]'L
M9(%MY+I&1]^YH6D4,T:EE#A21G')SBZ#\5]9O$\,:/X8\-03W.KIJMQYFK:Q
M*8[9;:[\IBSF-W?>7R!CY>!T%06/Q@\5>(O%?P_GL]/T^PT'5+/49-3MI[UF
MD26VD2.7:1 =P0[MI!7?GY@N!0,];\7>%[/QKX8U/0M0,BV>H0-;R/"P61 1
MPR$@@,#@@X."!7)GX+:=9Z5X8M](U?5-$U#P];O:VFJVS0O<21N!YJRB2-HW
MWLJNWR?> (Q7$^"_VI;/Q??6@A@T::VU*RNKVQBT[61<W<(AC,BK=Q",>270
M$\,VTC:>>:T-*^,OC/6;/P5Y/@_2X;_Q;;S7MI%-J[[+2W2**0-.P@)+'S"-
MJ @';SR2 #I5^"FG6VCZ+:V.L:I97VEZI)K U56ADN;FYD$BS/+OC*'>)7!
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MUB>)_BW=7LVG:5'9:CX6UZVU_28KVPO&A9I+6XGVAE>-W5D;:ZG!R"I! XR
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M@Q\LG;'\B@@#I5GQ-\%K+Q#J.N30Z]K.C66OJJZQIVGO"(;["",DEXF>,M&
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M(90%QC ZY/-4;?X+Z;IY\-FPU74K1]$GO)$8>2_VB.ZD,D\,@:,C:3C!4*P
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M_E0+$&&20_*!L$ =N>M96F? 7[/H,EA*/"NF7!O+"Z^U^'/#8T]I1;7"3%9
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MPA^-OA1M)L;Z"YOKQKV::WAL;73+F6]\R+_7*UNL9D0I_%N48R/49 .6UO\
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M'+"FQ6C2YECC./\ <5:N0_$O19/$W]@R#4;._996A-[IMQ!%<>5S((I'0*Y
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MTRQ,JR_NT0LI0L P8 @Y!Y!KJ_#?B33O%N@V>LZ5<BZTZ[C\R*7:R$CH058
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MGP9_PL+P-K'AW[9]@_M"'ROM/E>9Y?S YVY&>GJ*P_B7\)O^%B7$LO\ :O\
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M&5=L@8=#E<' [0?&;PV-%.JS+J]I:M-'!;K=:+=Q2WCR9\M8(FB#RDX)PH)
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MC>7+2.J( J DY9E' [UR<7[0?@Y[J6V>75;>>WFC@O4N-&NX_L#2$"/[06C
MB#[EVEL @YZ D C/_P"%2:K_ &6EM]HL@X\9MXB8AWP;<SM)M^Y_K-I QTS_
M !5RW@7]GN_\,V<6DW]A;:A'IL=TFFZS)XEU"3:9$D2-OL+J88VV2%6VM@9)
M4<X'J&I?%SPQI7B1]$N+NY%S'/%:37$=E,]K;SRX\N*2=4,:.VY<!F'WESC<
MN88OC-X6GUJ33(KF]EF66:VCF33KAK>XGB5FDAAF";)9%"-\B$DE6 R5( !F
MZ!\,]2TJY^&3R3697PQH\VG7@C9OGD>&% 8_E&5S$W7:<$<>FG\'/#6L^"_
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M% CSZV_9^UB\\#ZII5]IFGP:ZVCG2K;5I?$^HZA')EHR^(9T(@1O+4D*6((
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M WD?DR29(V*V<%L@C:.>#QQ6%X'^*L?C:57MI=)-E)J]YI\$JWV6N8H4++)
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MY^8\#U/2N<^%GQGT+XBZ5I:'5=,A\1W5NT\NCP7:O-& >?ESNX&TGCC</44
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M57"G<I5P=P;[K#)KJHM+UCQ'\%EL?'.C3ZOK%S9;+_3=,EBBFE;/&Q_,2-9
M-K$APH8':<8KT.B@#YZ3P-X_\9V.CPZPE[;16MSJL%M?:I);"_@M)K!X89+@
M0,49_,<CY,G:%+ '-9*VFMWWC;X=^';CPA_8EYI7A75+3>;JWD$O[B&(&'RW
M8B$L%PT@0Y(^7@X^F719%*L RD8((R"*Q/#G@3PUX.DN'T#P]I6AO<X\]M-L
MHK<RXZ;BBC=C)Z^M 'D=W\(->N/"?@'2+&U329]/\(WVC7,\<B 6<\MK#&@^
M4Y8>8C'*Y'RY]*YB'X,^(_$7@>YMKRR\2Q>(;'0TTR"WUF?2QI\JK+#(]O&;
M4!RC^0%#2* %8YP217U!10!Y)X*T[7=7^->J>++[P?<^&-,E\/V^FI)?3VSS
MS3).[D%897 50X )///3C/+^-/"/B@Z_\7K2T\#R:O;^,K6WM+#58KJU6-2+
M00L9P\BNJ(Q+#:K$X; SC/T'10!\]:/X'U"S^/5IX=\U+KP[:6]OXJNVW<_V
M@L)LT#+Z.4\X?[2$UZ+\4=,U2;6? VK:;I5QK":3K#3W5O:/$LHB>UGAWCS'
M12 TBDC.<9P#BNPT[P_I>CW=]=6&FV=C<W\@FNYK:!(WN'Q@/(P +MCC)R:T
M* /$+#X8:U9>$-/M8]*2*_3QT^N3*LL8/V=M0DD,Q.[!)A8<9W8.,9XK'^&O
MPIU[2->TS3_$:^*)X](UN\U2UNX9M,_LMS(\S)(2%%UEEF*LIR=Q.25P:^AZ
M* /-/&EKKFA_$_2O%&F^'KSQ'9_V/<Z9+#830)+%*TT4D;,)I$!0[&!()(..
M,5R_P?\ AGK^@:IX(O==TB*VETWPK<Z=<L)HY?(N9+F-_+4@DD%5/S 8XYYX
MKW.B@#YQ\%^!/%GP[MK*:X\'S^(FNO"T>B-9VUS:YLI8YIFV.9)57RI%E7)0
MMCR^1TK!T/X-^,O#UAH$5]9>(/L5QX.LM!OK'PS-I;O;2Q>9YL3_ &L$&-A*
M,-&W53N'0U]644#/%-+^$T>E6_Q#@U#P]?ZOI6IVFG6=M%#=0B^NX8+5(\>8
M9$"NK@G)9><D=JHZ)X2\>^([GPU)K<-]';Z?J&I)!=ZG);?;XK.2Q>*%[@0,
M4:3S'(&S)V[2P!S7O-(1D4"/EDZ1KL6I?"/P?<^$QI][HVF:C:B\%U;R)<[=
M/>'? $<L(F8H2THCP708)/'77?P@UZX\)^ =(L;5-)GT_P (WVC7,\<B 6<\
MMK#&@^4Y8>8C'*Y'RY]*];\/^ O#/A.[N;K0_#NDZ-=7/$\VGV,4#R\Y^9D4
M%N>>:WJ /E^'X,^(_$7@>YMKRR\2Q>(;'0TTR"WUF?2QI\JK+#(]O&;4!RC^
M0%#2* %8YP217HO@K3M=U?XUZIXLOO!]SX8TR7P_;Z:DE]/;//-,D[N05AE<
M!5#@ D\\].,^MT4 >(^+?AEK>M^+-=N?[+6YL+KQ/H>HQEY8\/!;+'YSX+9^
M4J>",G' -=QX.\-W^D>/O'VHW%MY-CJMU:36L@=3YNRU2-VP#D?,N.0,X]*[
M:B@#YV\)_"77+;Q1)IOB&/Q1=Z=#XEN=<MKFTETS^S'#RO+&TA(%T#A_+9><
M] 2O3*NO@5XQU/P;XNTF2(6\NF6J:-X9/VB(_:;)+L7)Y.X(7188,2+_ ,L<
MD%3S]/44 ?/+_"O5/$@BU.YTSQ-<ZE/K6C2WL?BB73!FWM9S(61;0A#LW-G=
M\QXQD 5=\0>%;R[_ &C;/2+<(WAR_2'Q3J48;E+FU!@B!7TD8P/GUMC7O-9]
MCX?TO3-1OM0L]-L[2_ORK7=U! B2W!484R,!E\#@9SB@9P'QMT;4[RWTW4?#
MNDZ[<^*;%9_[-U'19;15MW<+F.=+B55>*0JH8!6("Y!4@&N!\7^%_'S^'OB#
MHD?A*35M1\5&UNDOK*[MX[.)_LT$4Z-YDJR JT+;<*0P9>1SCZ-HH$>5^#[#
M7? WCKQ9;W'AF]U:R\0:L-0@URRFMBD<;0QQ^7.LDJR#R_+.-JL"I&.<BL7P
M;\,=:T'PK\([,Z4EK<:%J4]SJ2)+'^Y62"Z5FR&PVYY4SMR?FSV./;J* "BB
MB@#XR_X*O_\ )KUK_P!C#:?^BIZ^RHO]4GT%?&O_  5?_P"37K7_ +&&T_\
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M?PV^)VA?%?1+O5O#\LTMG:W]QITC3Q&,B:%]D@ /;(X/>NLH **** "BBB@
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M .JHKDOB3\3]"^%'@N?Q3X@EFBTB%X8W>"(R/F5U1/E'^TPKJT<2(KCHPR*
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MZ?\ #3XF^'?"?Q#^(/C#1/A@/#T]_::RVLW$4E_J[2EI!-<188LJG<D9..F
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M]*78N_?M&_&-V.<>E 7/FW]O>-IOV3];C60Q,UQIRB1>JDW4/(^E>%_$N_\
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MXDT2XU-&9#I]K?PM,K G</+5L@CG(Q70F)#()"BF0# ?'('IF@+GRY_P4/\
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M[\2-.M8KR2YDL(FU""$G;')YA7<!Q@'/&*TUU?P!\+)8]'6]\-^$)+^=KA+
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M.G^#7@&Y\(0^%9?!7A^3PS"_F1Z.VF0FU1_[RQ;=H;D\@9YH ^2FTK5-%_;
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MH!;.,#TJMJ_PD\#:_;ZG!J7@W0+^'4S$;Y+C3(7%T8AMB,F5^<H.%)SM'3%
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MVM$2/>L:&4&-7D/ 9@<8XKV*U^'OA6QCT2.V\-:/;IH>[^REBL(E&G[AAO(
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M;5Y+C2]"T,.=6@47#R)%#CSE&<.3MW8S@U\6Z'^TA\1-)O/%UH/%6KWUI=^
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MB^1P7P.?P]$^(/[(.C>./BCX!O/L5C9^ O#6B76EC2[.ZGM+F)W*F)H&AP5
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M""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M :>F_M@>!]3GU(A;Z"QM?"Z^+H+Z:-%CO+(@[A&-V=Z,-K*P'/<UD^(/VTM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XR_X*O_\ )KUK
M_P!C#:?^BIZ^RHO]4GT%?$'_  4_\2V'BOP3X.^%&CW,5_XXU_Q#:M;Z7"X:
M2./;(@=P.5!>5 ,]?F(^Z:^X57:H'H,4#Z"T444""BBB@ HHHH *\<^/W[)G
MPZ_:1CM9/%NF31ZM:)Y5MK.FS>1=Q)G.W=@JZYR0'5@"3C&3GV.B@#XP_P"'
M5?PS_P"AW^(G_@VMO_D6C_AU7\,_^AW^(G_@VMO_ )%K[/HH'=GQA_PZK^&?
M_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\
MT._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_
M !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q
M$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_
M\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\
M!M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM
M_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?
M_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(
MM'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'
M_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#
MJOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JO
MX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9
M_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]
M#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0
M[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\
M$3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3
M_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P
M;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &
MUM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_
M ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\
MBU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU
M]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]G
MT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4
M!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=
MGQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQ
MA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_
MPZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZ
MK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^
M&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?
M_0[_ !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\
MT._Q$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_
M !$_\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q
M$_\ !M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_
M\&UM_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\
M!M;?_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM
M_P#(M'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?
M_(M'_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(
MM'_#JOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'
M_#JOX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#
MJOX9_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JO
MX9_]#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9
M_P#0[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]
M#O\ $3_P;6W_ ,BU]GT4!=GQA_PZK^&?_0[_ !$_\&UM_P#(M'_#JOX9_P#0
M[_$3_P &UM_\BU]GT4!=GQA_PZK^&?\ T._Q$_\ !M;?_(M'_#JOX9_]#O\
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0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
